Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1396
Encontrada(s) 14 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

  • Fernández Tussy, Pablo
  • Rodríguez Agudo, Rubén
  • Fernández Ramos, David
  • Barbier Torres, Lucía
  • Zubiete Franco, Imanol
  • Davalillo, Sergio López de
  • Herráez, Elisa
  • Goikoetxea Usandizaga, Naroa
  • Lachiondo Ortega, Sofía
  • Simón, Jorge
  • Lopitz Otsoa, Fernando
  • Gutiérrez de Juan, Virginia
  • McCain, Misti V.
  • Perugorría, María J.
  • Mabe, Jon
  • Navasa Mayo, Nicolás
  • Rodrigues, Cecilia M. P.
  • Fabregat, Isabel
  • Boix, Loreto
  • Sapena, Víctor
  • Anguita, Juan
  • Lu, Shelly C.
  • Mato, José M.
  • Banales, Jesus M.
  • Villa, Erica
  • Reeves, Helen L.
  • Bruix, Jordi
  • Reig, María
  • Marín, José J. G.
  • Delgado, Teresa C.
  • Martínez Chantar, María L.
[EN]Dysregulation of miRNAs is a hallmark of cancer, modulating oncogenes, tumor suppressors, and drug responsiveness. The multi-kinase inhibitor sorafenib is one of the first-line drugs for advanced hepatocellular carcinoma (HCC), although the outcome for treated patients is heterogeneous. The identification of predictive biomarkers and targets of sorafenib efficacy are sorely needed. Thus, selected top upregulated miRNAs from the C19MC cluster were analyzed in different hepatoma cell lines compared to immortalized liver human cells, THLE-2 as control. MiR-518d-5p showed the most consistent upregulation among them. Thus, miR-518d-5p was measured in liver tumor/non-tumor samples of two distinct cohorts of HCC patients (n = 16 and n = 20, respectively). Circulating miR-518d-5p was measured in an independent cohort of HCC patients receiving sorafenib treatment (n = 100), where miR-518d-5p was analyzed in relation to treatment duration and patient’s overall survival. In vitro and in vivo studies were performed in human hepatoma BCLC3 and Huh7 cells to analyze the effect of miR-518d-5p inhibition/overexpression during the response to sorafenib. Compared with healthy individuals, miR-518d-5p levels were higher in hepatic and serum samples from HCC patients (n = 16) and in an additional cohort of tumor/non-tumor paired samples (n = 20). MiR-518d-5p, through the inhibition of c-Jun and its mitochondrial target PUMA, desensitized human hepatoma cells and mouse xenograft to sorafenib-induced apoptosis. Finally, serum miR-518d-5p was assessed in 100 patients with HCC of different etiologies and BCLC-stage treated with sorafenib. In BCLC-C patients, higher serum miR-518d-5p at diagnosis was associated with shorter sorafenib treatment duration and survival. Hence, hepatic miR-518d-5p modulates sorafenib resistance in HCC through inhibition of c-Jun/PUMA-induced apoptosis. Circulating miR-518d-5p emerges as a potential lack of response biomarker to sorafenib in BCLC-C HCC patients., SI, This work was supported by grants from NIH (US Department of Health and Human services) R01CA172086 (to S.C.L., J.M.M. and M.L.M.-C.) and P01CA233452 (to S.C.L.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C), MINECO: SAF2017-87301-R, SAF2014-52097-R, RTI2018-096759-A-100, SAF2016-75197-R and SAF2015-64149-R, integrated in the Plan Estatal de Investigación Cientifica y Técnica e Innovación 2017-2020 cofounded by FEDER funds/Development Fund—a way to build Europe (to M.L.M.-C., J.M.M., T.C.D., J.J.G.M., and I.F., respectively), Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain: PI16/00598 and PI19/00819 (to J.J.G.M.), PI15/01132 and PI18/01075 (to J.M.B.), PI14/00399 and PI17/00022 (to M.J.P.), PI18/0358 (to M.R.), BIOEF (Basque Foundation for Innovation and Health Research): EITB Maratoia BIO15/CA/014 and BIO15/CA/016/BD (to M.L.M.-C and J.M.B., respectively); Mitotherapeutix (to M.L.M.-C), Consejería de Educación, Junta de Castilla y León: SA063P17 (J.J.G.M.), Asociación Española Contra el Cáncer (T.C. D, P.F.-T., and M.L.M-C), Basque Government Postdoctoral Program (P.F.-T.), Daniel Alagille award from EASL (to T.C.D.), Asociación Española contra el Cáncer, Canceres raros (M.L.M.-C., J.M.B., and J.J.G.M.), La Caixa Foundation (to M.L.M.-C. and J.M.B.), Ayudas Fundación BBVA a equipos de Investigación Científica 2018 (to M.L.M.-C.), Fondo Europeo de Desarrollo Regional’ (FEDER) (to J.M.B.); CIBERehd, Spain (to J.M.B.); IKERBASQUE, Basque foundation for Science, Spain (to J.M.B.), Department of Health of the Basque Country (2017111010) (to J.M.B.), Euskadi RIS3 (2019222054, 2020333010) (to J.M.B.); Department of Industry of the Basque Country (J.M.B.: Elkartek: KK-2020/00008) (to J.M.B.), Ayudas para apoyar grupos de investigación del sistema Universitario Vasco IT971, Instituto de Salud Carlos III PI18/00768 (J.B.), AECC PI044031 (J.B.), Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement 2014 SGR 605 (J.B.), WCR (AICR) 16-0026 (J.B.), Programma di ricerca Regione-Università 2007–2009 and 2011–2012, Regione Emilia- Romagna (E.V.).
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

  • Fernández Ramos, David
  • Fernández Tussy, Pablo
  • Lopitz Otsoa, Fernando
  • Gutiérrez de Juan, Virginia
  • Navasa Mayo, Nicolás
  • Barbier Torres, Lucía
  • Zubiete Franco, Imanol
  • Simón, Jorge
  • Fernández, Agustín F.
  • Arbelaiz, Ander
  • Aransay, Ana M.
  • Lavín, José Luis
  • Beraza, Naiara
  • Perugorria, Maria J.
  • Banales, Jesus M.
  • Villa, Erica
  • Fraga, Mario F.
  • Anguita, Juan
  • Ávila, Matías A.
  • Berasain, Carmen
  • Iruzibieta, Paula
  • Crespo, Javier
  • Lu, Shelly C.
  • Varela Rey, Marta
  • Mato, José M.
  • Delgado, Teresa C.
  • Martínez Chantar, María L.
[EN]Glycine N-methyltransferase (GNMT) is the most abundant methyltransferase in the liver and a master regulator of the transmethylation flux. GNMT downregulation leads to loss of liver function progressing to fibrosis, cirrhosis, and hepatocellular carcinoma. Moreover, GNMT deficiency aggravates cholestasis-induced fibrogenesis. To date, little is known about the mechanisms underlying downregulation of GNMT levels in hepatic fibrosis and cirrhosis. On this basis, microRNAs are epigenetic regulatory elements that play important roles in liver pathology. In this work, we aim to study the regulation of GNMT by microRNAs during liver fibrosis and cirrhosis. Luciferase assay on the 3ʹUTR-Gnmt was used to confirm in silico analysis showing that GNMT is potentially targeted by the microRNA miR-873-5p. Correlation between GNMT and miR-873-5p in human cholestasis and cirrhosis together with miR-873-5p inhibition in vivo in different mouse models of liver cholestasis and fibrosis [bile duct ligation and Mdr2 (Abcb4)-/- mouse] were then assessed. The analysis of liver tissue from cirrhotic and cholestatic patients, as well as from the animal models, showed that miR-873-5p inversely correlated with the expression of GNMT. Importantly, high circulating miR-873-5p was also detected in cholestastic and cirrhotic patients. Preclinical studies with anti-miR-873-5p treatment in bile duct ligation and Mdr2-/- mice recovered GNMT levels in association with ameliorated inflammation and fibrosis mainly by counteracting hepatocyte apoptosis and cholangiocyte proliferation. In conclusion, miR-873-5p emerges as a novel marker for liver fibrosis, cholestasis, and cirrhosis and therapeutic approaches based on anti-miR-873-5p may be effective treatments for liver fibrosis and cholestatic liver disease., SI, This work was supported by grants from NIH (US Department of Health and Human services)- R01AT001576 (S.C.L., J.M.M., and M.L.M.-C.), Ministerio de Economía, Industria y Competitividad: SAF2017-87301-R (M.L.M.-C.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD (M.L.M.-C.), ELKARTEK 2016, Departamento de Industria del Gobierno Vasco (to M.L.M.-C.), Asociación Española contra el Cáncer (to T.C.D, P.F.-T. and M.L.M.-C.), Mitotherapeutix (to M.L.M.-C.), Daniel Alagille award from EASL (to T.C.D), Fundación Científica de la Asociación Española Contra el Cancer (AECC Scientific Foundation) Rare Tumor Calls 2017 (to M.L.M, J.M.B., and M.A), La Caixa Foundation Program (to M.L.M, J.M.B.), FIS: PI15/00892 (to M.F.F), FIS: PI15/01132 and FIS PI18/01075 (to J.M.B.), (to J.M.B.), FIS: PI14/00399 and PI17/00022 (to M.J.P.), Miguel Servet Program (CON14/00129 to J.M.B.), Ramon y Cajal Program (RYC-2015-17755 to M.J.P.), GRUPIN14-052 (to M.F.), PI14/00962 Instituto Carlos III (to J.B.), AECC Scientific Foundation (to J.B.), World Wide Cancer Research (to J.B.), Programma di Ricerca Regione-Università 2007-2009 and 2011-2012, Regione Emilia-Romagna (to E.V.), “Diputación Foral Gipuzkoa” (DFG15/010, DFG16/004 to J.M.B.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to J.M.B.), Department of Health of the Basque Country (2013111173 to J.M.B.; 2015111100 to M.J.P.). Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. “Hepacare Project” from Fundación La Caixa, Spain (to M.A.A and C.B.), BiO-Eusko Fundazioa project BIO15/CA/011 (to M.A.A and C.B.). We thank this work produced with the support of a 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation (to M.V.R.). We thank MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016-0644).
Docta Complutense
Publicación Artículo científico (JournalArticle)

Candida genotyping of blood culture isolates from patients admitted to 16 hospitals in Madrid: genotype spreading during the COVID-19 pandemic driven by fluconazole-resistant C. parapsilosis

  • Díaz García, Judith
  • Gómez, Ana
  • Machado, Marina
  • Alcalá, Luis
  • Reigadas Ramírez, Elena Manuela
  • Sánchez Carrillo, Carlos
  • Pérez Ayala, Ana
  • Gómez García De La Pedrosa, María Elia
  • González Romo, Fernando
  • Cuétara, María Soledad
  • García Esteban, Coral
  • Quiles Melero, Inmaculada
  • Zurita, Nelly Daniela
  • Muñoz Algarra, María
  • Durán Valle, María Teresa
  • Sánchez García, Aída
  • Muñoz García, Patricia Carmen
  • Escribano Subías, María Pilar
  • Guinea, Jesús
Background: Candidaemia and invasive candidiasis are typically hospital-acquired. Genotyping isolates from patients admitted to different hospitals may be helpful in tracking clones spreading across hospitals, especially those showing antifungal resistance. Methods: We characterized Candida clusters by studying Candida isolates (C. albicans, n = 1041; C. parapsilosis, n = 354, and C. tropicalis, n = 125) from blood cultures (53.8%) and intra-abdominal samples (46.2%) collected as part of the CANDIMAD (Candida in Madrid) study in Madrid (2019–2021). Species-specific microsatellite markers were used to define the genotypes of Candida spp. found in a single patient (singleton) or several patients (cluster) from a single hospital (intra-hospital cluster) or different hospitals (widespread cluster). Results: We found 83 clusters, of which 20 were intra-hospital, 49 were widespread, and 14 were intra-hospital and widespread. Some intra-hospital clusters were first detected before the onset of the COVID-19 pandemic, but the number of clusters increased during the pandemic, especially for C. parapsilosis. The proportion of widespread clusters was significantly higher for genotypes found in both compartments than those exclusively found in either the blood cultures or intra-abdominal samples. Most C. albicans- and C. tropicalis-resistant genotypes were singleton and presented exclusively in either blood cultures or intra-abdominal samples. Fluconazole-resistant C. parapsilosis isolates belonged to intra-hospital clusters harboring either the Y132F or G458S ERG11p substitutions; the dominant genotype was also widespread. Conclusions: the number of clusters—and patients involved—increased during the COVID-19 pandemic mainly due to the emergence of fluconazole-resistant C. parapsilosis genotypes.
Docta Complutense
Publicación Artículo científico (JournalArticle)

TGFB1 polymorphisms and TGF‐β1 plasma levels identify gastric adenocarcinoma patients with lower survival rate and disseminated disease

  • Gutierrez, Alberto
  • Vaquero‐Yuste, Christian
  • López, Adela
  • Lasa, Inmaculada
  • Gómez, Remedios
  • Juárez Martín-Delgado, Ignacio
  • Molanes López, Elisa María
  • Martín Villa, José Manuel
TGF‐β1 is involved in tumour growth. Four TGFB1 SNPs and TGF‐β1 production by stimulated PBMC were determined in seventy‐eight gastric adenocarcinoma patients. In addition, TGF‐β1 levels were measured in the plasma of further thirty patients. rs1800471‐G/C genotype was prevalent in patients (20.7%) compared to controls (8.4%), as it also was the rs1800468 SNP‐G/A genotype in stage IV patients (20.7%) compared to stage I, II and III patients, combined (10.3%). Conversely, the T/T rs1800469 SNP‐T/T genotype was absent in the former group and present in 19.0% in the latter. Furthermore, the rs1800469‐C/rs1800470‐T (CT) haplotype was found in 15.0% of stage IV patients as compared to 3.0% of the remaining patients (3.0%) and also identifies patients with worse five‐year life expectancy (<jats:italic>P</jats:italic> = .03). TGF‐β1 synthesis by stimulated PBMCs was significantly lower in patients with the risk SNPs or haplotype, compared to the alternative genotype. Finally, TGF‐β1 plasma levels were lower in patients with worse life expectancy. Analysis of TGFB1 SNPs and measurement of plasma TGF‐β1 levels serves to identify patients at risk of developing a more aggressive disease.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Protective Effect of Placental Mesenchymal Stromal Cells in an In Vitro Model of Parkinson's Disease Using Differentiated Neuroblastoma Cells

  • Almudena Coto-Vilcapoma
  • Laura Sánchez-Carretero
  • Daniel Arenas-Gonzalez
  • José A Molina
  • María José Morán-Jiménez
  • Paz de la Torre
  • Ana I Flores
  • Merino Martín, José Joaquín
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder. It is characterized by the accumulation of misfolded α-synuclein (α-syn) and progressive loss of dopaminergic neurons in the substantia nigra. Due to the limitations of current therapies, mesenchymal stromal cell (MSC) transplantation has emerged as a promising neuroprotective strategy. This study evaluated the neuroprotective potential of decidua-derived mesenchymal stromal cells (DMSCs) in vitro using a human neuroblastoma cell line (NB69) exposed to the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) as a PD model. The NB69 cells were differentiated into a mature dopaminergic phenotype using dibutyryl cyclic adenosine monophosphate (dbcAMP) and then exposed to MPP+. In proliferative NB69 cells, the effect of DMSCs was masked by their inherent antitumor activity against the neuroblastoma phenotype. Conversely, in the differentiated NB69 model, DMSCs demonstrated a significant protective role against MPP+-induced cytotoxicity. Interestingly, the mechanism by which DMSCs might exert a neuroprotective effect against MPP+ damage in differentiated NB69 cells appears to involve improving mitochondrial function by reducing free radicals. In summary, these findings suggest that DMSCs exert a neuroprotective effect in a dopaminergic-like context and highlight the importance of using differentiated cell models to accurately evaluate cell-based therapies for PD in the striatum.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Antifibrotic effect of novel neutrophil gelatinase‑associated lipocalin inhibitors in cardiac and renal disease models

  • Bonnard, Benjamin
  • Martínez Martínez, Ernesto
  • Jaisser, Frédéric
Neutrophil gelatinase-associated lipocalin (NGAL) is involved in cardiovascular and renal diseases. Gene inactivation of NGAL blunts the pathophysiological consequences of cardiovascular and renal damage. We aimed to design chemical NGAL inhibitors and investigate its effects in experimental models of myocardial infarction (MI) and chronic kidney disease induced by 5/6 nephrectomy (CKD) on respectively 8-12 weeks old C57Bl6/j and FVB/N male mice. Among the 32 NGAL inhibitors tested, GPZ614741 and GPZ058225 fully blocked NGAL-induced inflammatory and profibrotic markers in human cardiac fibroblasts and primary mouse kidney fibroblasts. The administration of GPZ614741 (100 mg/kg/day) for three months, was able to improve cardiac function in MI mice and reduced myocardial fibrosis and inflammation. The administration of GPZ614741 (100 mg/kg/day) for two months resulting to no renal function improvement but prevented the increase in blood pressure, renal tubulointerstitial fibrosis and profibrotic marker expression in CKD mice. In conclusion, we have identified new compounds with potent inhibitory activity on NGAL-profibrotic and pro-inflammatory effects. GPZ614741 prevented interstitial fibrosis and dysfunction associated with MI, as well as tubulointerstitial fibrosis in a CKD model. These inhibitors could be used for other diseases that involve NGAL, such as cancer or metabolic diseases, creating new therapeutic options.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Dihydropyrimidinase-Related Protein 2 Is a New Partner in the Binding between 4E-BP2 and eIF4E Related to Neuronal Death after Cerebral Ischemia

  • Martínez-Alonso, Emma
  • Escobar-Peso, Alejandro
  • Guerra Pérez, Natalia
  • Roca, Marcel
  • Masjuan, Jaime
  • Alcázar, Alberto
Transient cerebral ischemia induces neuronal degeneration, followed in time by secondary delayed neuronal death that is strongly correlated with a permanent inhibition of protein synthesis in vulnerable brain regions, while protein translational rates are recovered in resistant areas. In the translation-regulation initiation step, the eukaryotic initiation factor (eIF) 4E is a key player regulated by its association with eIF4E-binding proteins (4E-BPs), mostly 4E-BP2 in brain tissue. In a previous work, we identified dihydropyrimidinase-related protein 2 (DRP2) as a 4E-BP2-interacting protein. Here, using a proteomic approach in a model of transient cerebral ischemia, a detailed study of DRP2 was performed in order to address the challenge of translation restoration in vulnerable regions. In this report, several DRP2 isoforms that have a specific interaction with both 4E-BP2 and eIF4E were identified, showing significant and opposite differences in this association, and being differentially detected in resistant and vulnerable regions in response to ischemia reperfusion. Our results provide the first evidence of DRP2 isoforms as potential regulators of the 4E-BP2–eIF4E association that would have consequences in the delayed neuronal death under ischemic-reperfusion stress. The new knowledge reported here identifies DRP2 as a new target to promote neuronal survival after cerebral ischemia.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Proteomic and Biological Analysis of an In Vitro Human Endothelial System in Response to Drug Anaphylaxis

  • Yuste Montalvo, Alma
  • Fernandez Bravo, Sergio
  • Oliva, Tamara
  • Pastor Vargas, Carlos
  • Betancor, Diana
  • Goikoetxea, María José
  • Julio Laguna, José Julio
  • López, Juan Antonio
  • Alvarez Llamas, Gloria
  • Cuesta Herranz, Javier
  • Martin Lorenzo, Marta
  • Esteban, Vanesa
Anaphylaxis is a life-threatening systemic hypersensitivity reaction. During anaphylaxis, mediator release by effector cells causes endothelial barrier breakdown, increasing vascular permeability and leakage of fluids, which may lead to tissue edema. Although endothelial cells (ECs) are key players in this context, scant attention has been paid to the molecular analysis of the vascular system, and further analyses of this cell type are necessary, especially in humans. The protein expression pattern of human microvascular ECs was analyzed in response to sera from anaphylactic patients (EC-anaphylaxis) and sera from non-allergic subjects (EC-control) after 2 hours of contact. Firstly, a differential quantitative proteomic analysis of the protein extracts was performed by mass spectrometry using an isobaric labeling method. Second, the coordinated behavior of the identified proteins was analyzed using systems biology analysis (SBA). The proteome of the EC-anaphylaxis system showed 7,707 proteins, of which 1,069 were found to be significantly altered between the EC-control and EC-anaphylaxis groups (p-value < 0.05). Among them, a subproteome of 47 proteins presented a high rate of change (|ΔZq| ≥ 3). This panel offers an endothelial snapshot of the anaphylactic reaction. Those proteins with the highest individual changes in abundance were hemoglobin subunits and structural support proteins. The interacting network analysis of this altered subproteome revealed that the coagulation and complement systems are the main biological processes altered in the EC-anaphylactic system. The comprehensive SBA resulted in 5,512 functional subcategories (biological processes), 57 of which were significantly altered between EC-control and EC-anaphylaxis. The complement system, once again, was observed as the main process altered in the EC system created with serum from anaphylactic patients. Findings of the current study further our understanding of the underlying pathophysiological mechanisms operating in anaphylactic reactions. New target proteins and relevant signaling pathways operating in the in vitro endothelial-serum system have been identified. Interestingly, our results offer a protein overview of the micro-EC-anaphylaxis environment. The relevance of the coagulation, fibrinolytic, contact and complement systems in human anaphylaxis is described. Additionally, the untargeted high-throughput analysis used here is a novel approach that reveals new pathways in the study of the endothelial niche in anaphylaxis.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables

  • Wicke, Pablo Delgado
  • Fernández de Córdoba Oñate, Sara
  • Roy Vallejo, Emilia
  • Alegría Carrasco, Estibaliz
  • Rodríguez Serrano, Diego A.
  • Lamana Domínguez, Amalia
  • Montes, Nuria
  • Nicolao Gómez, Ana
  • Carracedo Rodríguez, Rosa
  • Marcos Jiménez, Ana
  • Díaz Fernández, Paula
  • Galván Román, José M.
  • Rabes Rodríguez, Laura
  • Sanz Alba, Marta
  • Álvarez Rodríguez, Jesús
  • Villa Martí, Almudena
  • Rodríguez Franco, Carlos
  • Villapalos García, Gonzalo
  • Zubiaur, Pablo
  • Abad Santos, Francisco
  • De los Santos, Ignacio
  • Pérez Gomáriz, Rosa María
  • García Vicuña, Rosario
  • Muñoz Calleja, Cecilia
  • González Álvaro, Isidoro
  • Fernández Ruiz, Elena
  • Suárez Fernández, Carmen
  • Barrios, Ana
  • Sanz, Jesús
  • Casado, Pedro
  • Gutiérrez, Ángela
  • Bautista, Azucena
  • Hernández, Pilar
  • Ruiz Giménez, Nuria
  • Moyano, Berta
  • Gil, Paloma
  • Delgado, María Jesús
  • Parra, Pedro
  • Sánchez, Beatriz
  • Sáez, Carmen
  • Fernández Rico, Marta
  • Arévalo Román, Cristina
  • Ciudad, Marianela
  • Castañeda, Santos
  • Llorente, Irene
  • Tomero, Eva G.
  • García Castañeda, Noelia
  • Uriarte, Miren
  • Cardeñoso, Laura
  • Fontán García-Rodrigo, Leticia
  • Domingo García, Diego
  • Alarcón Cavero, Teresa
  • Semiglia Chong, María Auxiliadora
  • Gutiérrez Cobos, Ainhoa
  • Zurita Cruz, Nelly D.
  • Sánchez Madrid, Francisco
  • Martín Gayo, Enrique
  • Sánchez Cerrillo, Ildefonso
  • Martínez Fleta, Pedro
  • López Sanz, Celia
  • Gabrie, Ligia
  • Del Campo Guerola, Luciana
  • Tejedor, Reyes
  • Ancochea, Julio
  • García Castillo, Elena
  • Ávalos, Elena
  • Sánchez Azofra, Ana
  • Alonso, Tamara
  • Cisneros, Carolina
  • Valenzuela, Claudia
  • García Pérez, Francisco J.
  • Girón, Rosa M.
  • Aspa, Javier
  • Marcos, Celeste
  • Socorro Churruca, M. del Perpetuo
  • Zamora, Enrique
  • Martínez, Adrián
  • Barrio Mayo, Mar
  • Henares Espi, Rosalina
  • Méndez, Rosa
  • Arribas, David
  • Chicot Llano, Marta
  • González, Begoña
  • Quicios, Begoña
  • Patiño, Pablo
  • Trigueros, Marina
  • Dominguez Peña, Cristina
  • Jiménez Jiménez, David
  • Villamayor, Pablo
  • Canabal, Alfonso
  • De la Cámara, Rafael
  • Ortiz, Javier
  • Iturrate, Isabel
The characteristics of the host are crucial in the final outcome of COVID-19. Herein, the influence of genetic and clinical variants in COVID-19 severity was investigated in a total of 1350 patients. Twenty-one single nucleotide polymorphisms of genes involved in SARS-CoV-2 sensing as Toll-like-Receptor 7, antiviral immunity as the type I interferon signalling pathway (TYK2, STAT1, STAT4, OAS1, SOCS) and the vasoactive intestinal peptide and its receptors (VIP/VIPR1,2) were studied. To analyse the association between polymorphisms and severity, a model adjusted by age, sex and different comorbidities was generated by ordinal logistic regression. The genotypes rs8108236-AA (OR 0.12 [95% CI 0.02–0.53]; p = 0.007) and rs280519-AG (OR 0.74 [95% CI 0.56–0.99]; p = 0.03) in TYK2, and rs688136-CC (OR 0.7 [95% CI 0.5–0.99]; p = 0.046) in VIP, were associated with lower severity; in contrast, rs3853839-GG in TLR7 (OR 1.44 [95% CI 1.07–1.94]; p = 0.016), rs280500-AG (OR 1.33 [95% CI 0.97–1.82]; p = 0.078) in TYK2 and rs1131454-AA in OAS1 (OR 1.29 [95% CI 0.95–1.75]; p = 0.110) were associated with higher severity. Therefore, these variants could influence the risk of severe COVID-19.
Docta Complutense
Publicación Artículo científico (JournalArticle)

HLA‐G: Function, polymorphisms and pathology

  • Suarez‐Trujillo, Fabio
  • López‐Nares, Adrián
  • Vaquero Yuste, Christian
  • Palacio‐Gruber, Jose
  • Arnaiz Villena, Antonio
  • Juárez Martín-Delgado, Ignacio
  • Martín Villa, José Manuel
HLA-G immune modulatory genes and molecules are presently being studied by a widespread number of research groups. In the present study, we do not aim to be exhaustive since the number of manuscripts published every year is overwhelming. Instead, our aim is pointing out facts about HLA-G function, polymorphism and pathology that have been confirmed by several different researchers, together with exposing aspects that may have been overlooked or not sufficiently remarked in this productive field of study. On the other hand, we question whether performing mainly studies on HLA-G and disease associations is going to give a clear answer in the future, since 40 years of study of classical HLA molecules association with disease has still given no definite answer on this issue.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Benefits of exercise and immunotherapy in a murine model of human non-small-cell lung carcinoma.

  • Martín Ruiz Valdepeñas, María Asunción
  • Fiuza Luces, C.
  • Rincón Castanedo, C.
  • Fernández Moreno, D.
  • González Gálvez, Beatriz
  • Martínez Martínez, Ernesto
  • Martín Acosta, P.
  • Coronado, M. J.
  • Franco Luzón, L.
  • González Murillo, A.
  • Ramírez, M.
  • Provencio, M.
  • Lucia, A.
Background: Lung cancer has the highest incidence and mortality rate in the world. One of the most promising new cancer therapies in recent years is immunotherapy, which is based on the blockade of immune checkpoints such as programmed cell death protein 1 (PD-1). Exercise training is beneficial to maintain and improve the quality of life of cancer patients, and it might also modulate the anti-tumoral efficiency of some chemotherapeutic agents. However, the potential of exercise combined with immunotherapy as a cancer therapy remains to be elucidated. Here, we examined the effects of exercise on tumor growth and its possible adjuvant effects when combined with anti-PD-1 immunotherapy (nivolumab) in a patient derived xenograft (PDX) model of non-small-cell lung carcinoma (NSCLC). Methods: We generated a PDX model using NOD-SCID gamma mice with subcutaneous grafts from tumor tissue of a patient with NSCLC. Animals were randomly assigned to one of four groups: non-exercise + isotype control (n=5), exercise + isotype control (n=5), non-exercise + nivolumab (n=6) or exercise + nivolumab (n=6). The animals undertook an 8- week moderate-intensity training regimen (treadmill aerobic exercise and strength training). Immunotherapy (nivolumab) or an isotype control was administered 2 days/week, for 6 weeks. Several tumor growth and microenvironment parameters were measured after the intervention. Results: Improvements in aerobic capacity and muscle strength (p=0.027 and p=0.005) were noted in exercised animals. Exercise alone reduced the tumor growth rate with respect to non-exercised mice (p=0.050). The double intervention (exercise + nivolumab) increased tumor necrosis and reduced apoptosis with respect to controls (p=0.026; p=0.030). All interventions achieved a reduction in proliferation compared with the control group (p=0.015, p=0.011, and p=0.011). Exercise alone increased myeloid tumor infiltrates (mostly neutrophils) with respect to the nivolumab only group (p=0.018). Finally, Vegf-a expression was higher in the nivolumab groups (in combination or not with exercise) than in exercise + isotype control group (p=0.045 and p=0.047, respectively). No other significant effects were found. Conclusions: Our results would suggest that aerobic and strength training should be studied as an adjuvant to cancer immunotherapy treatment.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Biodegradable polydioxanone stents: histologic and structural effects in an experimental model of tracheal stenosis

  • Morante Valverde, Rocío
  • Usategui, Alicia
  • Grau, Montserrat
  • Luna Paredes, María Carmen
  • Gimeno-Díaz de Atauri, Álvaro
  • Pablos Álvarez, José Luis
  • Antón-Pacheco Sánchez, Juan Luis
  • López Díaz, María Montserrat
Objectives: To evaluate the biologic impact of polydioxanone (PDO) stenting in an animal model of inflammatory tracheal stenosis (TS). Additionally, to compare these results with those obtained in the same model without a stent and after placing one PDO stent in a healthy trachea. Methods: 40 adult NZ rabbits were distributed into 3 groups: Group A, 8 animals with a healthy trachea and a PDO stent; group B, 17 rabbits with a TS and no stent; and group C, 15 animals with TS and a PDO stent. Histopathological studies included Masson's trichrome staining for submucosal fibrosis and Safranin O to assess structural integrity of cartilage. Morphometric analyses were performed in the 3 groups. Results: Stent placement was successful in every case. Histological studies did not show a significant increase in tracheal wall collagen area and cartilage structure was not modified in those rabbits with a PDO stent, even in a TS scenario. Stent implantation permitted recovery of normal tracheal lumen levels in the TS model. Conclusions: PDO stenting in the normal trachea and in a model of TS neither caused increase in the collagen matrix nor modification of the cartilaginous support. Additionally, radial force exhibited by PDO stents was effective in restoring normal tracheal lumen when placed in a stenotic lesion. These findings suggest that they may be safe and useful in the setting of an acquired TS.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Successful aging: insights from proteome analyses of healthy centenarians

  • Santos-Lozano, Alejandro
  • Valenzuela, Pedro L.
  • Llavero, Francisco
  • Lista, Simone
  • Carrera-Bastos, Pedro
  • Hampel, Harald
  • Pareja-Galeano, Helios
  • González Gálvez, Beatriz
  • López, Juan Antonio
  • Vázquez, Jesús
  • Emanuele, Enzo
  • Zugaza, José L.
  • Lucia, Alejandro
Healthy aging depends on a complex gene-environment network that is ultimately reflected in the expression of different proteins. We aimed to perform a comparative analysis of the plasma proteome of healthy centenarians (n=9, 5 women, age range 100-103 years) with a notably preserved ambulatory capacity (as a paradigm of 'successful' aging), and control individuals who died from a major age-related disease before the expected life expectancy (n=9, 5 women, age range: 67-81 years), and while having impaired ambulatory capacity (as a paradigm of 'unsuccessful' aging). We found that the expression of 49 proteins and 86 pathways differed between the two groups. Overall, healthy centenarians presented with distinct expression of proteins/pathways that reflect a healthy immune function, including a lower pro-inflammatory status (less 'inflammaging' and autoimmunity) and a preserved humoral immune response (increased B cell-mediated immune response). Compared with controls, healthy centenarians also presented with a higher expression of proteins involved in angiogenesis and related to enhanced intercellular junctions, as well as a lower expression of proteins involved in cardiovascular abnormalities. The identification of these proteins/pathways might provide new insights into the biological mechanisms underlying the paradigm of healthy aging.
Docta Complutense
Publicación Artículo científico (JournalArticle)

HLA alleles and haplotypes in Sudanese population and their relationship with Mediterraneans

  • Suarez-Trujillo, Fabio
  • El-Safi, Sayda
  • Juárez Martín-Delgado, Ignacio
  • Palacio-Gruber, José
  • Sanchez-Orta, Alejandro
  • Martín Villa, José Manuel
  • Arnaiz Villena, Antonio
The contribution of migrated people from once green Sahara (about 10,000–6000 years) towards Mediterranean area had probably a double effect: both genetic and cultural connections have been described between Western Europe and North Africa. Sudanese populations from different ethnicities have been studied for HLA-A, -B, -DRB1 and -DQB1 antigens by a standard microlymphotoxicity method. Results found show that Nubians are genetically related with African Sub-Saharan populations and distant from other Sudanese tribes, who are closer to Mediterranean populations than to Sub-Saharan ones. This is concordant with other authors and meta-analysis data. Our present work is, to our knowledge, the first and only one HLA research that studies Sudanese people according to different Sudan ethnic groups: samples were collected before Sudan partition between North and South. A prehistoric genetic and peoples exchange between Africa and the Mediterranean basin may be observed and is supported with the results obtained in this Sudanese HLA study. However, demic diffusion model of agriculture and other anthropological traits from Middle East to West Europe/Maghreb do not exist: a more detailed Sahel and North African countries ancient and recent admixture studies are also being carried out which may clearer explain pastoralists/agriculture innovations origins in Eurafrican Mediterranean and Atlantic façade.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Exercise Intolerance in McArdle Disease: A Role for Cardiac Impairment? A Preliminary Study in Humans and Mice.

  • Santos Lozano, Alejandro
  • Boraita, Araceli
  • Valenzuela, Pedro L.
  • Santalla, Alfredo
  • Villareal Salazar, Mónica
  • Bustos, Asunción
  • Brea Alejo, Lidia
  • Barranco Gil, David
  • Millán Parlanti, Daniela
  • López Ortiz, Susana
  • Peñín Grandes, Saúl
  • Naranjo Orellana, José
  • Fiuza Luces, Carmen
  • González Gálvez, Beatriz
  • García Fernández, Miguel Ángel
  • Pinós, Tomàs
  • Lucia, Alejandro
INTRODUCTION: Whether cardiac impairment can be fully discarded in McArdle disease-the paradigm of "exercise intolerance," caused by inherited deficiency of the skeletal muscle-specific glycogen phosphorylase isoform ("myophosphorylase")-remains to be determined. METHODS: Eight patients with McArdle disease and seven age/sex-matched controls performed a 15-min moderate, constant-load cycle-ergometer exercise bout followed by a maximal ramp test. Electrocardiographic and two-dimensional transthoracic (for cardiac dimension's assessment) and speckle tracking (for left ventricular global longitudinal strain (GLS) assessments) echocardiographic evaluations were performed at baseline. Electrocardiographic and GLS assessments were also performed during constant-load exercise and immediately upon maximal exertion. Four human heart biopsies were obtained in individuals without McArdle disease, and in-depth histological/molecular analyses were performed in McArdle and wild-type mouse hearts. RESULTS: Exercise intolerance was confirmed in patients ("second wind" during constant-load exercise, -55% peak power output vs controls). As opposed to controls, patients showed a decrease in GLS during constant-load exercise, especially upon second wind occurrence, but with no other between-group difference in cardiac structure/function. Human cardiac biopsies showed that all three glycogen phosphorylase-myophosphorylase, but also liver and especially brain-isoforms are expressed in the normal adult heart, thereby theoretically compensating for eventual myophosphorylase deficiency. No overall histological (including glycogen depots), cytoskeleton, metabolic, or mitochondrial (morphology/network/distribution) differences were found between McArdle and wild-type mouse hearts, except for lower levels of pyruvate kinase M2 and translocase of outer-membrane 20-kDa subunit in the former. CONCLUSIONS: This study provides preliminary evidence that cardiac structure and function seem to be preserved in patients with McArdle disease. However, the role for an impaired cardiac contractility associated with the second wind phenomenon should be further explored.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development and Evaluation of an NTM-IGRA to Guide Pediatric Lymphadenitis Diagnosis

  • Villar-Hernández, Raquel|||0000-0002-2249-0579
  • Latorre, Irene|||0000-0001-8159-2455
  • Noguera-Julian, Antoni|||0000-0001-7485-0583
  • Martínez-Planas, Aina
  • Minguell Domingo, Laura
  • Vallmanya, Teresa
  • Méndez Hernández, Maria|||0000-0001-5697-2763
  • Soriano-Arandes, Antoni|||0000-0001-9613-7228
  • Baquero-Artigao, Fernando|||0000-0002-6903-3826
  • Rodríguez-Molino, Paula
  • Guillén-Martín, Sara
  • Toro Rueda, Carlos
  • De Souza Galvão, Maria Luiza|||0000-0001-9703-989X
  • Jiménez-Fuentes, María Ángeles|||0000-0001-5181-4192
  • Stojanovic, Zoran|||0000-0001-5082-0750
  • Sabriá, Josefina
  • Santos, José Ramón|||0000-0002-0886-7114
  • Puig, Jordi|||0000-0002-4075-0346
  • Domínguez-Álvarez, Marisol
  • Millet, Joan Pau|||0000-0003-0200-2459
  • Altet, Neus
  • Galea, Yolanda
  • Muriel-Moreno, Beatriz|||0000-0002-6683-9082
  • García-García, Esther
  • Bach Griera, Marc|||0000-0001-9845-7225
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Julián, Esther|||0000-0002-6558-3978
  • Torrelles, Jordi B.|||0000-0001-7702-5941
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Domínguez, José|||0000-0001-7888-0309
Background: Diagnosis of nontuberculous mycobacteria (NTM) infections remains a challenge. In this study, we describe the evaluation of an immunological NTM-interferon (IFN)-γ release assay (IGRA) that we developed using glycopeptidolipids (GPLs) as NTM-specific antigens. Methods: We tested the NTM-IGRA in 99 samples from pediatric patients. Seventy-five were patients with lymphadenitis: 25 were NTM confirmed, 45 were of unknown etiology but compatible with mycobacterial infection and 5 had lymphadenitis caused by an etiologic agent other than NTM. The remaining 24 samples were from control individuals without lymphadenitis (latently infected with M.Tuberculosis, uninfected controls and active tuberculosis patients). Peripheral blood mononuclear cells were stimulated overnight with GPLs. Detection of IFN-γ producing cells was evaluated by enzyme-linked immunospot assay. Results: NTM culture-confirmed lymphadenitis patient samples had a significantly higher response to GPLs than the patients with lymphadenitis of unknown etiology but compatible with mycobacterial infection (P < 0.001) and lymphadenitis not caused by NTM (P < 0.01). We analyzed the response against GPLs in samples from unknown etiology lymphadenitis but compatible with mycobacterial infection cases according to the tuberculin skin test (TST) response, and although not statistically significant, those with a TST ≥5 mm had a higher response to GPLs when compared with the TST <5 mm group. Conclusions: Stimulation with GPLs yielded promising results in detecting NTM infection in pediatric patients with lymphadenitis. Our results indicate that the test could be useful to guide the diagnosis of pediatric lymphadenitis. This new NTM-IGRA could improve the clinical handling of NTM-infected patients and avoid unnecessary misdiagnosis and treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Proteomic profiling for prediction of recurrent cardiovascular event in patients with acute coronary syndrome and obstructive sleep apnea, A post-hoc analysis from the ISAACC study

  • Zapater, Andrea|||0000-0003-0543-2518
  • Gracia-Lavedan, Esther
  • Torres, Gerard|||0000-0002-1417-7320
  • Mínguez, Olga
  • Pascual, Lydia
  • Cortijo, Anunciación
  • Martínez López, Dolores
  • Benitez, Ivan David|||0000-0002-3558-5948
  • De Batlle, Jordi|||0000-0003-3500-6608
  • Henríquez-Beltrán, Mario E.
  • Abad Capa, Jorge|||0000-0002-8129-7859
  • Duran-Cantolla, Joaquin|||0000-0001-8172-9415
  • Urrutia Gajate, Amaia|||0000-0002-4088-4088
  • Mediano, Olga|||0000-0001-7824-1523
  • Masdeu, María José|||0000-0003-0437-2074
  • Ordax-Carbajo, Estrella
  • Masa, Juan Fernando
  • De la Peña, Mónica|||0000-0003-3276-776X
  • Mayos, Merce|||0000-0003-3972-3671
  • Coloma Navarro, Ramón|||0000-0002-4280-415X
  • Montserrat, Josep María
  • Chiner, Eusebi|||0000-0003-3374-4623
  • Barbé, Ferran|||0000-0002-2340-8928
  • Sánchez de la Torre, Manuel|||0000-0002-5695-348X
Obstructive sleep apnea (OSA) is associated with a recurrent cardiovascular event (CVE) risk in patients with a first acute coronary syndrome (ACS). However, the pathological pathways by which OSA promotes this deleterious role are unknown. We aim to explore the proteomic profile associated with OSA that promote the recurrent CVE risk in severe OSA patients with ACS without previous cardiovascular diseases. This post-hoc analysis from the ISAACC study (NCT01335087) included 86 patients admitted for ACS. Patients underwent respiratory polygraphy for the first 24-72 h to OSA diagnosis. We analyzed of 276 cardiovascular and inflammatory related proteins in baseline fasting plasma samples using proximity expression assay technology (Olink®, Sweden). Protein levels were compared between severe OSA patients with/without recurrent CVEs during follow-up. Random forest was conducted to select relevant proteins and generate a predictive model of recurrent CVE. We included 86 patients (median age: 61 years, median BMI: 29.4 kg/m and 86 % males) admitted for ACS with severe OSA (56 without recurrent CVE/30 with recurrent CVE). The plasma levels of 38 proteins were differentially expressed between groups. Additionally, 12 proteins had a significant association with respiratory polygraphy parameters. Three proteins discriminate with an AUC of 0.81 (95 % CI of 0.71-0.9) between severe OSA patients with and without recurrent CVE. These proteins were implicated in cell proliferation, communication and apoptosis, and regulation/response to the inflammatory and immune systems. In ACS patients with severe OSA, a proteomic profile was associated with recurrent CVEs. This proteomic profile was correlated with specific OSA parameters from respiratory polygraphy. Proteomic profiling may provide an new direction for patient risk stratification and clinical management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Brain correlates of impaired goal management in bipolar mania

  • Madre Rull, Mercè|||0000-0002-4660-3216
  • Fuentes-Claramonte, Paola|||0000-0002-1428-7976
  • Palau, Pol
  • Sáez, Naia
  • Moro, Noemí
  • Blanch, Clara
  • Verdolini, Norma|||0000-0001-9488-2881
  • Garcia-Leon, María Ángeles
  • Feria, Isabel
  • Munuera, Josep|||0000-0001-5154-1796
  • Sarró, Salvador|||0000-0003-1835-2189
  • Radua, Joaquim|||0000-0003-1240-5438
  • McKenna, Peter
  • Salvador, Raymond|||0000-0001-5557-1562
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
Although executive impairment has been reported in mania, its brain functional correlates have been relatively little studied. This study examined goal management, believed to be more closely related to executive impairment in daily life than other executive tasks, using a novel functional magnetic resonance imaging (fMRI) paradigm in patients in this illness phase. Twenty-one currently manic patients with bipolar disorder and 30 matched healthy controls were scanned while performing the Computerized Multiple Elements Test (CMET). This requires participants to sequentially play four simple games, with transition between games being made either voluntarily (executive condition) or automatically (control condition). CMET performance was impaired in the manic patients compared to the healthy controls. Manic patients failed to increase activation in the lateral frontal, cingulate and inferior parietal cortex when the executive demands of the task increased, while this increase was observed in the healthy controls. Activity in these regions was associated with task performance. Manic patients show evidence of impaired goal management, which is associated with a pattern of reduced medial and lateral frontal and parietal activity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study

  • García-Escobar, Eva|||0000-0002-0134-3473
  • Valdés, Sergio|||0000-0001-8623-4331
  • Soriguer, Federico|||0000-0002-1992-5666
  • Vendrell, Joan|||0000-0002-6994-6115
  • Urrutia Etxebarria, Inés M.|||0000-0001-5386-8776
  • Maldonado-Araque, Cristina
  • Ortega, Emilio|||0000-0002-2217-8905
  • Ocón, Pilar|||0000-0001-9257-2687
  • Montanya, Eduard|||0000-0003-2518-9076
  • Menéndez Torre, Edelmiro|||0000-0002-9548-7821
  • Lago-Sampedro, Ana Maria
  • González-Frutos, Teba
  • Gomis, Ramon|||0000-0002-7285-1328
  • Goday Arnó, Albert|||0000-0001-7356-1595
  • García-Serrano, Sara
  • Galán-García, José Luis|||0000-0002-8773-6998
  • Castell, Conxa|||0000-0003-2558-1959
  • Bordiú, Elena
  • Badía-Guillén, Rocío
  • Aguilera-Venegas, Gabriel|||0000-0002-5813-6184
  • Girbés, Juan|||0000-0002-1665-4549
  • Gaztambide, Sonia|||0000-0003-3569-2265
  • Delgado, Elias|||0000-0001-6114-9712
  • Chaves, Felilpe Javier|||0000-0001-8009-3689
  • Castaño, Luis|||0000-0003-0437-9401
  • Calle-Pascual, Alfonso
  • Rojo-Martínez, G.|||0000-0003-2179-2134
  • Franch-Nadal, Josep|||0000-0002-5175-1555
Our aim was to evaluate whether fatty liver index (FLI) is associated with the risk of type 2 diabetes (T2DM) development within the Spanish adult population and according to their prediabetes status; additionally, to examine its incremental predictive value regarding traditional risk factors. A total of 2260 subjects (Prediabetes: 641 subjects, normoglycemia: 1619 subjects) from the Di@bet.es cohort study were studied. Socio-demographic, anthropometric, clinical data and survey on habits were recorded. An oral glucose tolerance test was performed and fasting determinations of glucose, lipids and insulin were made. FLI was calculated and classified into three categories: Low (< 30), intermediate (30-60) and high (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Energy consumption and indoor environmental quality evaluation of a cooperative housing nZEB in Mediterranean climate

  • Ortiz, Joana|||0000-0002-2236-154X
  • Carrere, Juli|||0000-0001-5865-753X
  • Salom, Jaume|||0000-0001-7035-3248
  • Novoa, Ana M.|||0000-0002-5068-3503
A cooperative housing is a more democratic and affordable alternative that could contribute to ecological sustainability in local context. The paper evaluates the cooperative housing La Borda (Barcelona) from two points of view: energy consumption at building and household level and indoor environmental quality of six representative households. The evaluation aims to investigate how this housing alternative may contribute to reduce the energy impact of the building providing comfortable conditions to the users. A post-occupancy evaluation has been performed where energy consumption, environmental data and user perception have been gathered to make a qualitative and quantitate analysis. The paper wants to investigate how thermal comfort can be characterized in depth, analysing only air temperature, relative humidity and outdoor conditions. Furthermore, it has been paid especial attention to the overheating analysis and the impact of the relative humidity in the thermal comfort satisfaction of the occupants. The paper demonstrates that La Borda is a model that contributes to reduce the energy impact of the building, which can be related to some of the characteristics of the cooperative housings: sharing goods and resources; community support; training initiatives; strong involvement during the design of the project; and sustainable design of the building. The thermal comfort evaluation combines different tools (adaptive comfort model, Givoni psychometric chart, Heat Index and surveys) to achieve a good understanding of the thermal behaviour of households and comfort perception, achieving satisfactory results; However, some discrepancies have been found between the different indicators and qualitative perception of the users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sexismo y violencia de pareja en adolescentes, Sexism and intimate partner violence in adolescents

  • Madrona-Bonastre, Raquel|||0000-0002-4306-3744
  • Sanz-Barbero, Belén|||0000-0001-6030-061X
  • Pérez Martínez, Vanesa|||0000-0003-1811-0382
  • Abiétar, Daniel G.|||0000-0002-5268-3574
  • Sánchez-Martínez, Francesca|||0000-0001-8198-1661
  • Forcadell Díez, Lluís|||0000-0002-3934-4666
  • Pérez Albarracín, Glòria|||0000-0001-6653-3393
  • Vives-Cases, Carmen|||0000-0002-6797-5051
Objetivo: A pesar de los esfuerzos para reducir la desigualdad de género, el sexismo persiste. Todavía son escasos los estudios sobre este fenómeno que contemplen variables como el deseo sexual o los antecedentes migratorios. El objetivo del estudio es analizar las circunstancias sociales (individuales y del contexto inmediato) asociadas al sexismo y su relación con la conducta violenta en la pareja en población adolescente. Método: Estudio transversal con 1421 estudiantes de 13 a 17 años de Alicante y Terrassa (2019-2020). El sexismo se midió mediante el Ambivalent Sexism Inventory, que valora el sexismo ambivalente, hostil y benevolente. Se utilizaron modelos lineales generalizados estratificados por sexo para identificar variables asociadas al sexismo, y regresión logística para analizar la asociación del sexismo con la conducta violenta en la pareja. Resultados: La probabilidad de puntuar alto en sexismo ambivalente fue mayor en migrantes (chicas y chicos: p < 0,01) e hijos/as de migrantes (chicas: p < 0,01; chicos: p < 0,05). El deseo no heterosexual se asoció negativamente con el sexismo en chicas (benevolente: p < 0,01) y en chicos (ambivalente y hostil: p < 0,01; benevolente: p < 0,05). El sexismo hostil mostró asociación con cometer violencia de pareja, independientemente del resto de las variables, tanto en chicas (odds ratio [OR]: 1,07; intervalo de confianza del 95% [IC95%]: 1,00-1,14) como en chicos (OR: 1,11; IC95%: 1,03-1,20). Conclusiones: El sexismo está presente entre adolescentes y se confirma su relación con la conducta violenta en la pareja. El deseo sexual y los antecedentes migratorios son variables a tener en cuenta en su prevención., Despite the efforts to reduce gender inequality, sexism persists. There are still few studies on this matter that consider variables such as sexual desire or migration background. The aim of this study is to analyse the social circumstances (individual and from the immediate context) associated with sexism as well as its relationship with intimate partner violence perpetration amongst adolescents. Cross-sectional study with 1421 students aged 13-17 from Alicante and Terrassa (2019-2021). Sexism was measured with the Ambivalent Sexism Inventory, which assesses ambivalent, hostile and benevolent sexism. Generalized linear models were carried out and stratified by sex to identify variables associated with sexism. A logistic regression model was used to assess the association between sexism and intimate partner violence. The likelihood of a high score in ambivalent sexism was higher in migrants (girls and boys: p < 0.01) and adolescents with migrant parents (girls: p < 0.01; boys: p < 0.05). Non-heterosexual desire was negatively associated with sexism in girls (benevolent: p < 0.01) and boys (ambivalent and hostile: p < 0.01; benevolent: p < 0.05). Hostile sexism showed association with intimate partner violence perpetration, independently of the rest of the adjustment variables included in the model, for both girls (odds ratio [OR]: 1.07; 95% confidence interval [95% CI]: 1.00-1.14) and boys (OR: 1.11; 95% CI: 1.03-1.20). Sexism is present amongst teenagers and its relationship with intimate partner violence is confirmed. Sexual desire and migration background should be taken into account for intimate partner violence prevention.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Estrategia de promoción de relaciones equitativas y saludables en centros educativos de Barcelona, Strategy for the promotion of equitable and healthy relationships in educational centers in Barcelona

  • Pérez Albarracín, Glòria|||0000-0001-6653-3393
  • Bartroli, Montserrat|||0000-0002-4553-9961
  • Pasarín, M. Isabel|||0000-0002-4809-1250
  • Artazcoz, Lucía|||0000-0002-6300-5111
  • Juárez Martínez, Olga|||0000-0001-5343-6295
El sistema educativo es uno de los agentes de socialización más potentes. Puede contribuir a perpetuar el sistema de género o por el contrario reducir la violencia mediante la promoción de modelos de relación más equitativos y saludables. La Agència de Salut Pública de Barcelona se propuso diseñar una estrategia de prevención de la violencia mediante la promoción de las relaciones equitativas y saludables en los diferentes niveles educativos de los centros educativos de la ciudad de Barcelona. El objetivo de este artículo es presentar el proceso de desarrollo de esta estrategia. Sus características son: 1) utilización de un enfoque participativo para garantizar la calidad y la coherencia del proceso; 2) creación de un marco teórico para la estrategia; 3) utilización de la metodología de mapeo de intervenciones como estrategia para el diagnóstico, la planificación, el diseño, el desarrollo y la evaluación de las intervenciones de promoción de relaciones equitativas y saludables; y 4) adaptación o diseño y evaluación de diversos programas para incorporar a las diferentes etapas educativas. Se argumenta que la estrategia diseñada se considera adecuada porque planea las intervenciones de promoción de relaciones equitativas y saludables enmarcadas en una estrategia educativa global que se inicie en etapas tempranas de la educación infantil y se continúe en todas las etapas educativas obligatorias. Esta estrategia se basa en un marco conceptual que tiene en cuenta los determinantes y las desigualdades sociales en la salud, y que promueve un enfoque basado en la promoción de activos en salud y el uso de metodologías participativas., The educational system is one of the most powerful agents of socialization; it can contribute to perpetuate the gender system and tolerance towards violence or on the contrary, to reduce violence by promoting more equitable and healthy relationship models. The Agència de Salut Pública de Barcelona set out to design a strategy to prevent violence by promoting equitable and healthy relationships at different educational levels in schools in the city of Barcelona. The objective of this article is to present the process of developing this strategy. They characteristics are: (1) use of a participatory approach to ensure the quality and coherence of the process; (2) creation of a theoretical framework for the strategy; (3) use of the intervention mapping methodology as a strategy for the diagnosis, planning, design, development and evaluation of interventions to promote equitable and healthy relationships; and (4) adaptation or design and evaluation of different programs to incorporate different educational stages. It is argued that the strategy designed is considered adequate because it plans interventions to promote equitable and healthy relationships framed within a global educational strategy that starts in the early stages of early childhood education and is continued in all compulsory educational stages. This strategy is based on a conceptual framework that takes into account the determinants and social inequalities in health and promotes an approach based on the promotion of health assets and the use of participatory methodologies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Falls Predict Acute Hospitalization in Parkinson's Disease

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Cores, Carlos
  • Suarez Castro, Ester
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Mir, Pablo|||0000-0003-1656-302X
  • Cosgaya, Marina
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Pastor, Pau|||0000-0002-7493-8777
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • Seijo, Manuel
  • Legarda, Inés
  • Vives, Bárbara
  • Caballol, Nuria|||0000-0003-3363-3077
  • Ruiz Martinez, Javier
  • Croitoru, Ioana
  • Cubo, Esther|||0000-0003-0018-1182
  • Miranda, Javier
  • Alonso Losada, Maria Gema
  • Labandeira, Carmen
  • Lopez Ariztegui, Nuria
  • Morales-Casado, Mabel
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Infante, Jon|||0000-0003-4025-4606
  • Escalante, Sonia|||0000-0001-8931-1400
  • Bernardo, Noemí
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Menéndez González, Manuel
  • Garcia Caldentey, Juan
  • Borrue, Carmen
  • Vela, Lydia|||0000-0001-6663-395X
  • Catalán Alonso, Maria José
  • Gomez Mayordomo, Víctor
  • Kurtis, Mónica|||0000-0003-3037-9712
  • Prieto, Cristina|||0000-0002-0812-8100
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • Nogueira, Víctor
  • Lopez Manzanares, Lydia
  • Ávila Rivera, Maria Asunción
  • Puente, Victor
  • García Moreno, José Manuel
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Carrillo Padilla, Francisco
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Gaston, Itziar
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Valero, Caridad
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • González Ardura, Jessica
  • Lopez Diaz, Luis Manuel
  • Martínez Martín, Pablo|||0000-0003-0837-5280
There is a need for identifying risk factors for hospitalization in Parkinson's disease (PD) and also interventions to reduce acute hospital admission. Objective: To analyze the frequency, causes, and predictors of acute hospitalization (AH) in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015) cohort from January 2016 to November 2017, were included in the study. In order to identify predictors of AH, Kaplan-Meier estimates of factors considered as potential predictors were obtained and Cox regression performed on time to hospital encounter 1-year after the baseline visit. Thirty-five out of 605 (5.8%) PD patients (62.5±8.9 years old; 59.8% males) presented an AH during the 1-year follow-up after the baseline visit. Traumatic falls represented the most frequent cause of admission, being 23.7% of all acute hospitalizations. To suffer from motor fluctuations (HR [hazard ratio] 2.461; 95% CI, 1.065-5.678; p = 0.035), a very severe non-motor symptoms burden (HR [hazard ratio] 2.828; 95% CI, 1.319-6.063; p = 0.008), falls (HR 3.966; 95% CI 1.757-8.470; p = 0.001), and dysphagia (HR 2.356; 95% CI 1.124-4.941; p = 0.023) was associated with AH after adjustment to age, gender, disease duration, levodopa equivalent daily dose, total number of non-antiparkinsonian drugs, and UPDRS-IIIOFF. Of the previous variables, only falls (HR 2.998; 95% CI 1.080-8.322; p = 0.035) was an independent predictor of AH. Falls is an independent predictor of AH in PD patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Priming Mesenchymal Stem Cells with Lipopolysaccharide Boosts the Immunomodulatory and Regenerative Activity of Secreted Extracellular Vesicles

  • Areny-Balagueró, Aina|||0000-0001-9611-1781
  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Campaña-Duel, Elena|||0000-0002-0658-6255
  • Solé-Porta, Anna|||0000-0002-6129-4087
  • Ceccato, Adrian|||0000-0001-9454-062X
  • Roig i Serra, Anna|||0000-0001-6464-7573
  • Laffey, John|||0000-0002-1246-9573
  • Closa Autet, Daniel|||0000-0003-3797-3095
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
Background: Mesenchymal stem cells (MSCs)-derived extracellular vesicles (EVs) have been proposed as an alternative to live-cell administration for Acute Respiratory Distress Syndrome (ARDS). MSC-EVs can be chiefly influenced by the environment to which the MSCs are exposed. Here, lipopolysaccharide (LPS) priming of MSCs was used as a strategy to boost the natural therapeutic potential of the EVs in acute lung injury (ALI). Methods: The regenerative and immunemodulatory effect of LPS-primed MSC-EVs (LPS-EVs) and non-primed MSC-EVs (C-EVs) were evaluated in vitro on alveolar epithelial cells and macrophage-like THP-1 cells. In vivo, ALI was induced in adult male rats by the intrapulmonary instillation of HCl and LPS. Rats (n = 8 to 22/group) were randomized to receive a single bolus (1 × 10 particles) of LPS-EVs, C-EVs, or saline. Lung injury severity was assessed at 72 h in lung tissue and bronchoalveolar lavage. Results: In vitro, LPS-EVs improved wound regeneration and attenuated the inflammatory response triggered by the P. aeruginosa infection, enhancing the M2 macrophage phenotype. In in vivo studies, LPS-EVs, but not C-EVs, significantly decreased the neutrophilic infiltration and myeloperoxidase (MPO) activity in lung tissue. Alveolar macrophages from LPS-EVs-treated animals exhibited a reduced expression of CXCL-1, a key neutrophil chemoattractant. However, both C-EVs and LPS-EVs reduced alveolar epithelial and endothelial permeability, mitigating lung damage. Conclusions: EVs from LPS-primed MSCs resulted in a better resolution of ALI, achieving a greater balance in neutrophil infiltration and activation, while avoiding the complete disruption of the alveolar barrier. This opens new avenues, paving the way for the clinical implementation of cell-based therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis

  • Pose, Elisa|||0000-0002-0224-7686
  • Solà, Elsa|||0000-0001-6897-2760
  • Lozano, Juan José
  • Juanola, Adrià|||0000-0003-4832-5130
  • Sidorova, Julia
  • Zaccherini, Giacomo|||0000-0002-3219-6963
  • de Wit, Koos|||0000-0001-8472-8549
  • Uschner, Frank
  • Tonon, Marta
  • Kazankov, Konstantin
  • Jiménez, Cesar|||0000-0003-2455-2048
  • Campion, Daniela
  • Napoleone, Laura
  • Ma, Ann T.|||0000-0002-9059-111X
  • Carol, Marta
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Alessandria, Carlo|||0000-0001-5468-694X
  • Beuers, Ulrich
  • Caraceni, Paolo|||0000-0002-1439-056X
  • Francoz, Claire|||0000-0001-7391-8507
  • Durand, François
  • Mookerjee, Rajeshwar P.
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Vargas Blasco, Víctor|||0000-0002-7190-6948
  • Piano, Salvatore|||0000-0002-9356-5830
  • Watson, Hugh|||0000-0002-6931-3158
  • Abraldes, Juan G.|||0000-0003-3421-937X
  • Kamath, P.S.|||0000-0002-7888-1165
  • Davis, Mark M.
  • Ginès, Pere|||0000-0003-4657-4504
Patients with decompensated cirrhosis, particularly those with acute-on-chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma metabolites of patients with decompensated cirrhosis, specifically on compounds characteristic of the ACLF plasma metabolomic profile. Two cohorts of patients were investigated. The first was a descriptive cohort of patients with decompensated cirrhosis (n = 42), with and without ACLF. The second was an intervention cohort from the LIVERHOPE-SAFETY randomized, double-blind, placebo-controlled trial treated with simvastatin 20 mg/day plus rifaximin 1,200 mg/day (n = 12) or matching placebo (n = 13) for 3 months. Plasma samples were analyzed using ultrahigh performance liquid chromatography-tandem mass spectroscopy for plasma metabolomics characterization. ACLF was characterized by intense proteolysis and lipid alterations, specifically in pathways associated with inflammation and mitochondrial dysfunction, such as the tryptophan-kynurenine and carnitine beta-oxidation pathways. An ACLF-specific signature was identified. Treatment with simvastatin and rifaximin was associated with changes in 161 of 985 metabolites in comparison to treatment with placebo. A remarkable reduction in levels of metabolites from the tryptophan-kynurenine and carnitine pathways was found. Notably, 18 of the 32 metabolites of the ACLF signature were affected by the treatment. Conclusion: Treatment with simvastatin and rifaximin modulates some of the pathways that appear to be key in ACLF development. This study unveils some of the mechanisms involved in the effects of treatment with simvastatin and rifaximin in decompensated cirrhosis and sets the stage for the use of metabolomics to investigate new targeted therapies in cirrhosis to prevent ACLF development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer, A Mapping Review and Evidence Gap Map

  • Requeijo, Carolina|||0000-0003-3479-4550
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Meza, Nicolás|||0000-0001-9505-0358
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Salazar, Josefina|||0000-0002-6448-5946
  • Santero, Marilina|||0000-0001-5371-0979
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Rodríguez-Grijalva, Gerardo
  • Selva, Anna|||0000-0002-2754-3158
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Urrútia, Gerard|||0000-0002-8850-0960
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Despite being commonly recommended, the impact of anticancer drugs (ACDs) on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) may not have been sufficiently assessed. We aim to identify and map the evidence regarding ACDs versus best supportive care (BSC) for advanced HBCs, considering patient-centered outcomes. In this mapping review, we included systematic reviews, randomized controlled trials, quasi-experimental, and observational studies comparing ACDs (chemotherapy, immunotherapy, biological/targeted therapy) versus BSC for advanced HBCs. We searched MEDLINE (PubMed), EMBASE (Ovid), Cochrane Library, Epistemonikos, PROSPERO and clinicaltrials.gov for eligible studies. Two reviewers performed the screening and data extraction processes. We developed evidence maps for each type of cancer. We included 87 studies (60 for advanced liver cancer and 27 for gallbladder or bile duct cancers). Most of the evidence favored ACDs for survival outcomes, and BSC for toxicity. We identified several evidence gaps for non-survival outcomes, including quality of life or quality of end-of-life care. Patient-important outcomes beyond survival in advanced HBCs are insufficiently assessed by the available evidence. Future studies need to address these gaps to better inform decision-making processes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Scheeren Brum, Wagner|||0000-0002-9777-0559
  • Molfetta, Guglielmo Di
  • Benedet, Andréa Lessa
  • Arslan, Burak
  • Jonaitis, Erin Mc Mullen
  • Langhough, Rebecca E.
  • Cody, Karly Alex
  • Wilson, Rachael E.
  • Carlsson, Cynthia M.
  • Vanmechelen, Eugeen|||0000-0002-9466-5366
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Rahmouni, Nesrine
  • Tissot, Cécile
  • Stevenson, Jenna
  • Servaes, Stijn|||0000-0002-4431-957X
  • Therriault, Joseph
  • Pascoal, Tharick|||0000-0001-9057-8014
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Johnson, Sterling C.
  • Jeromin, Andreas
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
IMPORTANCE Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests. OBJECTIVE To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across 3 selected cohorts. DESIGN, SETTING, AND PARTICIPANTS This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017-August 2021) and Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort (visits February 2007-November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009-November 2021). Participants included individuals with and without cognitive impairment grouped by amyloid and tau (AT) status using PET or CSF biomarkers. Data were analyzed from February to June 2023. EXPOSURES Magnetic resonance imaging, Aβ positron emission tomography (PET), tau PET, cerebrospinal fluid (CSF) biomarkers (Aβ42/40 and p-tau immunoassays), and plasma p-tau217 (ALZpath pTau217 assay). MAIN OUTCOMES AND MEASURES Accuracy of plasma p-tau217 in detecting abnormal amyloid and tau pathology, longitudinal p-tau217 change according to baseline pathology status. RESULTS The study included 786 participants (mean [SD] age, 66.3 [9.7] years; 504 females [64.1%] and 282 males [35.9%]). High accuracy was observed in identifying elevated Aβ (area under the curve [AUC], 0.92-0.96; 95% CI, 0.89-0.99) and tau pathology (AUC, 0.93-0.97; 95% CI, 0.84-0.99) across all cohorts. These accuracies were comparable with CSF biomarkers in determining abnormal PET signal. The detection of abnormal Aβ pathology using a 3-range reference yielded reproducible results and reduced confirmatory testing by approximately 80%. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. CONCLUSIONS AND RELEVANCE This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction

  • Planas-Cerezales, Lurdes|||0000-0001-7636-444X
  • Arias-Salgado, Elena G.
  • Berastegui García, Cristina|||0000-0001-9774-9349
  • Montes-Worboys, Ana|||0000-0002-3204-779X
  • González-Montelongo, Rafaela
  • Lorenzo-Salazar, José. M.
  • Vicens-Zygmunt, Vanesa|||0000-0002-0940-3215
  • Garcia-Moyano, Marta
  • Dorca, Jordi|||0000-0002-8137-878X
  • Flores, Carlos|||0000-0001-5352-069X
  • Perona, Rosario|||0000-0002-2973-5153
  • Roman Broto, Antonio|||0000-0002-9417-3484
  • Molina Molina, Maria|||0000-0002-1852-1723
Introduction: Fibrotic interstitial lung diseases (ILDs) are the first indication for lung transplantation (LT). Telomere dysfunction has been associated with poor post-transplant outcomes. The aim of the study was to evaluate the morbi-mortality and quality of life in fibrotic ILDs after lung transplant depending on telomere biology. Methods: Fibrotic ILD patients that underwent lung transplant were allocated to two arms; with or without telomere dysfunction at diagnosis based on the telomere length and telomerase related gene mutations revealed by whole-exome sequencing. Post-transplant evaluation included: (1) short and long-term mortality and complications and (2) quality of life. Results: Fifty-five percent of patients that underwent LT carried rare coding mutations in telomerase-related genes. Patients with telomere shortening more frequently needed extracorporeal circulation and presented a higher rate of early post-transplant hematological complications, longer stay in the intensive care unit (ICU), and a higher number of long-term hospital admissions. However, post-transplant 1-year survival was higher than 80% regardless of telomere dysfunction, with improvement in the quality of life and oxygen therapy withdrawal. Conclusions: Post-transplant morbidity is higher in patients with telomere dysfunction and differs according to elapsed time from transplantation. However, lung transplant improves survival and quality of life and the associated complications are manageable.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Widespread intra-axonal signal fraction abnormalities in bipolar disorder from multicompartment diffusion, Sensitivity to diagnosis, association with clinical features and pharmacologic treatment

  • Canales-Rodriguez, Erick Jorge|||0000-0001-6421-2633
  • Verdolini, Norma|||0000-0001-9488-2881
  • Alonso-Lana, Silvia|||0000-0002-3063-6929
  • Torres, María Llanos
  • Panicalli, Francesco
  • Argila-Plaza, Isabel|||0000-0002-1604-4708
  • Rodriguez-Cano, Elena
  • Montoro, Irene
  • Garcia-Ruiz, Beatriz
  • Jimenez, Esther|||0000-0001-6929-6207
  • Varo, Cristina|||0000-0002-8859-3052
  • Lluch, Anna
  • del Mar Bonnin, Caterina
  • Maluf, Silvana
  • Pujol, Marc
  • Jaurrieta Guarner, Núria
  • Sarró, Salvador|||0000-0003-1835-2189
  • Vieta, Eduard|||0000-0002-0548-0053
  • Vilella, Elisabet|||0000-0002-1887-5919
  • Salvador, Raymond|||0000-0001-5557-1562
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
Despite diffusion tensor imaging (DTI) evidence for widespread fractional anisotropy (FA) reductions in the brain white matter of patients with bipolar disorder, questions remain regarding the specificity and sensitivity of FA abnormalities as opposed to other diffusion metrics in the disorder. We conducted a whole-brain voxel-based multicompartment diffusion MRI study on 316 participants (i.e., 158 patients and 158 matched healthy controls) employing four diffusion metrics: the mean diffusivity (MD) and FA estimated from DTI, and the intra-axonal signal fraction (IASF) and microscopic axonal parallel diffusivity (Dpar) derived from the spherical mean technique. Our findings provide novel evidence about widespread abnormalities in other diffusion metrics in BD. An extensive overlap between the FA and IASF results suggests that the lower FA in patients may be caused by a reduced intra-axonal volume fraction or a higher macromolecular content in the intra-axonal water. We also found a diffuse alteration in MD involving white and grey matter tissue and more localised changes in Dpar. A Machine Learning analysis revealed that FA, followed by IASF, were the most helpful metric for the automatic diagnosis of BD patients, reaching an accuracy of 72%. Number of mood episodes, age of onset/duration of illness, psychotic symptoms, and current treatment with lithium, antipsychotics, antidepressants, and antiepileptics were all significantly associated with microstructure abnormalities. Lithium treatment was associated with less microstructure abnormality. A whole-brain voxel-based approach combining DTI and SMT diffusion-derived metrics to reveal specific brain tissue microstructure abnormalities in bipolar disorder (BD) was carried out. We also evaluate the sensitivity of various diffusion metrics for the automatic diagnosis of BD through machine learning algorithms and cross-validation. Finally, we look for differences between BD subtypes and the possible effect of duration of illness, age at onset, history of psychosis, and pharmacological treatment with lithium, antidepressant, antipsychotic, and antiepileptic drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Factors Associated with Non-Adherence to Tuberculosis Preventive Treatment among Adult Contacts of Pulmonary Tuberculosis Cases with Latent Tuberculosis Infection in Catalonia, Spain, in 2019-2021

  • Plans-Rubió, Pedro|||0000-0002-4424-2971
  • Godoy, Sofia
  • Toledo, Diana|||0000-0003-0794-9238
  • Domínguez, Ángela|||0000-0003-0219-1907
  • Caylà, Joan A.|||0000-0003-3891-111X
  • Parrón, Ignacio|||0000-0002-4875-0236
  • Millet, Joan Pau|||0000-0003-0200-2459
  • Godoy, Pere|||0000-0002-2896-7286
The aim of this study was to identify factors associated with non-adherence to tuberculosis (TB) preventive treatment among contacts with latent TB infection for new cases of pulmonary TB cases reported in Catalonia in 2019-2021. All contacts aged 18 years or older with a latent TB infection who received a TB preventive treatment were included in the study. The Chi square test and the odds ratios (OR) were used to assess the association between non-adherence to TB preventive treatment and the study variables; a p < 0.05 was considered statistically significant. Multiple logistic regression analysis was used to detect the independent factors associated with TB preventive treatment non-adherence; a p < 0.05 was considered statistically significant. The percentage of non-adherence to TB preventive treatment found in this study was 23.7%. A multivariable logistic regression analysis determined that the following factors were significantly associated with TB preventive treatment non-adherence among adult contacts: "exposure at school or workplace" (aOR = 3.34), "exposure to an index case without laboratory confirmation of TB" (aOR = 2.07), "immigrant contact" (aOR = 1.81), "male gender" (aOR = 1.75) and "exposure duration < 6 h per week or sporadic" (aOR = 1.60. By contrast, the factor "short-term TB preventive treatment regimen" (aOR = 0.38) was significantly associated with a lower treatment non-adherence. Adherence to TB preventive treatment should be improved among adult contacts of TB pulmonary cases with latent TB infection by recommending short-term treatment regimens and by developing health education activities, with a greater focus on contacts with factors associated with treatment non-adherence.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Survival Outcomes in Sinonasal Mucosal Melanoma, Systematic Review and Meta-Analysis

  • Rojas-Lechuga, María Jesús|||0000-0002-1402-5167
  • Jubés, Sara
  • Molina-García, Manuel|||0000-0003-4218-9756
  • da Silva-Júnior, Rui Milton Patricio
  • Sampieri, Claudio
  • Langdon, Cristóbal
  • Gras Cabrerizo, Juan Ramón|||0000-0001-9674-1783
  • Bernal Sprekelsen, Manuel
  • Puig, Susana|||0000-0003-1337-9745
  • Alobid, Isam|||0000-0001-7204-5599
Background/Objectives : Sinonasal mucosal melanomas (SNMMs) are rare and aggressive malignancies with poor survival outcomes. Our systematic review and meta-analysis aim to evaluate overall survival (OS) rates in patients with SNMM; Methods : We conducted a systematic search, following PRISMA guidelines across PubMed, Web of Science (WOS), and citation searching for studies reporting survival and prognosis outcomes for SNMMs. Inclusion criteria included studies with 5-year OS rates. Studies were excluded if they included tumor sites other than the paranasal sinuses or nasal cavity, were published in languages other than English and Spanish, or had a sample size of fewer than 15 patients. Two reviewers independently screened studies, extracted data, and assessed study quality using the Joanna Briggs Institute (JBI) critical appraisal checklist. Analyses of survival probabilities were conducted. Meta-analyses were performed using a random-effects model. PROSPERO ID CRD42024565137; Results : A total of 515 articles were identified after removing duplicates, and 99 reports were assessed for eligibility. Of these, 35 studies were included in the meta-analysis, encompassing a total of 2383 SNMM patients, of whom 1192 (50%) were female, with a weighted mean age of 65.4 years (SD = 5.4). Fifteen studies were from Europe (42.9%), six (17.1%) were from America, eleven (31.4%) were from Asia, two (5.7%) were from Australia, and one (2.9%) combined European, United Kingdom, and American populations. The 5-year OS was 34.8 [95% CI = 30.6-39.5], with the highest OS in America at 40.5 [95% CI = 34.1-48.1], followed by Europe at 36.6 [95% CI = 30.6-43.7], Australia at 32.3 [95% CI = 12.5-83.8], and Asia at 28.1 [95% CI = 19.5-40.7]. The age-standardized incidence rate (ASIR) for SNMM ranges was between 0.07 and 0.14 per 100,000 persons/year, with a slightly higher incidence in women than in men; Conclusions : This meta-analysis, one of the largest to date on SNMM, confirms the aggressive nature of this melanoma subtype with poor survival outcomes. Despite geographic differences in survival rates, the overall 5-year survival remains low, highlighting the urgent need for improved treatment strategies and more research to improve patient outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhancing immunotherapy through -1 upregulation, the promising combination of anti--1 plus m inhibitors

  • Hernández-Prat, Anna|||0000-0002-8233-1035
  • Rodriguez-Vida, Alejo|||0000-0002-7304-6857
  • Cardona, Laura
  • Qin, Mengjuan|||0000-0001-7014-7188
  • Arpí-Llucià, Oriol
  • Soria-Jiménez, Luis|||0000-0002-2182-8953
  • Menéndez, Sílvia|||0000-0002-9116-8743
  • Quimis, Fabricio Gerel
  • Galindo, Miguel
  • Arriola, Edurne|||0000-0001-8960-7519
  • Salido, Marta|||0000-0001-9988-5977
  • Juanpere-Rodero, Nuria
  • Rojo, Federico|||0000-0001-9989-0290
  • Muntasell i Castellví, Aura|||0000-0003-2894-0486
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Rovira, Ana|||0000-0003-1301-2599
  • Bellmunt, Joaquim|||0000-0003-2328-3421
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway have transformed urothelial cancer (UC) therapy. The correlation between PD-L1 expression and ICI effectiveness is uncertain, leaving the role of PD-L1 as a predictive marker for ICI efficacy unclear. Among several ways to enhance the efficacy of ICI, trials are exploring combining ICIs with serine/threonine-protein kinase mTOR (mTOR) inhibitors in different tumor types. The potential interaction between mTOR inhibitors and PD-L1 expression in UC has not been well characterized. In our study, we investigated how phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway inhibitors (TAK-228, everolimus and TAK-117) affect PD-L1 expression and function in preclinical bladder cancer cell models. TAK-228 increased cell surface levels of glycosylated PD-L1 in all but one of the seven cell lines, regardless of baseline levels. TAK-228 promoted the secretion of epidermal growth factor (EGF) and interferon-β (IFNβ), both linked to PD-L1 protein induction. Blocking EGF and IFNβ receptors reversed the TAK-228-induced PD-L1 increase. Additionally, TAK-228 enhanced IFN-γ-induced PD-L1 expression and intracellular HLA-I levels in some cells. TAK-228-treated bladder cancer cells exhibited resistance to the cytotoxic effects of peripheral blood mononuclear cells (PBMCs) and cluster of differentiation 8 (CD8)+ T cells. The addition of an anti-PD-L1 antibody diminished this resistance in T24 cells. Increased expression of PD-L1 under TAK-228 exposure was confirmed in patient-derived explants (PDEs) treated ex vivo. These preclinical findings suggest that mTOR inhibition with TAK-228 can increase PD-L1 levels, potentially impacting the specific immune response against UC cells. This highlights the rationale for exploring the combination of mTOR inhibitors with ICIs in patients with advanced UC. mTOR inhibition with TAK-228 can increase PD-L1 levels, potentially impacting the specific immune response against bladder cancer cell lines.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI

  • Aranha, Mateus|||0000-0001-9594-292X
  • Montal, Victor|||0000-0002-5714-9282
  • van den Brink, Hilde
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Benejam, Bessy|||0000-0002-6789-8615
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Ribas, Laia
  • Alcolea, Daniel|||0000-0002-3819-3245
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Bargalló, Núria|||0000-0001-6284-5402
  • Biessels, Geert Jan|||0000-0001-6862-2496
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Coutinho, Artur Martins|||0000-0002-5555-4583
  • Leite, Cláudia Costa
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Fortea, Juan|||0000-0002-1340-638X
Cortical microinfarcts (CMI) were attributed to cerebrovascular disease and cerebral amyloid angiopathy (CAA). CAA is frequent in Down syndrome (DS) while hypertension is rare, yet no studies have assessed CMI in DS. We included 195 adults with DS, 63 with symptomatic sporadic Alzheimer's disease (AD), and 106 controls with 3T magnetic resonance imaging. We assessed CMI prevalence in each group and CMI association with age, AD clinical continuum, vascular risk factors, vascular neuroimaging findings, amyloid/tau/neurodegeneration biomarkers, and cognition in DS. CMI prevalence was 11.8% in DS, 4.7% in controls, and 17.5% in sporadic AD. In DS, CMI increased in prevalence with age and the AD clinical continuum, was clustered in the parietal lobes, and was associated with lacunes and cortico-subcortical infarcts, but not hemorrhagic lesions. In DS, CMI are posteriorly distributed and related to ischemic but not hemorrhagic findings suggesting they might be associated with a specific ischemic CAA phenotype. This is the first study to assess cortical microinfarcts (assessed with 3T magnetic resonance imaging) in adults with Down syndrome (DS). We studied the prevalence of cortical microinfarcts in DS and its relationship with age, the Alzheimer's disease (AD) clinical continuum, vascular risk factors, vascular neuroimaging findings, amyloid/tau/neurodegeneration biomarkers, and cognition. The prevalence of cortical microinfarcts was 11.8% in DS and increased with age and along the AD clinical continuum. Cortical microinfarcts were clustered in the parietal lobes, and were associated with lacunes and cortico-subcortical infarcts, but not hemorrhagic lesions. In DS, cortical microinfarcts are posteriorly distributed and related to ischemic but not hemorrhagic findings suggesting they might be associated with a specific ischemic phenotype of cerebral amyloid angiopathy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Two Novel Variants in YARS2 Gene Are Responsible for an Extended MLASA Phenotype with Pancreatic Insufficiency

  • Carreño Gago, Lidia
  • Juarez-Flores, Diana Luz|||0000-0003-3615-7803
  • Grau, Josep M.|||0000-0001-7560-224X
  • Ramón, Javier|||0000-0002-0673-9338
  • Lozano, Ester|||0000-0002-6307-9807
  • Vila-Julià, Ferran
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Garrabou, Glòria|||0000-0001-8973-9933
  • García Arumí, Elena|||0000-0003-1848-005X
Pathogenic variants in the mitochondrial tyrosyl-tRNA synthetase gene (YARS2) were associated with myopathy, lactic acidosis, and sideroblastic anemia (MLASA). However, patients can present mitochondrial myopathy, with exercise intolerance and muscle weakness, leading from mild to lethal phenotypes. Genes implicated in mtDNA replication were studied by Next Generation Sequencing (NGS) and whole exome sequence with the TruSeq Rapid Exome kit (Illumina, San Diego, CA, USA). Mitochondrial protein translation was studied following the Sasarman and Shoubridge protocol and oxygen consumption rates with Agilent Seahorse XF24 Analyzer Mitostress Test, (Agilent, Santa Clara, CA, USA). We report two siblings with two novel compound heterozygous pathogenic variants in YARS2 gene: a single nucleotide deletion in exon 1, c.314delG (p.(Gly105Alafs*4)), which creates a premature stop codon in the amino acid 109, and a single nucleotide change in exon 5 c.1391T.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased grey matter volumes in the temporal lobe and its relationship with cognitive functioning in euthymic patients with bipolar disorder

  • Porta-Casteràs, Daniel|||0000-0002-3921-3607
  • Vicent Gil, Muriel|||0000-0001-7534-5095
  • Serra Blasco, Maria|||0000-0001-5793-9906
  • Navarra-Ventura, Guillem|||0000-0001-9839-7357
  • Solé, Brisa|||0000-0003-1673-8248
  • Montejo, Laura|||0000-0003-4407-9454
  • Torrent, Carla|||0000-0003-0335-582X
  • Martínez-Àran, Anabel|||0000-0002-0623-6263
  • De la Peña-Arteaga, Víctor|||0000-0001-8627-2653
  • Palao, Diego|||0000-0002-3323-6568
  • Vieta, Eduard|||0000-0002-0548-0053
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Cano, Marta|||0000-0003-0675-9483
Bipolar disorder (BD) is characterized by episodic mood dysregulation, although a significant portion of patients suffer persistent cognitive impairment during euthymia. Previous magnetic resonance imaging (MRI) research suggests BD patients may have accelerated brain aging, observed as lower grey matter volumes. How these neurostructural alterations are related to the cognitive profile of BD is unclear. We aim to explore this relationship in euthymic BD patients with multimodal structural neuroimaging. A sample of 27 euthymic BD patients and 24 healthy controls (HC) underwent structural grey matter MRI and diffusion-weighted imaging (DWI). BD patient's cognition was also assessed. FreeSurfer algorithms were used to obtain estimations of regional grey matter volumes. White matter pathways were reconstructed using TRACULA, and four diffusion metrics were extracted. ANCOVA models were performed to compare BD patients and HC values of regional grey matter volume and diffusion metrics. Global brain measures were also compared. Bivariate Pearson correlations were explored between significant brain results and five cognitive domains. Euthymic BD patients showed higher ventricular volume (F(1, 46) = 6.04; p = 0.018) and regional grey matter volumes in the left fusiform (F(1, 46) = 15.03; pFDR = 0.015) and bilateral parahippocampal gyri compared to HC (L: F(1, 46) = 12.79, pFDR = 0.025/ R: F(1, 46) = 15.25, pFDR = 0.015). Higher grey matter volumes were correlated with greater executive function (r = 0.53, p = 0.008). We evaluated a modest sample size with concurrent pharmacological treatment. Higher medial temporal volumes in euthymic BD patients may be a potential signature of brain resilience and cognitive adaptation to a putative illness neuroprogression. This knowledge should be integrated into further efforts to implement imaging into BD clinical management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

GPCRmd uncovers the dynamics of the 3D-GPCRome

  • Rodríguez-Espigares, Ismael|||0000-0002-1602-8679
  • Torrens-Fontanals, Mariona|||0000-0001-6233-8945
  • Tiemann, Johanna K. S|||0000-0001-7551-6245
  • Aranda-García, David|||0000-0002-5476-2903
  • Ramírez-Anguita, Juan Manuel|||0000-0002-8509-0927
  • Stepniewski, Tomasz Maciej|||0000-0002-6828-9192
  • Worp, Nathalie
  • Varela-Rial, Alejandro|||0000-0002-6918-1765
  • Morales-Pastor, Adrián
  • Medel-Lacruz, Brian|||0000-0003-2831-7731
  • Pándy-Szekeres, Gáspár|||0000-0002-7697-2696
  • Mayol, Eduardo|||0000-0003-3120-8667
  • Giorgino, Toni|||0000-0001-6449-0596
  • Carlsson, Jens|||0000-0003-4623-2977
  • Deupi, Xavier|||0000-0003-4572-9316
  • Filipek, Slawomir|||0000-0003-3147-3858
  • Filizola, Marta|||0000-0002-4382-8276
  • Gómez-Tamayo, José Carlos|||0000-0003-4709-6030
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Gutiérrez-de-Terán, Hugo|||0000-0003-0459-3491
  • Jiménez-Rosés, Mireia|||0000-0002-4049-8670
  • Jespers, Willem|||0000-0002-4951-9220
  • Kapla, Jon|||0000-0003-3328-1921
  • Khelashvili, George
  • Kolb, Peter|||0000-0003-4089-614X
  • Latek, Dorota|||0000-0002-0429-0637
  • Marti-Solano, Maria|||0000-0003-0373-8927
  • Matricon, Pierre
  • Matsoukas, Minos-Timotheos|||0000-0002-4642-8163
  • Miszta, Przemyslaw
  • Olivella, Mireia|||0000-0002-6035-3399
  • Pérez-Benito, Laura|||0000-0001-9607-9048
  • Provasi, Davide|||0000-0002-2868-303X
  • Ríos, Santiago
  • Rodríguez Torrecillas, Iván
  • Sallander, Jessica
  • Sztyler, Agnieszka|||0009-0008-9459-0078
  • Vasile, Silvana|||0000-0001-5578-7996
  • Weinstein, Harel|||0000-0003-3473-9818
  • Zachariae, Ulrich|||0000-0003-3287-8494
  • Hildebrand, Peter Werner|||0000-0003-0063-1104
  • De Fabritiis, Gianni|||0000-0003-3913-4877
  • Sanz, Ferran|||0000-0002-7534-7661
  • Gloriam, David E.|||0000-0002-4299-7561
  • Cordomí Montoya, Arnau|||0000-0002-3848-2928
  • Guixà González, Ramon|||0000-0003-0397-9800
  • Selent, Jana|||0000-0002-1844-4449
G-protein-coupled receptors (GPCRs) are involved in numerous physiological processes and are the most frequent targets of approved drugs. The explosion in the number of new three-dimensional (3D) molecular structures of GPCRs (3D-GPCRome) over the last decade has greatly advanced the mechanistic understanding and drug design opportunities for this protein family. Molecular dynamics (MD) simulations have become a widely established technique for exploring the conformational landscape of proteins at an atomic level. However, the analysis and visualization of MD simulations require efficient storage resources and specialized software. Here we present GPCRmd (http://gpcrmd.org/), an online platform that incorporates web-based visualization capabilities as well as a comprehensive and user-friendly analysis toolbox that allows scientists from different disciplines to visualize, analyze and share GPCR MD data. GPCRmd originates from a community-driven effort to create an open, interactive and standardized database of GPCR MD simulations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps

  • Segarra Casas, Alba|||0000-0001-5185-5031
  • Iruzubieta, Pablo
  • Kapetanovic, Solange
  • Hernández-Laín, Aurelio
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Fernández-Torrón, Roberto
  • Maneiro, Miren
  • Marco-Moreno, Pablo|||0000-0002-0302-9031
  • Zelaya-Huerta, M. Victoria
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Calafell, Francesc|||0000-0002-1083-9438
  • Töpf, Ana
  • Straub, Volker|||0000-0001-9046-3540
  • Vallejo-Illarramendi, Ainara
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • Gallano, Pia|||0000-0001-8104-2197
  • González Quereda, Lidia|||0000-0003-0715-6414
Background and purpose: Pathogenic variants in the RYR1 gene have been associated with a variety of conditions, ranging from congenital myopathy to adult manifestations. Our aim was to characterize the p.Leu2286Val variant in 17 Basque patients, to accurately determine its correlation with clinical features and to explore the possible founder effect of the variant. Methods: Families harbouring the p.Leu2286 RYR1 variant underwent a detailed clinical evaluation, including muscle magnetic resonance imaging, electromyography and muscle biopsy. Haplotypes were analysed in available patients and their relatives. Results: Individuals carrying the p.Leu2286Val shared a common haplotype, suggesting a founder event in the Basque Country population. The most prevalent features were exertional myalgia, high creatine kinase (CK) levels, cramps and muscle hypertrophy. None of the patients carrying only the p.Leu2286Val showed progression to severe muscle weakness and muscle magnetic resonance imaging showed a heterogeneous muscle involvement. Muscle biopsy revealed non-specific findings in two patients and features associated with central core disease in one patient carrying only the p.Leu2286Val and two patients harbouring an additional RYR1 variant. Three individuals carrying an in trans RYR1 variant presented with an earlier onset and more severe phenotype. Conclusion: Here, it is shown that the dominantly inherited p.Leu2286Val RYR1 founder variant is associated with a milder phenotype of exercise intolerance, myalgia and hyperCKemia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epidemiological and Clinical Insights into the Enterovirus D68 Upsurge in Europe 2021-2022 and Emergence of Novel B3-Derived Lineages, ENPEN Multicentre Study

  • Simoes, Margarida Pires|||0000-0003-0997-5683
  • Hodcroft, Emma B.|||0000-0002-0078-2212
  • Simmonds, Peter|||0000-0002-7964-4700
  • Albert, Jan|||0000-0001-9020-0521
  • Alidjinou, Enagnon K.
  • Ambert-Balay, Katia|||0000-0002-2624-712X
  • Andrés, Cristina|||0000-0002-3200-0895
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Auvray, Christelle|||0000-0001-9782-170X
  • Bailly, Jean-Luc|||0000-0002-9770-6450
  • Baldanti, Fausto|||0000-0002-3358-8969
  • Bastings, Capser
  • Beard, Stuart
  • Berengua, Carla|||0000-0001-9963-3809
  • Berginc, Natasa
  • Bloemen, Mandy
  • Blomqvist, Soile
  • Bosma, Froukje
  • Böttcher, Sindy|||0000-0002-7521-093X
  • Bubba, Laura
  • Buderus, Stafan
  • Cabrerizo, Maria
  • Calvo, Cristina|||0000-0002-6503-3423
  • Celma, Cristina
  • Ceriotti, Ferruccio|||0000-0002-0958-5354
  • Clark, Gemma|||0000-0002-4471-4641
  • Costa, Inës|||0000-0003-2430-0721
  • Coste-Burel, Marianne
  • Couderé, Karen
  • Cremer, Jeroen
  • del Cuerpo Casas, Margarita|||0000-0001-7973-5496
  • Daehne, Theo
  • De Beer, Jessica
  • De Ceano-Vivas, Maria
  • De Gascun, Cillian
  • De Rougemont, Alexis
  • Dean, Jonathan
  • Dembinski, Jennifer L.
  • Diedrich, Sabine
  • Diez-Domingo, Javier|||0000-0003-1008-3922
  • Dillner, Lena
  • Dorenberg, Dagny H.
  • Ducancelle, Alexandra
  • Dudman, Susanne|||0000-0001-5047-4982
  • Dyrdak, Robert|||0000-0001-8456-4898
  • Eis-Huebinger, Anna-Maria
  • Falces Romero, Iker|||0000-0001-5888-7706
  • Farkas, Agnes
  • Feeney, Susan
  • Fernandez-Garcia, Maria D.
  • Flipse, Jacky
  • Franck, Kristina T.
  • Galli, Cristina
  • Garrigue, Isabelle
  • Geeraedts, Felix
  • Georgieva, Irina
  • Giardina, Federica
  • Guiomar, Raquel|||0000-0002-4563-6315
  • Hauzenberger, Elenor
  • Heikens, Esther
  • Henquell, Cécille
  • Hober, Didier
  • Hönemann, Mario
  • Howson-Wells, Hannah
  • Hruškar, Željka
  • Ikonen, Niina
  • Imbert, Berthemarie
  • Jansz, Arjan R.
  • Jeannoël, Marion
  • Jiřincová, Helena
  • Josset, Laurence
  • Keeren, Kathrin
  • Kramer-Lindhout, Naomie
  • Krokstad, Sidsel
  • Lazrek, Mouna
  • Le Guillou-Guillemette, Hélène
  • Lefeuvre, Caroline
  • Lind, Andreas
  • Lunar, Maja M.
  • Maier, Melanie
  • Marque-Juillet, Stéphanie
  • McClure, C. Patrick
  • McKenna, James
  • Meijer, Adam|||0000-0001-8074-7582
  • Menasalvas Ruiz, Ana
  • Mengual-Chuliá, Beatriz
  • Midgley, Sofie
  • Mirand, Audrey
  • Molenkamp, Richard
  • Montes, Milagrosa|||0000-0001-6554-4912
  • Moreno-Docón, Antonio
  • Morley, Ursula
  • Murk, Jean Luc
  • Navascués-Ortega, Ana
  • Nijhuis, Roel|||0000-0003-4203-3858
  • Nikolaeva-Glomb, Lubomira
  • Nordbø, Svein A.
  • Numanovic, Sanela
  • Oggioni, Massimo
  • Oñate Vergara, Eider
  • Pacaud, Jordi
  • Pacreau, Marie L.
  • Panning, Marcus
  • Pariani, Elena
  • Pekova, Lili
  • Pellegrinelli, Laura
  • Petrovec, Miroslav
  • Pietsch, Corinna
  • Pilorge, Léa
  • Piñeiro, Luis
  • Piralla, Antonio|||0000-0002-6062-2579
  • Poljak, Mario|||0000-0002-3216-7564
  • Prochazka, Birgit
  • Rabella, Núria|||0000-0002-3409-0468
  • Rahamat-Langendoen, Janette C.
  • Rainetova, Petra
  • Reynders, Marijke
  • Riezebos-Brilman, Annelies
  • Roorda, Lieuwe
  • Savolainen-Kopra, Carita
  • Schuffenecker, Isabelle
  • Smeets, Leo C.
  • Stoyanova, Asya
  • Stefic, Karl|||0000-0002-9686-9194
  • Swanink, Caroline
  • Tabain, Irena
  • Tjhie, Jeroen
  • Thouault, Luc
  • Tumiotto, Camille
  • Uceda Renteria, Sara|||0000-0002-2027-8478
  • Uršič, Tina
  • Vallet, Sophie
  • Van Ranst, Marc
  • Van Wunnik, Peter
  • Verweij, Jaco J.
  • Vila, Jorgina|||0000-0001-9715-0627
  • Wintermans, Bas
  • Wollants, Elke
  • Wolthers, Katja C.
  • Xavier López-Labrador, F.|||0000-0002-9403-8258
  • Fischer, Thea K.|||0000-0003-4812-980X
  • Harvala, Heli
  • Benschop, Kimberley S. M.|||0000-0002-8328-0882
Enterovirus D68 (EV-D68) infections are associated with severe respiratory disease and acute flaccid myelitis (AFM). The European Non-Polio Enterovirus Network (ENPEN) aimed to investigate the epidemiological and genetic characteristics of EV-D68 infections and its clinical impact during the fall-winter season of 2021-2022. From 19 European countries, 58 institutes reported 10 481 (6.8%) EV-positive samples of which 1004 (9.6%) were identified as EV-D68 (including 852 respiratory samples). Clinical data were reported for 969 cases; 78.9% of infections were reported in children (0-5 years); and 37.9% of cases were hospitalized. Acute respiratory distress was commonly noted (93.1%) followed by fever (49.4%). Neurological problems were observed in 6.4% of cases including 6 diagnosed with AFM. Phylodynamic/Nextstrain and phylogenetic analyses based on 694 sequences showed the emergence of 2 novel B3-derived lineages, with no regional clustering. In conclusion, we describe a large-scale European EV-D68 upsurge with severe clinical impact and the emergence of B3-derived lineages. The study describes a large-scale EV-D68 European upsurge during the fall-winter season of 2021-2022 with severe clinical impact, including respiratory distress and neurological problems such as acute flaccid myelitis, and the emergence of novel B3-derived lineages.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Endogenous LXR signaling controls pulmonary surfactant homeostasis and prevents lung inflammation

  • Hernández-Hernández, Irene
  • De La Rosa, Juan V.
  • Martín-Rodríguez, Patricia
  • Díaz-Sarmiento, Mercedes
  • Recio, Carlota
  • Guerra, Borja
  • Fernández-Pérez, Leandro
  • León, Theresa E.
  • Torres Blanch, Rosa|||0000-0002-9109-4035
  • Font-Díaz, Joan|||0000-0002-7686-2278
  • Roig, Angela
  • Mora Pérez, Fernando de|||0000-0002-3002-6004
  • Boscá, Lisardo|||0000-0002-0253-5469
  • Díaz, Mario
  • Valledor, Annabel F.|||0000-0003-4232-2633
  • Castrillo, Antonio|||0000-0002-2057-2159
  • Tabraue, Carlos|||0000-0001-9920-8116
The online version contains supplementary material available at 10.1007/s00018-024-05310-3.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown. We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A+) or negative (A-) according to CSF Aβ/Aβ ratio. Plasma pTau, pTau, Aβ and Aβ were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A + and A- groups, evaluated Spearman's correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF Aβ/Aβ ratio. We analyzed the potential of pTau to predict amyloidosis in CSF. Plasma pTau and pTau concentration were higher in A + than A- while the plasma Aβ/Aβ ratio was lower in A + compared to A-. pTau and the Aβ/Aβ ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively). The areas under the ROC curve to discriminate A + from A- participants were 0.94 (95% CI 0.92-0.97) for pTau, and 0.88 (95% CI 0.84-0.92) for both pTau and Aβ/Aβ. Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau had the highest fold change (x4.2) and showed high predictive capability in discriminating A + from A-, having 4-7% misclassification rate. The global accuracy of plasma pTau using a two-threshold approach was robust in symptomatic groups, exceeding 90%. The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic value of single-subject grey matter networks in early multiple sclerosis

  • Fleischer, Vinzenz
  • González-Escamilla, Gabriel|||0000-0002-7209-1736
  • Pareto, Deborah|||0000-0001-7356-3769
  • Rovira, Alex|||0000-0002-2132-6750
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Høgestøl, Einar A.|||0000-0001-8446-2111
  • Harbo, Hanne F.
  • Bellenberg, Barbara|||0000-0001-7484-6787
  • Ruggieri, Serena|||0000-0001-5287-3290
  • Gasperini, Claudio|||0000-0002-3959-4067
  • Uher, Tomas|||0000-0003-3160-9022
  • Vaneckova, Manuela|||0000-0002-8784-7997
  • Bittner, Stefan|||0000-0003-2179-3655
  • Othman, Ahmed E.
  • Collorone, Sara|||0000-0003-1506-8983
  • Toosy, Ahmed T.|||0000-0002-4441-3750
  • Meuth, Sven G.
  • Zipp, Frauke|||0000-0002-1231-1928
  • Barkhof, Frederik|||0000-0003-3543-3706
  • Ciccarelli, Olga|||0000-0001-7485-1367
  • Groppa, Sergiu|||0000-0002-2551-5655
The identification of prognostic markers in early multiple sclerosis (MS) is challenging and requires reliable measures that robustly predict future disease trajectories. Ideally, such measures should make inferences at the individual level to inform clinical decisions. This study investigated the prognostic value of longitudinal structural networks to predict 5-year Expanded Disability Status Scale (EDSS) progression in patients with relapsing-remitting MS (RRMS). We hypothesized that network measures, derived from MRI, outperform conventional MRI measurements at identifying patients at risk of developing disability progression. This longitudinal, multicentre study within the Magnetic Resonance Imaging in MS (MAGNIMS) network included 406 patients with RRMS (mean age = 35.7 ± 9.1 years) followed up for 5 years (mean follow-up = 5.0 ± 0.6 years). EDSS was determined to track disability accumulation. A group of 153 healthy subjects (mean age = 35.0 ± 10.1 years) with longitudinal MRI served as controls. All subjects underwent MRI at baseline and again 1 year after baseline. Grey matter atrophy over 1 year and white matter lesion load were determined. A single-subject brain network was reconstructed from T1-weighted scans based on grey matter atrophy measures derived from a statistical parameter mapping-based segmentation pipeline. Key topological measures, including network degree, global efficiency and transitivity, were calculated at single-subject level to quantify network properties related to EDSS progression. Areas under receiver operator characteristic (ROC) curves were constructed for grey matter atrophy and white matter lesion load, and the network measures and comparisons between ROC curves were conducted. The applied network analyses differentiated patients with RRMS who experience EDSS progression over 5 years through lower values for network degree [H(2) = 30.0, P < 0.001] and global efficiency [H(2) = 31.3, P < 0.001] from healthy controls but also from patients without progression. For transitivity, the comparisons showed no difference between the groups [H(2) = 1.5, P = 0.474]. Most notably, changes in network degree and global efficiency were detected independent of disease activity in the first year. The described network reorganization in patients experiencing EDSS progression was evident in the absence of grey matter atrophy. Network degree and global efficiency measurements demonstrated superiority of network measures in the ROC analyses over grey matter atrophy and white matter lesion load in predicting EDSS worsening (all P -values < 0.05). Our findings provide evidence that grey matter network reorganization over 1 year discloses relevant information about subsequent clinical worsening in RRMS. Early grey matter restructuring towards lower network efficiency predicts disability accumulation and outperforms conventional MRI predictors. Fleischer et al. examine the prognostic value of brain networks derived from MRI for predicting disability progression in patients with multiple sclerosis. They conclude that early brain network alterations identify clinical deterioration in multiple sclerosis and outperform classical MRI predictors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

  • Verberk, I.M.W.
  • Jutte, J.
  • Kingma, M.Y.
  • Vigneswaran, S.
  • Gouda, M.M.T.E.E.
  • van Engelen, M.P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Chevalier, C.
  • Marizzoni, M.
  • van de Giessen, E.M.
  • Lemstra, A.W.
  • Pijnenburg, Y.A.L.
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • den Braber, A.
  • Wilson, D.
  • Schut, M.C.
  • van Harten, A.C.
  • Teunissen, C.E.
INTRODUCTION: We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P-)tau181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). METHODS: We measured the plasma biomarkers with Simoa (n = 1199), applied LASSO regression for biomarker selection and receiver operating characteristics (ROC) analyses to determine diagnostic accuracy. We validated our findings in two independent cohorts and constructed a visualization approach. RESULTS: P-tau181, GFAP, and NfL were selected. This combination had area under the curve (AUC) = 83% to identify amyloid positivity in pre-dementia stages, AUC = 87%-89% to differentiate Alzheimer's or controls from frontotemporal dementia, AUC = 74%-76% to differentiate Alzheimer's or controls from dementia with Lewy bodies. Highly reproducible AUCs were obtained in independent cohorts. The resulting visualization tool includes UpSet plots to visualize the stand-alone biomarker results and density plots to visualize the biomarker results combined. DISCUSSION: Our multimarker blood test interpretation tool is ready for testing in real-world clinical dementia settings. Highlights: We developed a multimarker blood test interpretation tool for clinical dementia practice. Our interpretation tool includes plasma biomarkers P-tau, GFAP, and NfL. Our tool is particularly useful for Alzheimer's and frontotemporal dementia diagnosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Emotional intelligence and neurocognition profiles in first-episode psychosis, A two-year follow-up study

  • Clougher, Derek|||0000-0001-7631-3845
  • Forte, Maria Florencia|||0000-0001-5930-5501
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Sánchez Torres, Ana Maria|||0000-0002-9505-2406
  • Serra-Navarro, Maria|||0000-0002-9736-4630
  • Penadés, Rafael|||0000-0002-1564-3717
  • Lobo, Antonio|||0000-0002-9098-655X
  • Pinto, A.G.
  • Panadero, Rocío
  • Roldan-Bejarano, Alexandra|||0000-0001-9905-3943
  • Vieta, Eduard|||0000-0002-0548-0053
  • de la Serna, Elena|||0000-0002-7869-9881
  • Trabsa, Amira|||0000-0002-8669-0676
  • Martínez-Àran, Anabel|||0000-0002-0623-6263
  • Torrent, Carla|||0000-0003-0335-582X
  • Tortorella, A.
  • Menculini, G.
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Cuesta, M.J.
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Salmerón, Sergi|||0000-0002-0212-4491
  • Arbelo, Néstor|||0000-0002-2630-3259
  • Ferrer-Quintero, Marta|||0000-0002-7935-9424
  • Echevarría, A.
  • Selma, Judit
  • Grasa, Eva|||0000-0003-1100-7489
  • Marin, Julen
  • Mar, Lorea
  • Cámara, Concepción de la|||0000-0003-2284-7862
  • Ruíz-Lázaro, P.M.
  • Nacher, Juan|||0000-0001-7599-3957
  • Cañete Nicolas, Carlos
  • Mané, Anna|||0000-0003-2127-349X
  • Toll, Alba|||0000-0003-2399-5250
  • Solé, Brisa|||0000-0003-1673-8248
  • Mallorquí, Aida|||0000-0003-4038-3045
  • Castro-Fornieles, Josefina|||0000-0003-0632-2687
  • Baeza, Inmaculada|||0000-0003-2611-5781
  • Contreras, Fernando|||0000-0003-2929-2804
  • Sáiz, Pilar A.|||0000-0002-5705-4523
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Segarra, R.
  • Zabala Torres, Alaitz|||0000-0002-3931-4221
  • Scala, Marcello|||0000-0003-2194-7239
  • Rodriguez-Jimenez, Roberto|||0000-0003-2251-7249
  • Usall, J.
  • Butjosa Molines, Anna|||0000-0001-5317-9508
  • Pomarol-Clotet, E.
  • García-León, M.Á.
  • Ibañez, A.
  • Moreno-Izco, L.
  • Balanzá-Martínez, Vicent|||0000-0001-7772-7396
Emotional intelligence (EI) and neurocognition (NC) impairments are common in first-episode psychosis (FEP), yet their evolution over time remains unclear. This study identified patient profiles in EI and NC performance in FEP. 98 adult FEP patients and 128 healthy controls (HCs) were tested on clinical, functional, EI, and NC variables at baseline and two-year follow-up (FUP). A repeated-measures ANOVA compared the effects of group (patients and HCs) and time on EI. Significant EI improvements were observed in both groups. Four groups were created based on NC and EI performance at baseline and FUP in patients: impairment in NC and EI, impairment in NC only, impairment in EI only, and no impairment. At FUP, patients impaired in NC and EI showed less cognitive reserve (CR), greater negative and positive symptoms, and poorer functional outcomes. At FUP, three group trajectories were identified: (I) maintain dual impairment (II) maintain no impairment or improve, (III) maintain sole impairment or worsen. The maintain dual impairment group had the lowest levels of CR. EI and NC impairments progress differently in FEP. Greater CR may protect against comorbid EI/NC impairment. Identifying these patient characteristics could contribute to the development of personalised interventions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of white matter hyperintensities in Down syndrome

  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Aranha, Mateus|||0000-0001-9594-292X
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Padilla, Concepción|||0000-0003-4102-6787
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernandez, S.
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Bargalló, Núria|||0000-0001-6284-5402
  • Ribas, Laia
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Belbin, Olivia|||0000-0002-6109-6371
  • Camacho, Valle|||0000-0003-0748-0847
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Bejanin, Alexandre|||0000-0002-9958-0951
INTRODUCTION: In Down syndrome (DS), white matter hyperintensities (WMHs) are highly prevalent, yet their topography and association with sociodemographic data and Alzheimer's disease (AD) biomarkers remain largely unexplored. METHODS: In 261 DS adults and 131 euploid controls, fluid-attenuated inversion recovery magnetic resonance imaging scans were segmented and WMHs were extracted in concentric white matter layers and lobar regions. We tested associations with AD clinical stages, sociodemographic data, cerebrospinal fluid (CSF) AD biomarkers, and gray matter (GM) volume. RESULTS: In DS, total WMHs arose at age 43 and showed stronger associations with age than in controls. WMH volume increased along the AD continuum, particularly in periventricular regions, and frontal, parietal, and occipital lobes. Associations were found with CSF biomarkers and temporo-parietal GM volumes. DISCUSSION: WMHs increase 10 years before AD symptom onset in DS and are closely linked with AD biomarkers and neurodegeneration. This suggests a direct connection to AD pathophysiology, independent of vascular risks. Highlights: White matter hyperintensities (WMHs) increased 10 years before Alzheimer's disease symptom onset in Down syndrome (DS). WMHs were strongly associated in DS with the neurofilament light chain biomarker. WMHs were more associated in DS with gray matter volume in parieto-temporal areas.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL), GELLC-7 trial from the Spanish group of CLL (GELLC)

  • Abrisqueta, Pau|||0000-0001-9625-7422
  • González Barca, Eva|||0000-0002-1323-1508
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Ríos-Herranz, Eduardo
  • Fernández de la Mata, Margarita
  • Delgado, Julio|||0000-0002-5157-4376
  • Andreu, Rafael|||0000-0002-9220-3352
  • Hernández-Rivas, José Ángel
  • Terol, María José
  • Navarro, Almudena
  • Vidriales, M. Belén
  • Baltasar, Patricia
  • De La Serna, Javier|||0000-0003-3904-1101
  • Ramírez, Á.ngel
  • Ballester, C.
  • Moreno, Carol|||0000-0003-3275-0271
  • García-Marco, J.A.|||0000-0002-8993-5982
  • Córdoba, Raúl|||0000-0002-7654-8836
  • Yáñez, Lucrecia|||0000-0001-9925-3048
  • Casado, Luis Felipe
  • González, Marcos
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
BTK inhibitors have been concurrently administered with anti-CD20 monoclonal antibodies (mAbs) in chronic lymphocytic leukemia (CLL). However, the optimal regimen for combining these two drugs remains pending. Methods: This multi-center phase 2 study aimed to analyze whether consolidation with ofatumumab improved the response in patients with CLL receiving front-line treatment with ibrutinib. Patients received 12 cycles of ibrutinib monotherapy. Those who achieved CR after this induction were maintained on ibrutinib. Conversely, those who did not attain CR continued with ibrutinib in addition to a consolidation, which involved 7 doses of ofatumumab. The primary objective was the complete response (CR) rate at cycle 20. This study is registered within the EU Clinical Trials Register (EudraCT 2016-004937-26). Findings: Between September 8, 2017, and May 21, 2018, 84 patients (median age, 69 years) were included. After completion of 12 cycles of ibrutinib (n = 80), 4 patients (5%) were in CR, 67 (84%) in partial response (PR), and 6 patients (7%) had a PR with lymphocytosis (PRL). After consolidation with ofatumumab, 20 patients improved the response from PR to CR and 6 patients with PRL obtained a PR. Seventy-one patients (85%) completed 20 cycles of treatment, with a CR rate of 24/71 (34%). According to the intention-to-treat analysis at cycle 20, the ORR was 69/84 (82.2%), with a CRR of 24/84 (28.6%). Progression-free survival and overall survival at 48-months were 89.9% (CI: 82.4-95.5) and 92.2% (CI: 85.3-97.1), respectively. Interpretation: These findings underscore the potential for a consolidation strategy in CLL, wherein the addition of a mAb in patients with low tumor burden might enhance the quality of the response. Funding: The study was funded by Janssen that also supplied ibrutinib, whereas ofatumumab was supplied by Novartis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Utilising systematic reviews to assess potential overtreatment and claim for better evidence-based research, an analysis of anticancer drugs versus supportive care in advanced esophageal cancer

  • Santero, Marilina|||0000-0001-5371-0979
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Selva, Anna|||0000-0002-2754-3158
  • Savall-Esteve, Olga|||0009-0002-2685-1797
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Macias Declara, Ismael
  • Leache, Leire|||0000-0003-2272-7086
  • Cerdà, Paula|||0000-0003-0101-188X
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Antequera, Alba|||0000-0002-1670-6302
  • Auladell-Rispau, Ariadna|||0000-0002-0364-4827
  • Cantero-Fortiz, Yahveth|||0000-0003-0329-6487
  • Hernández, Edgar D.
  • Irassar, Juan
  • Meinardi, Pamela
  • Merchán Galvis, Ángela María|||0000-0003-2375-5513
  • Meza, Nicolás|||0000-0001-9505-0358
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Requeijo, Carolina|||0000-0003-3479-4550
  • Rodríguez-Grijalva, Gerardo
  • Salas-Gama, Karla|||0000-0003-4845-4899
  • Salazar, Josefina|||0000-0002-6448-5946
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Urrútia, Gerard|||0000-0002-8850-0960
Background: Highlighting the identified gaps in evidence-based research concerning advanced esophageal cancer (EC) treatment and care, this review evaluates the efficacy and safety of anticancer drugs compared to supportive care for advanced EC patients, aiming to assess the appropriateness of usual treatments and identify the gaps that need to be filled with primary research. Methods: We searched (May 2022) MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Epistemonikos, and trial registries (ClinicalTrials.gov and PROSPERO) for randomised controlled trials (RCTs) comparing anticancer drugs (chemotherapy, immunotherapy, or biological/targeted therapy) with supportive care in advanced EC. The results were summarised using GRADE summary of finding tables. Results: We included 15 RCTs. Most studies did not have a special focus on EC, did not detail the treatment lines in all patients, and did not evaluate all outcomes. Anticancer drugs may result in a slight increase in overall survival (OS) (HR 0.78; 95% CI 0.71, 0.86; MD 0.83 months) and better progression-free survival (PFS) (HR 0.56 95% CI 0.49, 0.64, MD 0.68 months), but also may increase toxicity (RR 1.37; 95% CI 1.13, 1.65), without a significant improvement in quality of life. The certainty of evidence was low or very low due to indirectness of results and lack of specific focus on EC in some studies. Conclusion: RCTs on advanced EC lack specificity, detailed treatment line information, and evaluation of all relevant outcomes. Moreover, when they find any benefit, this is negligible. Therefore, the certainty to justify anticancer drug treatments instead of supportive care in advanced EC is low or very low, and this information should be actively shared with affected patients. More and better RCTs should be conducted to assess whether any old or new proposed treatment for advanced EC patients provides a better balance of benefits and harms than the supportive care. Systematic review registration: The study protocol was registered in OSF (https://doi.org/10.17605/OSF.IO/7CHX6) on 2022-03-29.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cooperative housing under a grant-of-use in Catalonia and health, pre-post analysis

  • Reyes, Alexia|||0000-0003-3900-1978
  • Macaya Munell, Irene|||0000-0002-0424-5246
  • Borrell i Thió, Carme|||0000-0002-1170-2505
  • Carmezim, João
  • Fernández Sánchez, Ana|||0000-0002-0333-1345
  • Vásquez-Vera, Constanza|||0000-0001-6370-4126
  • Pérez, Catherine|||0000-0001-5892-2807
  • Carrere, Juli|||0000-0001-5865-753X
  • Daví, L.
  • Novoa, Ana M.|||0000-0002-5068-3503
Housing is considered a social determinant of health. In Catalonia and Spain, ensuring affordable housing is challenging and cooperative housing under a grant-of-use emerges as an alternative, challenging traditional housing models. This study aims to quantify its impact on health before and after moving to the cooperative house. A longitudinal study of individuals in cooperative housing projects in Catalonia (July 2018-April 2023) was conducted. Data, including sociodemographic, housing information, and health-related details, were collected through baseline and follow-up surveys. Seventy participants (42 women, 28 men) showed positive changes in housing conditions during follow-up. Improved perceptions of health, mental health, and social support were observed. Despite limitations in sample size and short follow-up, initial findings suggest improvements in health. Cooperative housing under a grant-of-use in Catalonia appears promising for improving health and living conditions. Further research is warranted to explore its full potential as an alternative amid housing challenges in the region.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome

  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • O'Connor, A.
  • Llibre-Guerra, J.
  • Lao, P.|||0000-0003-2243-3547
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Fortea, Juan|||0000-0002-1340-638X
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
Autosomal dominant Alzheimer's disease (ADAD) and Down syndrome (DS) constitute genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in understanding the biomarker changes and disease progression, notably in advancing our knowledge of the natural history of AD. However, some specific characteristics of biomarkers in genetically determined forms and, most importantly, the near full penetrance and predictability of disease onset lead to a very different context of use for biomarkers in these populations. This article delves into the similarities and differences in biomarker profiles between genetically determined AD and sporadic cases, discussing the implications for research and clinical practice. It also emphasizes the need to account for factors that may affect biomarker reliability differently in genetically determined AD. Enhancing our understanding of the disease will pave the way for more personalized therapeutic approaches for affected individuals.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of Genetic Loci Associated With Intracerebral Hemorrhage Using a Multitrait Analysis Approach

  • Muiño, Elena|||0000-0001-5839-7328
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cullell, Natalia|||0000-0001-5118-1014
  • Lledós, Miquel|||0000-0001-8832-789X
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Villatoro-González, Paula|||0009-0001-0287-4073
  • Sierra-Marcos, Alba|||0000-0001-6570-9318
  • Ros-Castelló, Victoria|||0000-0002-9523-3012
  • Aguilera-Simón, Ana|||0000-0003-1428-8212
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Background and Objectives Genome-wide association studies (GWASs) have only 2 loci associated with spontaneous intracerebral hemorrhage (ICH): APOE for lobar and 1q22 for nonlobar ICH. We aimed to discover new loci through an analysis that combines correlated traits (multi-trait analysis of GWAS [MTAG]) and explore a gene-based analysis, transcriptome-wide association study (TWAS), and proteome-wide association study (PWAS) to understand the biological mechanisms of spontaneous ICH providing potential therapeutic targets. Methods We use the published MTAG of ICH (patients with spontaneous intraparenchymal bleeding) and small-vessel ischemic stroke. For all ICH, lobar ICH, and nonlobar ICH, a pairwise MTAG combined ICH with traits related to cardiovascular risk factors, cerebrovascular diseases, or Alzheimer disease (AD). For the analysis, we assembled those traits with a genetic correlation ≥0.3. A new MTAG combining multiple traits was performed with those traits whose pairwise MTAG yielded new GWAS-significant single nucleotide polymorphisms (SNPs), with a posterior-probability of model 3 (GWAS-pairwise) ≥0.6. We perform TWAS and PWAS that correlate the genetic component of expression or protein levels with the genetic component of a trait. We use the ICH cohort from UK Biobank as replication. Results For all ICH (1,543 ICH, 1,711 controls), the mean age was 72 ± 2 in cases and 70 ± 2 in controls, and half of them were women. Replication cohort: 700 ICH and 399,717 controls. Novel loci were found only for all ICH (the trait containing lobar and nonlobar ICH), combining data of ICH and small vessel stroke, white matter hyperintensities volume, fractional anisotropy, mean diffusivity, and AD. We replicated 6 SNPs belonging to 2q33.2 (ICA1L, β = 0.20, SE = 0.03, p value = 8.91 × 10), 10q24.33 (OBFC1, β = -0.12, SE = 0.02, p value = 1.67 × 10), 13q34 (COL4A2, β = 0.02, SE = 0.02, p value = 2.34 × 10), and 19q13.32 (APOC1, β = -0.19, SE = 0.03, p value = 1.38 × 10; APOE, β = 0.21, SE = 0.03, p value = 2.70 × 10; PVRL2:CTB-129P6.4, β = 0.15, SE = 0.03, p value = 1.38 × 10); 2 genes (SH3PXD2A, Z-score = 4.83, p value = 6.67 × 10; and APOC1, Z-score: = 5.11, p value = 1.60 × 10); and ICA1L transcript (Z-score = 6.8, p value = 9.1 × 10) and protein levels (Z-score = -5.8, p value = 6.7 × 10).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrated miRNA-mRNA Analysis Reveals Critical miRNAs and Targets in Diet-Induced Obesity-Related Glomerulopathy

  • López-Martínez, Marina
  • Armengol Barnils, Maria del Pilar|||0000-0002-9423-2966
  • Pey, Irina
  • Farré Ramon, Xavier|||0000-0001-6838-9479
  • Rodriguez Martinez, Paula|||0000-0002-9001-2501
  • Ferrer, Mireia
  • Porrini, Esteban
  • Luis-Lima, Sergio|||0000-0003-3540-8252
  • Díaz-Martín, Laura
  • Rodríguez-Rodríguez, Ana Elena|||0000-0002-0803-864X
  • Cruz-Perera, Coriolano
  • Alcalde-Herraiz, Marta
  • Navarro Diaz, Maruja Isabel|||0000-0003-3001-0595
This study aimed to investigate obesity-related glomerulopathy (ORG) at cellular, structural, and transcriptomic levels. Thirty Wistar rats were randomized into two groups: 15 rats were fed with a standard diet (SD-rats), and 15 rats were fed with a high-fat diet (HFD-rats). After 10 weeks, the weight, kidney function, histological features, and transcriptomic changes were assessed. HFD-rats gained significantly more weight (55.8% vs. 29.2%; p < 0.001) and albuminuria (10,384.04 ng/mL vs. 5845.45 ng/mL; p < 0.001) compared to SD-rats. HFD-rats exhibited early stages of ORG, with predominant mesangial matrix increase and podocyte hypertrophy (PH). These lesions correlated with differentially expressed (DE) genes and miRNAs. Functional analysis showed that miR-205, which was DE in both the kidneys and urine of HFD-rats, negatively regulated the PTEN gene, promoting lipid endocytosis in podocytes. The downregulation of PTEN was proved through a higher PTEN/nephrin ratio in the SD-rats and the presence of lipid vacuoles in HFD-podocytes. This study has found a specific targetome of miRNAs and gene expression in early stages of ORG. Also, it emphasizes the potential value of miR-205 as a urinary biomarker for detecting podocyte injury in ORG, offering a tool for early diagnosis, and opening new avenues for future therapeutic research of obesity-related glomerulopathy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19

  • Karachaliou, Marianna|||0000-0002-3014-0747
  • Ranzani, Otavio|||0000-0002-4677-6862
  • Espinosa, Ana|||0000-0001-7399-3267
  • Iraola-Guzmán, Susana|||0000-0003-3359-1241
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Vidal, M.
  • Jiménez, A.
  • Bañuls, Marc
  • Nogués, E.A.
  • Aguilar, R.
  • Garcia-Aymerich, Judith|||0000-0002-7097-4586
  • de Cid, Rafael|||0000-0003-3579-6777
  • Dobaño, C.
  • Moncunill, G.
  • Kogevinas, Manolis|||0000-0002-9605-0461
Limited research suggests that certain viruses reactivate in severe-acute-respiratory-syndrome-coronavirus 2 infection, contributing to the development of postacute sequelae of COVID-19 (PASC). We examined 1083 infected individuals from a population-based cohort, and assessed differences in plasma immunoglobulin (Ig)G and immunoglobulin A levels against Epstein-Barr virus (EBV), cytomegalovirus, varicella zoster virus (VZV), BK polyomavirus, KI polyomavirus, WU polyomavirus (WUPyV), respiratory syncytial virus, and Adv-36 according to the severity of previous COVID-19 and PASC history. Individuals who had experienced severe COVID-19 had higher antibody responses to latent viruses. Ever PASC, active persistent PASC, and PASC with neuropsychiatric symptoms were associated with higher immnoglobulin G to EBV early antigen-diffuse, VZV, and WUPyV even among individuals without previous severe COVID-19.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The transition to motherhood, linking hormones, brain and behaviour

  • Servin-Barthet, Camila|||0000-0002-4771-898X
  • Martínez-García, Magdalena|||0000-0002-5054-9427
  • Pretus, Clara|||0000-0003-2172-1184
  • Paternina-Die, María|||0000-0002-5100-4955
  • Soler Campillo, Anna
  • Khymenets, Olha|||0000-0002-8668-580X
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • Leuner, Benedetta|||0000-0002-8919-6892
  • Vilarroya Oliver, Óscar|||0000-0001-8285-5624
  • Carmona Cañabate, Susana|||0000-0001-5853-6527
We are witnessing a stark increase in scientific interest in the neurobiological processes associated with pregnancy and maternity. Convergent evidence suggests that around the time of labour, first-time mothers experience a specific pattern of neuroanatomical changes that are associated with maternal behaviour. Here we provide an overview of the human neurobiological adaptations of motherhood, focusing on the interplay between pregnancy-related steroid and peptide hormones, and neuroplasticity in the brain. We discuss which brain plasticity mechanisms might underlie the structural changes detected by MRI, which hormonal systems are likely to contribute to such neuroanatomical changes and how these brain mechanisms may be linked to maternal behaviour. This Review offers an overarching framework that can serve as a roadmap for future investigations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multiplex real-time PCR in non-invasive respiratory samples to reduce antibiotic use in community-acquired pneumonia, a randomised trial

  • Abelenda-Alonso, Gabriela|||0000-0001-8158-9934
  • Calatayud, Laura|||0000-0001-6182-4538
  • Rombauts, Alexander|||0000-0003-0227-5916
  • Meije, Yolanda
  • Oriol, Isabel|||0000-0001-5542-7878
  • Sopena, Nieves|||0000-0001-6382-9500
  • Padullés, Ariadna|||0000-0003-1541-6001
  • Niubó, Jordi|||0000-0001-9511-0138
  • Duarte, Alejandra
  • Llaberia-Marcual, Jaume|||0000-0002-8675-2777
  • Aranda, Judit
  • Gudiol, Carlota|||0000-0003-3095-4422
  • Satorra, Pau|||0000-0002-8144-4089
  • Tebé, Cristian|||0000-0003-2320-1385
  • Ardanuy, Carmen|||0000-0003-0225-607X
  • Carratalà, Jordi|||0000-0003-3209-2563
We assessed whether multiplex real-time PCR plus conventional microbiological testing is safe and more effective than conventional microbiological testing alone for reducing antibiotic use in community-acquired pneumonia (CAP). In this randomised trial, we recruited adults hospitalised with CAP at four Spanish hospitals. Patients were randomly assigned (1:1) to undergo either multiplex real-time PCR in non-invasive respiratory samples plus conventional microbiological testing or conventional microbiological testing alone. The primary endpoint was antibiotic use measured by days of antibiotic therapy (DOT). Between February 20, 2020, and April 24, 2023, 242 patients were enrolled; 119 were randomly assigned to multiplex real-time PCR plus conventional microbiological testing and 123 to conventional microbiological testing alone. All but one of the patients allocated to multiplex real-time PCR plus conventional microbiological testing underwent PCR, which was performed in sputum samples in 77 patients (65.2%) and in nasopharyngeal swabs in 41 (34.7%). The median DOT was 10.04 (IQR 7.98, 12.94) in the multiplex PCR plus conventional microbiological testing group and 11.33 (IQR 8.15, 16.16) in the conventional microbiological testing alone group (difference -1.04; 95% CI, -2.42 to 0.17; p = 0.093). No differences were observed in adverse events and 30-day mortality. Our findings do not support the routine implementation of multiplex real-time PCR in the initial microbiological testing in hospitalised patients with CAP. Clinicaltrials.gov registration: NCT04158492.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline

  • Rodríguez Antigüedad, Jon|||0000-0002-9316-1772
  • Martínez-Horta, Saul|||0000-0003-0125-7249
  • Puig-Davi, Arnau|||0000-0001-8883-4947
  • Horta-Barba, Andrea|||0000-0003-0050-5466
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • de Deus Fonticoba, Teresa
  • Jesús, Silvia
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Ávila, Asunción|||0000-0001-8357-0751
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Gómez Mayordomo, Víctor|||0000-0001-9343-8439
  • González Ardura, Jessica
  • Dotor García-Soto, Julio
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Mendoza, Zebenzui
  • Pareés, Isabel|||0000-0002-6873-4823
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, María G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, Itziar
  • Ruiz Martínez, Javier|||0000-0001-7326-6270
  • Buongiorno, María Teresa
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • Valero, Caridad
  • Puente, Víctor
  • Kurtis, Mónica|||0000-0003-3037-9712
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
  • Santos García, Diego|||0000-0002-3126-5111
  • Kulisevsky, Jaime|||0000-0003-4870-1431
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunotherapy or Targeted Therapy Versus Best Supportive Care for Advanced Gastric Cancer, A Systematic Review and Meta-analysis of Randomized Trials

  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Santero, Marilina|||0000-0001-5371-0979
  • Savall-Esteve, Olga|||0009-0002-2685-1797
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Leache, Leire|||0000-0003-2272-7086
  • Selva, Anna|||0000-0002-2754-3158
  • Macias Declara, Ismael
  • Cerdà, Paula|||0000-0003-0101-188X
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Purpose: To assess the efficacy and safety of non-chemotherapy anticancer drugs (immunotherapy or targeted therapy) compared to best supportive care (BSC) or placebo for the treatment of advanced gastric cancer (GC). Methods: Systematic review of randomized controlled trials (RCTs) searching (May 2022) MEDLINE, EMBASE, CENTRAL, Epistemonikos, ClinicalTrials.gov, and PROSPERO. Certainty of evidence was evaluated following GRADE. Results: Six RCTs included. Targeted therapies likely result in a slight increase in overall survival (OS) (HR 0.84, 95% CI 0.75, 0.93; moderate certainty) and progression-free survival (PFS) (HR 0.52, 95% CI 0.43, 0.62; moderate certainty). Toxicity had a slightly increased risk (RR 1.19, 95% CI 0.95, 1.48; low certainty). Immunotherapy also showed a likely improvement in PFS (HR 0.60, 95% CI 0.49, 0.73; moderate certainty), while toxicity showed a likely higher risk (RR 2.72, 95% CI 1.24, 5.94; moderate certainty). However, benefits in survival translated to time gains of slightly over a month for OS and less than a month for PFS. No data were reported on performance status (PS), hospital admissions, or quality of life (QoL). Conclusions: Our study suggests some survival benefits with low toxicity from these treatments, but gains are marginal. Uncertainties persist regarding their impact on QoL and outcomes for patients with poor PS. Caution is advised in treatment selection for advanced GC patients, who should actively participate in decision-making. Future research should include diverse patient populations and assess patient-centered outcomes with consistent comparator groups for BSC. Trial Registration: The study protocol was registered in OSF (https://doi.org/10.17605/OSF.IO/7CHX6) on 2022-04-01.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The prognostic impact of SIGLEC5-induced impairment of CD8 + T cell activation in sepsis

  • Lozano-Rodríguez, Roberto
  • Avendaño-Ortíz, José
  • Montalbán-Hernández, Karla
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Martín-Quirós, Alejandro
  • Maroun-Eid, Charbel
  • González-López, Juanjo|||0000-0003-2419-5909
  • Fàbrega-Santamaria, Anna|||0000-0002-3866-2291
  • Terrón-Arcos, Verónica
  • Gutiérrez-Fernández, María
  • Alonso-López, Elisa
  • Cubillos-Zapata, Carolina
  • Fernández Velasco, María|||0000-0002-3293-3046
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Pelegrín, Pablo|||0000-0002-9688-1804
  • García-Palenciano, Carlos
  • Cueto, Francisco J.
  • del Fresno, Carlos
  • López-Collazo, Eduardo
Sepsis is associated with T-cell exhaustion, which significantly reduces patient outcomes. Therefore, targeting of immune checkpoints (ICs) is deemed necessary for effective sepsis management. Here, we evaluated the role of SIGLEC5 as an IC ligand and explored its potential as a biomarker for sepsis. In vitro and in vivo assays were conducted to both analyse SIGLEC5's role as an IC ligand, as well as assess its impact on survival in sepsis. A multicentre prospective cohort study was conducted to evaluate the plasmatic soluble SIGLEC5 (sSIGLEC5) as a mortality predictor in the first 60 days after admission in sepsis patients. Recruitment included sepsis patients (n = 346), controls with systemic inflammatory response syndrome (n = 80), aneurism (n = 11), stroke (n = 16), and healthy volunteers (HVs, n = 100). SIGLEC5 expression on monocytes was increased by HIF1α and was higher in septic patients than in healthy volunteers after ex vivo LPS challenge. Furthermore, SIGLEC5-PSGL1 interaction inhibited CD8 + T-cell proliferation. Administration of sSIGLEC5r (0.8 mg/kg) had adverse effects in mouse endotoxemia models. Additionally, plasma sSIGLEC5 levels of septic patients were higher than HVs and ROC analysis revealed it as a mortality marker with an AUC of 0.713 (95% CI, 0.656-0.769; p < 0.0001). Kaplan-Meier survival curve showed a significant decrease in survival above the calculated cut-off (HR of 3.418, 95% CI, 2.380-4.907, p < 0.0001 by log-rank test) estimated by Youden Index (523.6 ng/mL). SIGLEC5 displays the hallmarks of an IC ligand, and plasma levels of sSIGLEC5 have been linked with increased mortality in septic patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Socioeconomic Inequalities in the External Exposome in European Cohorts, The EXPANSE Project

  • Saucy, Apolline|||0000-0002-6432-2098
  • Coloma, Fabian
  • Olmos, Sergio
  • Åström, Christofer
  • Blay, Natalia|||0000-0002-7160-8529
  • Boer, Jolanda M. A.
  • Dadvand, Payam|||0000-0002-2325-1027
  • De Bont, Jeroen|||0000-0001-9924-5961
  • de Cid, Rafael|||0000-0003-3579-6777
  • de Hoogh, Kees|||0000-0001-5974-2007
  • Dimakopoulou, Konstantina
  • Gehring, Ulrike
  • Huss, Anke
  • Ibi, Dorina
  • Katsouyanni, Klea
  • Koppelman, GGerard
  • Ljungman, Petter
  • Melén, Erik|||0000-0002-8248-0663
  • Nieuwenhuijsen, Mark|||0000-0001-9461-7981
  • Nobile, Federica
  • Peters, Annette|||0000-0001-6645-0985
  • Pickford, Regina
  • Vermeulen, Roel|||0000-0003-4082-8163
  • Vienneau, Danielle
  • Vlaanderen, jelle
  • Wolf, Kathrin
  • Yu, Zhebin
  • Samoli, Evangelia
  • Stafoggia, Massimo
  • Tonne, Cathryn|||0000-0003-3919-8264
Socioeconomic inequalities in the exposome have been found to be complex and highly context-specific, but studies have not been conducted in large population-wide cohorts from multiple countries. This study aims to examine the external exposome, encompassing individual and environmental factors influencing health over the life course, and to perform dimension reduction to derive interpretable characterization of the external exposome for multicountry epidemiological studies. Analyzing data from over 25 million individuals across seven European countries including 12 administrative and traditional cohorts, we utilized domain-specific principal component analysis (PCA) to define the external exposome, focusing on air pollution, the built environment, and air temperature. We conducted linear regression to estimate the association between individual- and area-level socioeconomic position and each domain of the external exposome. Consistent exposure patterns were observed within countries, indicating the representativeness of traditional cohorts for air pollution and the built environment. However, cohorts with limited geographical coverage and Southern European countries displayed lower temperature variability, especially in the cold season, compared to Northern European countries and cohorts including a wide range of urban and rural areas. The individual- and area-level socioeconomic determinants (i.e., education, income, and unemployment rate) of the urban exposome exhibited significant variability across the European region, with area-level indicators showing stronger associations than individual variables. While the PCA approach facilitated common interpretations of the external exposome for air pollution and the built environment, it was less effective for air temperature. The diverse socioeconomic determinants suggest regional variations in environmental health inequities, emphasizing the need for targeted interventions across European countries.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multiomic integration analysis identifies atherogenic metabolites mediating between novel immune genes and cardiovascular risk

  • Carreras-Torres, Robert|||0000-0002-2925-734X
  • Galván-Femenía, Iván|||0000-0002-6124-3730
  • Farré Ramon, Xavier|||0000-0001-6838-9479
  • Cortés, Beatriz|||0000-0002-2656-7051
  • Díez-Obrero, Virginia|||0000-0002-0163-9872
  • Carreras Nolla, Anna|||0000-0002-8789-067X
  • Moratalla-Navarro, Ferran|||0000-0001-7858-5713
  • Iraola-Guzmán, Susana|||0000-0003-3359-1241
  • Blay, Natalia|||0000-0002-7160-8529
  • Obón-Santacana, Mireia|||0000-0003-4646-3513
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • de Cid, Rafael|||0000-0003-3579-6777
Background: Understanding genetic-metabolite associations has translational implications for informing cardiovascular risk assessment. Interrogating functional genetic variants enhances our understanding of disease pathogenesis and the development and optimization of targeted interventions. Methods: In this study, a total of 187 plasma metabolite levels were profiled in 4974 individuals of European ancestry of the GCAT| Genomes for Life cohort. Results of genetic analyses were meta-analysed with additional datasets, resulting in up to approximately 40,000 European individuals. Results of meta-analyses were integrated with reference gene expression panels from 58 tissues and cell types to identify predicted gene expression associated with metabolite levels. This approach was also performed for cardiovascular outcomes in three independent large European studies (N = 700,000) to identify predicted gene expression additionally associated with cardiovascular risk. Finally, genetically informed mediation analysis was performed to infer causal mediation in the relationship between gene expression, metabolite levels and cardiovascular risk. Results: A total of 44 genetic loci were associated with 124 metabolites. Lead genetic variants included 11 non-synonymous variants. Predicted expression of 53 fine-mapped genes was associated with 108 metabolite levels; while predicted expression of 6 of these genes was also associated with cardiovascular outcomes, highlighting a new role for regulatory gene HCG27. Additionally, we found that atherogenic metabolite levels mediate the associations between gene expression and cardiovascular risk. Some of these genes showed stronger associations in immune tissues, providing further evidence of the role of immune cells in increasing cardiovascular risk. Conclusions: These findings propose new gene targets that could be potential candidates for drug development aimed at lowering the risk of cardiovascular events through the modulation of blood atherogenic metabolite levels.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Amyloid deposition in adults with drug-resistant temporal lobe epilepsy

  • Fonseca, Elena|||0000-0002-3895-1237
  • Lallana, Sofía|||0000-0002-5999-9889
  • Ortega, Gemma
  • Cano, Amanda|||0000-0001-9567-4283
  • Sarria Estrada, Silvana|||0000-0003-0083-362X
  • Pareto, Deborah|||0000-0001-7356-3769
  • Quintana, Manuel|||0000-0003-0288-9088
  • Lorenzo Bosquet, Carles|||0000-0002-8824-4602
  • López Maza, Samuel|||0000-0003-3660-2604
  • Gifreu, Ariadna
  • Campos Fernández, Daniel|||0000-0003-4795-5309
  • Abraira del Fresno, Laura|||0000-0002-5119-7929
  • Santamarina Perez, Estevo|||0000-0003-1915-0335
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Aguilera, Núria
  • Ramis, Maribel
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Rovira, Alex|||0000-0002-2132-6750
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Toledo, Manuel|||0000-0003-1550-3316
Objective: Pathological amyloid-β (Aβ) accumulation and hyperphosphorylated tau proteins have been described in resected temporal lobe specimens of epilepsy patients. We aimed to determine cerebrospinal fluid (CSF) Aβ1-42 and p181-tau levels and cerebral Aβ deposits on positron emission tomography (Aβ PET) and correlate these findings with cognitive performance in adults with drug-resistant temporal lobe epilepsy (TLE). Methods: In this cross-sectional study, we enrolled individuals with drug-resistant TLE who were 25-55 years old. Each participant underwent F-flutemetamol PET, determination of CSF Aβ1-42, p181-tau, and total tau, and a comprehensive neuropsychological assessment. We evaluated normalized standard uptake value ratios (SUVRs) for different brain regions on Aβ PET. Results: Thirty patients (mean age = 41.9 ± SD 8.1 years, 57% men) were included. The median disease duration was 9.5 (interquartile range = 4-24) years. Twenty-six patients (87%) had a clinically significant cognitive impairment on neuropsychological evaluation, 18 (69%) of the amnesic type. On Aβ PET, high uptake was observed in both mesial temporal regions (ipsilateral: SUVR z-score =.90, 95% confidence interval [CI] =.60-1.20; contralateral: SUVR z-score =.92, 95% CI =.57-1.27; p <.001), which was higher when compared to SUVR z-scores in all the remaining regions (p <.001) and in the ipsilateral anterior cingulate (SUVR z-score =.27, 95% CI =.04-.49, p =.020). No significant deposition was observed in other regions. Seven patients (23%) had low Aβ1-42 levels, and two (7%) had elevated p181-tau levels in CSF. Higher p181-tau levels correlated with poorer verbal fluency (R = -.427, p =.044). Significance: Our findings reveal a considerable Aβ deposition in mesial temporal regions and ipsilateral anterior cingulate among adults with drug-resistant TLE. Additionally, abnormal CSF Aβ1-42 levels were observed in a significant proportion of patients, and p181-tau levels were associated with verbal fluency. These results suggest that markers of neuronal damage can be observed in adults with TLE, warranting further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis, Role of Immunosenescence

  • Dema, María|||0000-0003-4812-4304
  • Eixarch, Herena|||0000-0001-7525-9533
  • Hervera Abad, Arnau|||0000-0001-8362-369X
  • Castillo Juárez, Mireia|||0000-0001-8979-3219
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Montalban, Xavier|||0000-0002-0098-9918
  • Espejo, Carmen|||0000-0001-9949-5901
The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability accumulation. This phenomenon can be related to age-related changes in the immune system: with age, the immune system undergoes a process called immunosenescence, characterized by a decline in the function of both the innate and adaptive immune responses. This decline can lead to a decreased ability to control inflammation and repair damaged tissue. Additionally, older individuals often experience a shift toward a more pro-inflammatory state, known as inflammaging, which can exacerbate the progression of neurodegenerative diseases like MS. Therefore, age-related alterations in the immune system could be responsible for the difference in the phenotype of MS observed in older and younger patients. In this study, we investigated the effects of age on the immunopathogenesis of experimental autoimmune encephalomyelitis (EAE). Our findings indicate that EAE is more severe in aged mice due to a more inflammatory and neurodegenerative environment in the central nervous system. Age-related changes predominantly affect adaptive immunity, characterized by altered T cell ratios, a pro-inflammatory Th1 response, increased regulatory T cells, exhaustion of T cells, altered B cell antigen presentation, and reduced NK cell maturation and cytotoxicity. Transcriptomic analysis reveals that fewer pathways and transcription factors are activated with age in EAE. These findings allow us to identify potential therapeutic targets specific to elderly MS patients and work on their development in the future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

  • Jiménez, Natalia|||0000-0002-7057-0426
  • Garcia de Herreros, Marta
  • Reig, Oscar|||0000-0003-1166-6943
  • Marín Aguilera, Mercedes
  • Aversa, Caterina
  • Ferrer-Mileo, Laura
  • García-Esteve, Samuel|||0000-0002-7680-2048
  • Rodríguez-Carunchio, Leonardo|||0000-0002-7019-554X
  • Trias, Isabel|||0000-0001-9841-4380
  • Font, Albert|||0000-0003-3908-1111
  • Rodriguez-Vida, Alejo|||0000-0002-7304-6857
  • Climent, Miguel Ángel|||0000-0001-7523-0212
  • Cros Costa, Sara|||0000-0001-8279-784X
  • Chirivella, Isabel|||0000-0002-0733-3276
  • Domènech, Montserrat|||0000-0003-3973-0986
  • Figols, Mariona
  • Carles, Joan|||0000-0002-9983-5934
  • Suárez, Cristina|||0000-0002-0502-5528
  • Herrero Rivera, Daniel
  • Gonzalez-Billalabeitia, Enrique|||0000-0003-3143-3143
  • Cívico, Claudia
  • Sala-González, Núria
  • Ruiz de Porras, Vicenç|||0000-0002-4352-1784
  • Ribal, María J.|||0000-0001-8142-5382
  • Prat, Aleix|||0000-0003-2377-540X
  • Mellado, Begoña|||0000-0002-8088-5966
BACKGROUND: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with an aggressive evolution and treatment resistance in castration-resistant prostate cancer (CRPC). OBJECTIVE: To study the clinical implications of TSG mRNA expression in mHSPC patients. DESIGN, SETTING, AND PARTICIPANTS: This is a multicenter retrospective biomarker study in mHSPC patients. TSGlow status was defined when two or more out of the three TSGs presented low RNA expression by nCounter in formalin-fixed paraffin-embedded samples and TSGwt for the remaining cases. The microarray data from the CHAARTED trial were analyzed as an independent validation cohort. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Molecular data were correlated with CRPC-free survival (CRPC-FS) and overall survival (OS) by the Kaplan-Meier method and multivariate Cox analysis. RESULTS AND LIMITATIONS: A total of 226 patients were included, of whom 218 were eligible: 93 were treated with ADT and 125 with ADT + D; 75.7% presented de novo stage IV and 67.9% high-volume disease. TSGlow (19.2%) was independently correlated with shorter CRPC-FS (hazard ratio [HR] 1.8, p = 0.002) and OS (HR 2, p = 0.002). In the CHAARTED trial, TSGlow was independently correlated with lower CRPC-FS (HR 2.2, p = 0.02); no differences in clinical outcomes according to treatment were observed in TSGlow patients, while a significant benefit was observed for ADT + D in the TSGwt group for CRPC-FS (HR 0.4, p < 0.001) and OS (HR 0.4, p = 0.001). However, no interaction was observed between TSG signature and treatment in either series. Study limitations are the retrospective design, small sample size, and lack of inclusion of patients treated with ADT + ART. CONCLUSIONS: TSGlow expression correlates with adverse outcomes in patients with mHSPC. The investigation of new therapeutic strategies in these patients is warranted. PATIENT SUMMARY: The low RNA expression of tumor suppressor genes in the tumors is correlated with adverse outcomes in patients with metastatic hormone-sensitive prostate cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early Detection of Cancer and Precancerous Lesions in Persons With HIV Through a Comprehensive Cancer Screening Protocol

  • Gutiérrez, Félix|||0000-0002-9485-6867
  • López, Leandro
  • Galera, Carlos
  • Tiraboschi, Juan Manuel|||0000-0002-0073-873X
  • Portu, Joseba
  • García-Fraile Fraile, Lucio|||0000-0002-2512-6107
  • García del Toro, Miguel
  • Bernal, Enrique|||0000-0002-4041-0579
  • Rivero Román, Antonio|||0000-0002-8643-4250
  • García-Abellán, Javier|||0000-0002-5217-3726
  • Flores, Juan
  • González Cordón, Ana|||0000-0002-0894-3711
  • Martínez, Onofre
  • Bravo Urbieta, Joaquín|||0000-0003-2079-0305
  • Rosado, Dácil
  • Montero, Marta|||0000-0002-3432-5394
  • Sirera, Guillem|||0000-0003-4014-9355
  • Torralba, Miguel|||0000-0003-2166-7405
  • Galindo Puerto, María José
  • Macías, Juan|||0000-0002-4778-790X
  • Gónzalez Cuello, Inmaculada|||0000-0001-8519-7823
  • Boix, Vicente|||0000-0002-7015-3948
  • Vivancos, María Jesús
  • Dios Diez, Paula|||0000-0003-2700-6595
  • Blanco, José Ramón|||0000-0002-4268-0150
  • Padilla Urrea, Sergio|||0000-0002-8420-7310
  • Fernández-González, Marta|||0000-0001-9949-8504
  • Gutiérrez Ortiz de la Tabla, Ana|||0000-0002-6080-0195
  • Martínez, Esteban|||0000-0002-6911-8846
  • Masiá, Mar|||0000-0001-9878-2458
Background. Non-AIDS defining malignancies present a growing challenge for persons with human immunodeficiency virus (HIV, PWH), yet tailored interventions for timely cancer diagnosis are lacking. The Spanish IMPAC-Neo protocol was designed to compare two comprehensive cancer screening strategies integrated into routine HIV care. This study reports baseline data on the prevalence and types of precancerous lesions and early-stage cancer among participants at enrolment. Acceptability of the procedure was additionally assessed. Methods. Cross-sectional analysis of a comprehensive screening protocol to detect precancer and cancer. The readiness of healthcare providers to implement the protocol was evaluated using a validated 4-item survey. Results. Among the 1430 enrolled PWH, 1172 underwent 3181 screening tests, with positive findings in 29.4% of cases, leading to further investigation in 20.7%. Adherence to the protocol was 84%, with HIV providers expressing high acceptability (97.1%), appropriateness (91.4%), and feasibility (77.1%). A total of 145 lesions were identified in 109 participants, including 60 precancerous lesions in 35 patients (3.0%), 9 early-stage cancers in 9 patients (0.8%), and 76 low-risk lesions in 65 subjects (5.5%). Adverse events related to screening occurred in 0.8% of participants, all mild. The overall prevalence of cancer precursors or early-stage cancer was 3.8% (95% confidence interval [CI], 2.74%-5.01%), with highest rates observed in individuals screened for anal and colorectal cancers. Conclusions. The baseline comprehensive cancer screening protocol of the IMPAC-Neo study successfully identified a significant proportion of PWH with precancerous lesions and early-stage cancer. High adherence rates and positive feedback from providers suggest effective implementation potential in real-world healthcare settings.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Machine learning for anxiety and depression profiling and risk assessment in the aftermath of an emergency

  • Villanueva Benito, Guillermo
  • Goldberg, Ximena|||0000-0001-9681-5826
  • Brachowicz, Nicolai
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Blay, Natalia|||0000-0002-7160-8529
  • Espinosa, Ana|||0000-0001-7399-3267
  • Davidhi, Flavia
  • Torres, Diego
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • de Cid, Rafael|||0000-0003-3579-6777
  • Petrone, Paula Marcela
Background & objectives: Mental health disorders pose an increasing public health challenge worsened by the COVID-19 pandemic. The pandemic highlighted gaps in preparedness, emphasizing the need for early identification of at-risk groups and targeted interventions. This study aims to develop a risk assessment tool for anxiety, depression, and self-perceived stress using machine learning (ML) and explainable AI to identify key risk factors and stratify the population into meaningful risk profiles. Methods: We utilized a cohort of 9291 individuals from Northern Spain, with extensive post-COVID-19 mental health surveys. ML classification algorithms predicted depression, anxiety, and self-reported stress in three classes: healthy, mild, and severe outcomes. A novel combination of SHAP (SHapley Additive exPlanations) and UMAP (Uniform Manifold Approximation and Projection) was employed to interpret model predictions and facilitate the identification of high-risk phenotypic clusters. Results: The mean macro-averaged one-vs-one AUROC was 0.77 (± 0.01) for depression, 0.72 (± 0.01) for anxiety, and 0.73 (± 0.02) for self-perceived stress. Key risk factors included poor self-reported health, chronic mental health conditions, and poor social support. High-risk profiles, such as women with reduced sleep hours, were identified for self-perceived stress. Binary classification of healthy vs. at-risk classes yielded F1-Scores over 0.70. Conclusions: Combining SHAP with UMAP for risk profile stratification offers valuable insights for developing effective interventions and shaping public health policies. This data-driven approach to mental health preparedness, when validated in real-world scenarios, can significantly address the mental health impact of public health crises like COVID-19.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sex-specific chrono-nutritional patterns and association with body weight in a general population in Spain (GCAT study)

  • Pons-Muzzo, Luciana
  • de Cid, Rafael|||0000-0003-3579-6777
  • Obón-Santacana, Mireia|||0000-0003-4646-3513
  • Straif, Kurt
  • Papantoniou, Kyriaki|||0000-0002-0340-9659
  • Santonja, Isabel|||0000-0002-6736-7988
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Palomar-Cros, Anna|||0000-0001-8151-9290
  • Lassale, Camille|||0000-0002-9340-2708
Background: Altered meal timing patterns can disrupt the circadian system and affect metabolism. Our aim was to describe sex-specific chrono-nutritional patterns, assess their association with body mass index (BMI) and investigate the role of sleep in this relationship. Methods: We used the 2018 questionnaire data from the population-based Genomes for Life (GCAT) (n = 7074) cohort of adults aged 40-65 in Catalonia, Spain, for cross-sectional analysis and its follow-up questionnaire data in 2023 (n = 3128) for longitudinal analysis. We conducted multivariate linear regressions to explore the association between mutually adjusted meal-timing variables (time of first meal, number of eating occasions, nighttime fasting duration) and BMI, accounting for sleep duration and quality, and additional relevant confounders including adherence to a Mediterranean diet. Finally, cluster analysis was performed to identify chrono-nutritional patterns, separately for men and women, and sociodemographic and lifestyle characteristics were compared across clusters and analyzed for associations with BMI. Results: In the cross-sectional analysis, a later time of first meal (β 1 h increase = 0.32, 95% CI 0.18, 0.47) and more eating occasions (only in women, β 1 more eating occasion = 0.25, 95% CI 0.00, 0.51) were associated with a higher BMI, while longer nighttime fasting duration with a lower BMI (β 1 h increase=-0.27, 95% CI -0.41, -0.13). These associations were particularly evident in premenopausal women. Longitudinal analyses corroborated the associations with time of first meal and nighttime fasting duration, particularly in men. Finally, we obtained 3 sex-specific clusters, that mostly differed in number of eating occasions and time of first meal. Clusters defined by a late first meal displayed lower education and higher unemployment in men, as well as higher BMI for both sexes. A clear "breakfast skipping" pattern was identified only in the smallest cluster in men. Conclusions: In a population-based cohort of adults in Catalonia, we found that a later time of first meal was associated with higher BMI, while longer nighttime fasting duration associated with a lower BMI, both in cross-sectional and longitudinal analyses.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU, Short-Term Results of a Multicenter Trial of GETECCU

  • Aguas, Mariam|||0000-0003-4353-569X
  • Del Hoyo, Javier|||0000-0003-3603-5793
  • Vicente, Raquel|||0000-0002-7605-3534
  • Barreiro de-Acosta, Manuel|||0000-0001-5915-1477
  • Melcarne, Luigi|||0000-0002-9718-9692
  • Hernández Camba, Alejandro|||0000-0002-8653-207X
  • Madero, Lucía
  • Arroyo, María Teresa
  • Sicilia Aladrén, Beatriz|||0000-0002-4495-9358
  • Chaparro, María|||0000-0002-9275-4242
  • Martín-Arranz, María Dolores|||0000-0002-1872-0917
  • Pajares, Ramón|||0000-0003-0549-6036
  • Mesonero, Francisco|||0000-0002-7864-8187
  • Mañosa i Ciria, Míriam|||0000-0002-9051-2581
  • Martinez Tirado, Pilar
  • Chacón, Silvia
  • Tosca, Joan
  • Marín, Sandra
  • Sanroman, Luciano
  • Calvo, Marta
  • Monfort, David
  • Saiz, Empar
  • Zabana, Yamile|||0000-0003-4023-8868
  • Guerra, Iván|||0000-0002-5175-2515
  • Varela, Pilar|||0000-0003-1737-3236
  • Baydal Bertomeu, Virginia
  • Faubel, Raquel|||0000-0002-8716-8003
  • Corsino, Pilar|||0000-0002-3412-8104
  • Porto-Silva, Sol
  • Brunet, Eduard|||0000-0001-8661-0608
  • González, Melodi
  • Gutiérrez Casbas, Ana|||0000-0002-5460-4139
  • Nos, Pilar|||0000-0002-6619-1511
Background: Telemonitoring for inflammatory bowel disease (IBD) has not consistently demonstrated superiority over standard care; however, noninferiority may be an acceptable outcome if remote care proves to be more efficient. Objective: This study aims to compare the remission time and quality of life of patients with active IBD managed through standard care versus the TECCU (Telemonitoring of Crohn Disease and Ulcerative Colitis) app. Methods: A 2-arm, randomized, multicenter trial with a noninferiority design was conducted across 24 hospitals in Spain. The study included adult patients with IBD who were starting immunosuppressive or biological therapy. Participants were randomized into 2 groups: the telemonitoring group (G_TECCU) and the standard care group (G_Control). The follow-up schedule for the telemonitoring group (G_TECCU) was based on contacts via the TECCU app, while the control group (G_Control) adhered to standard clinical practice, which included in-person visits and telephone calls. In both groups, treatment adjustments were made based on the progression of disease activity and medication adherence, assessed using specific indices and biological markers at each check-up. The primary outcome was the duration of remission after 12 weeks, while secondary outcomes included quality of life, medication adherence, adverse events, and patient satisfaction. Results: Of the 169 patients enrolled, 158 were randomized and 150 were analyzed per protocol: telemonitoring (n=71) and control (n=79). After 12 weeks, the time in clinical remission was not inferior in the telemonitoring group (mean 4.20, SD 3.73 weeks) compared with the control group (mean 4.32, SD 3.28 weeks), with a mean difference between arms of -0.12 weeks (95% CI -1.25 to 1.01; noninferiority P=.02). The mean reduction in C-reactive protein values was -15.40 mg/L (SD 90.15 mg/L; P=.19) in the G_TECCU group and -13.16 mg/L (SD 54.61 mg/L; P=.05) in the G_Control group, with no significant differences between the 2 arms (P=.73). Similarly, the mean improvement in fecal calprotectin levels was 832.3 mg/L (SD 1825.0 mg/L; P=.003) in the G_TECCU group and 1073.5 mg/L (SD 3105.7 mg/L; P=.03) in the G_Control group; however, the differences were not statistically significant (P=.96). Quality of life improved in both groups, with a mean increase in the 9-item Inflammatory Bowel Disease Questionnaire score of 13.44 points (SD 19.1 points; P<.001) in the G_TECCU group and 18.23 points (SD 22.9 points; P=.001) in the G_Control group. Additionally, the proportion of patients who adhered to their medication significantly increased from 35% (25/71) to 68% (48/71) in the G_TECCU group (P=.001) and from 46% (36/79) to 73% (58/79) in the G_Control group (P=.001). The satisfaction rate remained stable at around 90%, although noninferiority was not demonstrated for the secondary outcomes. Conclusions: Telemonitoring patients with active IBD is not inferior to standard care for achieving and maintaining short-term remission. The TECCU app may serve as a viable alternative follow-up tool, pending confirmation of improved health outcomes and cost-effectiveness over the long-term.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

  • Jimenez-Leon, Maria Reyes|||0000-0003-2723-319X
  • Gasca-Capote, Carmen|||0000-0002-7211-8599
  • Roca-Oporto, Cristina|||0000-0003-0079-5491
  • Espinosa, Nuria|||0000-0003-2249-2352
  • Sobrino, Salvador
  • Fontillon-Alberdi, Maria|||0000-0003-4031-8067
  • Gao, Ce
  • Roseto, Isabelle
  • Gladkov, Gregory
  • Rivas-Jeremias, Inmaculada
  • Neukam, Karin
  • Sánchez Hernández, José Germán
  • Rigo Bonnin, Raül|||0000-0001-5511-074X
  • Cervera-Barajas, Antonio J.
  • Mesones, Rosario
  • García, Federico
  • Alvarez-Rios, Ana Isabel
  • Bachiller, Sara
  • Vitalle, Joana
  • Perez-Gomez, Alberto
  • Camacho-Sojo, María Inés
  • Gallego, Isabel
  • Brander, Christian|||0000-0002-0548-5778
  • McGowan, Ian
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Yu, Xu
  • Lichterfeld, Mathias
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
BACKGROUND. We evaluated the safety and viral rebound, after analytical treatment interruption (ATI), of vedolizumab and ART in recent HIV-1 infection. We used this model to analyze the effect of α4β7 on the HIV-1 reservoir size. METHODS. Participants started ART with monthly vedolizumab infusions, and ATI was performed at week 24. Biopsies were obtained from ileum and cecum at baseline and week 24. Vedolizumab levels, HIV-1 reservoir, flow cytometry, and cell-sorting and antibody competition experiments were assayed. RESULTS. Vedolizumab was safe and well tolerated. No participant achieved undetectable viremia off ART 24 weeks after ATI. Only a modest effect on the time to achieve more than 1,000 HIV-1 RNA copies/mL and the proportion of participants off ART was observed, being higher in the vedolizumab group compared with historical controls. Just before ATI, α4β7 expression was associated with HIV-1 DNA and RNA in peripheral blood and with PD1 and TIGIT levels. Importantly, a complete blocking of α4β7 was observed on peripheral CD4 T cells but not in gut (ileum and cecum), where α4β7 blockade and vedolizumab levels were inversely associated with HIV-1 DNA. CONCLUSION. Our findings support α4β7 as an important determinant in HIV-1 reservoir size, suggesting the complete α4β7 blockade in tissue as a promising tool for HIV-cure combination strategies. TRIAL REGISTRATION. ClinicalTrials.gov NCT03577782. FUNDING. This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, "a way to make Europe," research contracts FI17/00186 and FI19/00083 and research projects PI18/01532, PI19/01127, PI22/01796), Conserjería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (research projects P20/00906), the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020), and the Spanish National Research Council.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

New Insights into the Exosome-Induced Migration of Uveal Melanoma Cells and the Pre-Metastatic Niche Formation in the Liver

  • Ramos, Raquel
  • Vinyals, Antònia|||0000-0003-3925-0050
  • Campos-Martin, Rafael|||0000-0002-1395-8571
  • Cabré i Gelada, Eduard|||0000-0002-1807-6981
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Vaquero, Javier
  • Gonzalez-Sanchez, Ester|||0000-0002-9636-9624
  • Bertran Rodríguez, Esther|||0000-0001-9356-7409
  • Ferreres, Josep Ramon
  • Lorenzo, Daniel|||0000-0001-7545-7257
  • De La Torre, Carolina G.
  • Fabregat, Isabel|||0000-0003-0136-8440
  • Caminal, J.M.|||0000-0001-9563-0344
  • Fabra Fres, Àngels
UM is an aggressive intraocular tumor characterized by high plasticity and a propensity to metastasize in the liver. However, the underlying mechanisms governing liver tropism remain poorly understood. Given the emerging significance of exosomes, we sought to investigate the contribution of UM-derived exosomes to specific steps of the metastatic process. Firstly, we isolated exosomes from UM cells sharing a common genetic background and different metastatic properties. A comparison of protein cargo reveals an overrepresentation of proteins related to cytoskeleton remodeling and actin filament-based movement in exosomes derived from the parental cells that may favor the detachment of cells from the primary site. Secondly, we assessed the role of macrophages in reprogramming the HHSCs by exosomes. The activation of HHSCs triggered a pro-inflammatory and pro-fibrotic environment through cytokine production, upregulation of extracellular matrix molecules, and the activation of signaling pathways. Finally, we found that activated HHSCs promote increased adhesion and migration of UM cells. Our findings shed light on the pivotal role of exosomes in pre-metastatic niche construction in the liver.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effect of Mediterranean diet or mindfulness-based stress reduction during pregnancy on placental volume and perfusion, A subanalysis of the IMPACT BCN randomized clinical trial

  • Nakaki, Ayako|||0000-0002-4395-3878
  • Denaro, Eugenio
  • Crimella, Maddalena
  • Castellani, Roberta
  • Vellvé, Kilian|||0000-0002-2376-7664
  • Izquierdo, Nora
  • Basso, Annachiara
  • Paules, Cristina|||0000-0001-6795-0367
  • Casas, Rosa|||0000-0002-0211-9166
  • Benitez, Leticia|||0000-0002-4950-036X
  • Casas, Irene
  • Larroya, Marta|||0000-0001-7929-6630
  • Genero, Mariona
  • Castro Barquero, Sara|||0000-0002-6876-5443
  • Gomez-Gomez, A|||0000-0001-8172-1827
  • Pozo, Oscar J|||0000-0002-1735-9728
  • Vieta, Eduard|||0000-0002-0548-0053
  • Estruch, Ramón|||0000-0003-1260-4445
  • Nadal, Alfons
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Crispi, Fatima|||0000-0002-7422-5240
  • Youssef, Lina|||0000-0002-0554-5507
Introduction: The IMPACT BCN trial-a parallel-group randomized clinical trial where 1221 pregnant women at high risk for small-for-gestational age (SGA) newborns were randomly allocated at 19- to 23-week gestation into three groups: Mediterranean diet, Mindfulness-based Stress reduction or non-intervention-has demonstrated a positive effect of Mediterranean diet and Stress reduction in the prevention of SGA. However, the mechanism of action of these interventions remains still unclear. The aim of this study is to investigate the effect of Mediterranean diet and Stress reduction on placental volume and perfusion. Material and Methods: Participants in the Mediterranean diet group received monthly individual and group educational sessions, and free provision of extra-virgin olive oil and walnuts. Women in the Stress reduction group underwent an 8-week Stress reduction program adapted for pregnancy, consisting of weekly 2.5-h and one full-day sessions. Non-intervention group was based on usual care. Placental volume and perfusion were assessed in a subgroup of randomly selected women (n = 165) using magnetic resonance (MR) at 36-week gestation. Small placental volume was defined as MR estimated volume <10th centile. Perfusion was assessed by intravoxel incoherent motion. Results: While mean MR placental volume was similar among the study groups, both interventions were associated with a lower prevalence of small placental volume (3.9% Mediterranean diet and 5% stress reduction vs. 17% non-intervention; p = 0.03 and p = 0.04, respectively). Logistic regression showed that small placental volume was significantly associated with higher risk of SGA in both study groups (OR 7.48 [1.99-28.09] in Mediterranean diet and 20.44 [5.13-81.4] in Stress reduction). Mediation analysis showed that the effect of Mediterranean diet on SGA can be decomposed by a direct effect and an indirect effect (56.6%) mediated by a small placental volume. Similarly, the effect of Stress reduction on SGA is partially mediated (45.3%) by a small placental volume. Results on placental intravoxel incoherent motion perfusion fraction and diffusion coefficient were similar among the study groups. Conclusions: Structured interventions during pregnancy based on Mediterranean diet or Stress reduction are associated with a lower proportion of small placentas, which is consistent with the previously observed beneficial effects of these interventions on fetal growth.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of the 2008 economic crisis on the burden of hepatitis B and C diseases in Southern European countries

  • Palladino, Claudia
  • Ramis, Rebeca|||0000-0001-6154-9142
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Biondi, Antonio
  • Carreras, Giulia|||0000-0002-1427-637X
  • Fischer, Florian
  • Gallus, Silvano|||0000-0002-8967-0400
  • Golinelli, Davide
  • Gorini, Giuseppe|||0000-0002-1413-5948
  • Hassan, Shoaib
  • Kabir, Zubair
  • Koyanagi, Ai|||0000-0002-9565-5004
  • Lazarus, Jeffrey V.|||0000-0001-9618-2299
  • Mentis, Alexios-Fotios A.
  • Meretoja, Tuomo|||0000-0002-2691-0710
  • Mokdad, Ali H.
  • Monasta, Lorenzo|||0000-0001-7774-548X
  • Mulita, Francesk|||0000-0001-7198-2628
  • Postma, Maarten J.
  • Tabarés-Seisdedos, Rafael|||0000-0002-1089-2204
  • Thiyagarajan, Arulmani
  • Taveira, Nuno|||0000-0003-0176-5585
  • Briz, Verónica|||0000-0003-2297-5098
Background: The economic crisis that began in 2008 has severely affected Southern (Greece, Italy, Portugal, Spain) Western European (SWE) countries of Western Europe (WE) and may have affected ongoing efforts to eliminate viral hepatitis. This study was conducted to investigate the impact of the economic crisis on the burden of HBV and HCV disease. Methods: Global Burden of Diseases 2019 data were used to analyse the rates of epidemiological metrics of HBV and HCV acute and chronic infections in SWE and WE. Time series modelling was performed to quantify the impact of healthcare expenditure on the time trend of HBV and HCV disease burden in 2000-2019. Results: Declining trends in incidence and prevalence rates of acute HBV (aHBV) and chronic HBV were observed in SWE and WE, with the pace of decline being slower in the post-austerity period (2010-2019) and mortality due to HBV stabilised in SWE. Acute HCV (aHCV) metrics and chronic HCV incidence and mortality showed a stable trend in SWE and WE, whereas the prevalence of chronic HCV showed an oscillating trend, decreasing in WE in 2010-2019 (p < 0.001). Liver cancer due to both hepatitis infections showed a stagnant burden over time. An inverse association was observed between health expenditure and metrics of both acute and chronic HBV and HCV. Conclusions: Epidemiological metrics for HBV and HCV showed a slower pace of decline in the post-austerity period with better improvement for HBV, a stabilisation of mortality and a stagnant burden for liver cancer due to both hepatitis infections. The economic crisis of 2008 had a negative impact on the burden of hepatitis B and C. Elimination of HBV and HCV by 2030 will be a major challenge in the SWE countries.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Mediterranean Diet in Pregnancy, Implications for Maternal Brain Morphometry in a Secondary Analysis of the IMPACT BCN Randomized Clinical Trial

  • Nakaki, Ayako|||0000-0002-4395-3878
  • Gomez, Yvan|||0000-0003-0794-7750
  • Castro Barquero, Sara|||0000-0002-6876-5443
  • Conti, Allegra|||0000-0003-4210-5065
  • Vellvé, Kilian|||0000-0002-2376-7664
  • Casas, Irene
  • Genero, Mariona
  • Youssef, Lina|||0000-0002-0554-5507
  • Segalés Tañà, Laura|||0000-0002-8583-8835
  • Benitez, Leticia|||0000-0002-4950-036X
  • Casas, Rosa|||0000-0002-0211-9166
  • Vieta, Eduard|||0000-0002-0548-0053
  • Bargalló, Núria|||0000-0001-6284-5402
  • Toschi, Nicola
  • Estruch, Ramón|||0000-0003-1260-4445
  • Crispi, Fatima|||0000-0002-7422-5240
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crovetto, Francesca|||0000-0003-0140-7411
INTRODUCTION: A Mediterranean diet has positive effects on the brain in mid-older adults; however, there is scarce information on pregnant individuals. We aimed to evaluate the effect of a structured Mediterranean diet intervention on the cortical structure of the maternal brain during pregnancy. METHODS: This study was a secondary analysis of the IMPACT BCN, a randomized clinical trial with 1221 high-risk pregnant women randomly allocated into three groups at 19-23 weeks of gestation: Mediterranean diet intervention, a mindfulness-based stress reduction program, or usual care. Maternal brain magnetic resonance imaging was performed during the third trimester of pregnancy in a random subgroup of participants. For this study, data from the Mediterranean diet and usual groups were analyzed. Maternal dietary intake, adherence to the Mediterranean diet and metabolite biomarkers were evaluated using a food frequency questionnaire, a 17-item dietary screener and plasma/urine samples, respectively. RESULTS: The cluster-wise analysis showed that the Mediterranean diet group participants (n = 34) had significantly larger surface areas in the right precuneus (90%CI: <0.0001-0.0004, p < 0.001) and left superior parietal (90%CI: 0.026-0.033, p = 0.03) lobules compared to the usual care group participants (n = 37). A larger right precuneus area was associated with high improvements in adherence to the Mediterranean diet, a high intake of walnuts and high concentrations of urinary hydroxytyrosol. A larger left superior parietal area was associated with a high intake of walnuts and high concentrations of urinary hydroxytyrosol. CONCLUSIONS: The promotion of a Mediterranean diet during pregnancy has a significant effect on maternal brain structure.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity

  • Núñez-Manchón, Judith
  • Capó, Júlia
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Juanola, Eduard
  • Pesovic, Jovan
  • Mosqueira-Martín, Laura
  • González-Imaz, Klaudia
  • Maestre-Mora, P.
  • Odria, Renato|||0000-0002-3420-797X
  • Savic-Pavicevic, Dusanka
  • Vallejo-Illarramendi, Ainara
  • Mamchaoui, Kamel
  • Bigot, Anne|||0000-0003-0337-5425
  • Mouly, Vicent
  • Suelves, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
Historically, cellular models have been used as a tool to study myotonic dystrophy type 1 (DM1) and the validation of therapies in said pathology. However, there is a need for in vitro models that represent the clinical heterogeneity observed in patients with DM1 that is lacking in classical models. In this study, we immortalized three DM1 muscle lines derived from patients with different DM1 subtypes and clinical backgrounds and characterized them at the genetic, epigenetic, and molecular levels. All three cell lines display DM1 hallmarks, such as the accumulation of RNA foci, MBNL1 sequestration, splicing alterations, and reduced fusion. In addition, alterations in early myogenic markers, myotube diameter and CTCF1 DNA methylation were also found in DM1 cells. Notably, the new lines show a high level of heterogeneity in both the size of the CTG expansion and the aforementioned molecular alterations. Importantly, these immortalized cells also responded to previously tested therapeutics. Altogether, our results show that these three human DM1 cellular models are suitable to study the pathophysiological heterogeneity of DM1 and to test future therapeutic options.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia

  • Karachaliou, Marianna|||0000-0002-3014-0747
  • Espinosa, Ana|||0000-0001-7399-3267
  • Farré Ramon, Xavier|||0000-0001-6838-9479
  • Blay, Natalia|||0000-0002-7160-8529
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Iraola-Guzmán, Susana|||0000-0003-3359-1241
  • Rubio, Rocio
  • Vidal, Marta
  • Jiménez, Alfons
  • Bañuls, Marc
  • Aguilar, Ruth|||0000-0003-3277-3107
  • Garcia-Aymerich, Judith|||0000-0002-7097-4586
  • Dobaño Lazaro, Carlota|||0000-0002-6751-4060
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Moncunill, Gemma|||0000-0001-5105-9836
  • de Cid, Rafael|||0000-0003-3579-6777
Background Mental illnesses have been overlooked as a potential factor influencing antibody responses to COVID-19 vaccine. Associations between mental disorders and antibody response might vary by specific disorders, depend on the long-term course of the illness and relate to psychotropic treatment. Methods: The association between mental illness diagnoses (mood affective disorders, anxiety disorders, other) over ten years and psychotropic drug prescription based on electronic health records with antibody levels (IgG and IgA) post COVID-19 vaccination was assessed in 939 vaccinated adults from Catalonia, Spain. We employed linear regression models to assess associations between specific mental illnesses and psychotropic drugs with antibody levels, correcting for demographics, comorbidities and lifestyle factors. In a genotyped subset (n = 247) we assessed the effect of polygenic risk scores (PRS) for mental illnesses and performed a two-sample mendelian randomization (MR) analysis to examine causality between mental illness and antibody responses. Results: Mood affective disorders were associated with lower IgG to receptor binding domain (RBD) [percentage change = -26.37 (95 % CI, -42.00, -6.54)]. Diagnosis of anxiety disorders was not associated with the outcome. The group of other diagnoses (mainly including insomnia and nicotine dependence) were associated with lower IgG RBD levels [percentage change: -21.53 (95 % CI, -35.38, -4.71)] and recent onset cases (≤5 years ago) showed greater decline in antibody levels. Participants on second-generation antipsychotics and multiple classes of psychotropic drugs in the last 6 months exhibited lower antibody levels. In the genotyped population, higher genetic liability (higher PRS) to schizophrenia was associated with lower IgG RBD levels [percentage change = -35.49 (95 % CI, -56.55, -4.23)]. MR analysis revealed a causal relationship between major depression genetic instrumental variables and lower IgG RBD and S levels. Conclusions: These findings raise concerns about the efficacy of COVID-19 vaccines and potentially of other vaccines as well, in individuals with mood affective disorders, current/recent insomnia and nicotine dependence and people on multiple psychotropic drugs. Whether these associations are translated into increased risk for breakthrough infections and immune mediated long-term sequels of the SARS-CoV-2 infection warrants further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High Hepatitis B Prevalence and Vaccination Needs Among Transgender Women and Men Sex Workers in Barcelona, Spain

  • Antuori Torres, Adrián|||0000-0002-2782-3125
  • Not, Anna|||0000-0001-8756-1094
  • Mesías-Gazmuri, Jocelyn|||0000-0001-8475-152X
  • González Soler, Victoria|||0000-0002-0983-2052
  • Montoro-Fernandez, Marcos|||0000-0003-2425-4120
  • Folch, Cinta|||0000-0001-8400-2668
  • Saludes, Verónica|||0000-0003-2139-3360
  • Villar, Marta
  • Meroño, Merçè
  • Paytubi, Sonia
  • Alemany, Laia|||0000-0003-0945-6015
  • Casabona-Barbarà, Jordi|||0000-0003-4816-5536
  • Martró, Elisa|||0000-0002-2867-6649
Background. Transgender women sex workers (TWSWs) and men sex workers (MSWs) are especially vulnerable to acquiring hepatitis B virus (HBV) infection. We aimed to describe HBV prevalence (hepatitis B surface antigen [HBsAg] and core antibody [HBcAb]) and associated risk factors for HBV exposure (HBcAb), to assess vaccination status and risk factors for no prior vaccination, and to compare HBV prevalence and vaccination status between TWSWs and MSWs. Methods. The SexCohort study was advertised to TWSWs and MSWs through several communication channels. At cohort entry through 2 community-based organizations in Barcelona, the study population was screened for HBV and other sexually transmitted infections, and an epidemiological questionnaire was administered (n = 271). Results. Overall, 93.0% of participants were migrants, mostly from South and Central American countries. HBsAg prevalence was 1.9% (TWSWs, 2.4%; vs MSWs, 0.9%; P =.42), and previous exposure to HBV was 31.8% (TWSWs, 38.5%; vs MSWs, 20.8%; P =.002). Over 5 years of sex work (adjusted odds ratio [aOR], 9.35), prior exposure to Treponema pallidum (aOR, 3.49), and treatment with anxiolytic drugs (aOR, 3.23) were associated with HBV exposure. Overall, 33.7% of participants exhibited immunity from vaccination (TWSWs, 30.8%; vs MSWs, 38.61%; P <.001), while 34.4% were candidates to HBV vaccination (TWSWs, 30.8%; vs MSWs, 40.6%; P <.001). Never having been on pre-exposure prophylaxis for HIV (odds ratio [OR], 4.23) and non-Spanish origin (OR, 5.00) were associated with no prior HBV vaccination. Conclusions. There is a need to reinforce screening and vaccination programs aimed at TWSWs and MSWs as integrated services offered at the community centers commonly accessed by these populations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Correction, ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5)

  • Leary, Alexandra
  • Estévez-García, Purificación
  • Sabatier, Renaud
  • Ray-Coquard, Isabelle|||0000-0003-2472-8306
  • Romeo, Margarita|||0000-0003-1725-8115
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil-Martin, Marta|||0000-0002-8548-5355
  • Garralda, Elena|||0000-0002-4412-7842
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • Morán, Teresa
  • Martin-Martorell, Paloma
  • Nadal, Ernest|||0000-0002-9674-5554
  • Gascón, Pere|||0000-0001-9690-9873
  • Rodon Ahnert, Jordi|||0000-0001-6467-3632
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Muñoz-Guardiola, Pau|||0000-0002-0741-4463
  • Fierro-Durán, Gemma
  • Pedrós-Gámez, Oriol
  • Pérez-Montoyo, Hector
  • Yeste-Velasco, Marc|||0000-0001-7788-0913
  • Cortal, Marc
  • Perez Campos, Antonio
  • Alfón, José|||0000-0002-1874-0184
  • Domenech, Carles|||0000-0002-2817-3750
  • Pérez-Fidalgo, Alejandro
  • Oaknin, Ana|||0000-0002-3592-7194
Following publication of the original article [1], the authors reported the the equal contribution statement was missing in the original submission. The correct equal contribution statement is: Alejandro Pérez-Fidalgo and Ana Oaknin contributed equally to this work.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

  • Leary, Alexandra
  • Estévez-García, Purificación
  • Sabatier, Renaud
  • Ray-Coquard, Isabelle|||0000-0003-2472-8306
  • Romeo, Margarita|||0000-0003-1725-8115
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil-Martin, Marta|||0000-0002-8548-5355
  • Garralda, Elena|||0000-0002-4412-7842
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • Morán, Teresa
  • Martin-Martorell, Paloma
  • Nadal, Ernest|||0000-0002-9674-5554
  • Gascón, Pere|||0000-0001-9690-9873
  • Rodon Ahnert, Jordi|||0000-0001-6467-3632
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Muñoz-Guardiola, Pau|||0000-0002-0741-4463
  • Fierro-Durán, Gemma
  • Pedrós-Gámez, Oriol
  • Pérez-Montoyo, Hector
  • Yeste-Velasco, Marc|||0000-0001-7788-0913
  • Cortal, Marc
  • Perez Campos, Antonio
  • Alfón, José|||0000-0002-1874-0184
  • Domenech, Carles|||0000-0002-2817-3750
  • Pérez-Fidalgo, Alejandro
  • Oaknin, Ana|||0000-0002-3592-7194
Background: Carboplatin and paclitaxel (CP) have been the standard of care for advanced/recurrent endometrial cancer (EC) for many years. However, this chemotherapy combination shows limited efficacy and recurrences often occur in less than 12 months. ABTL0812 is a novel drug that selectively kill cancer cells by cytotoxic autophagy and has shown anticancer efficacy in preclinical models of EC in combination with CP. Methods: ENDOLUNG was an open-label, phase 1/2 clinical trial designed to determine the safety and efficacy of Ibrilatazar (ABTL0812) with CP in patients with advanced/recurrent EC and non-irradiable stage III and IV squamous non-small cell lung cancer (sq-NSCLC). The phase 1 part consisted of a 3 + 3 de-escalation design followed by an expansion cohort with 12 patients. The primary endpoint was safety. ABTL0812 starting dose was 1300 mg tid combined with carboplatin at area under the curve (AUC) 5 and paclitaxel at 175 mg/m both administered every 21 days for up to 8 cycles. The phase 2 part included a total of 51 patients. The primary endpoint was overall response rate (ORR) and the secondary endpoints included duration of response (DOR), progression-free survival (PFS) and overall survival (OS). Results: During the phase 1 only one dose limiting toxicity (DLT), a grade 4 neutropenia, was observed in 1 out of 6 patients, thus no de-escalation was applied. One additional DLT, a grade 3 febrile neutropenia, was observed in the expansion cohort, thus the recommended phase 2 dose (RP2D) for ABTL0812 was established at 1300 mg tid. Most frequent hematological adverse events (AE) of the combination were neutropenia (52.9%), anemia (37.3%) and thrombocytopenia (19.6%). Nausea (66.7%), asthenia (66.7%), diarrhea (54.9%) and vomiting (54.9%) were the most frequent non-hematological adverse events (AEs). The combination of ABTL0812 plus CP showed an ORR of 65.8% (13.2% complete response and 52.6% partial response) with a median DOR of 7.4 months (95% CI: 6.3-10.8 months). Median PFS was 9.8 months (95% CI: 6.6-10.6) and median OS 23.6 months (95% CI 6.4-ND). Pharmacokinetic parameters were compatible with target engagement observed in preclinical studies, and blood pharmacodynamic biomarkers indicated sustained target regulation during, at least, 28 days after starting the treatment. Conclusions: This study suggests that the combination of ABTL0812 with CP is safe and feasible with an encouraging activity in patients with advanced/recurrent EC. Our data warrant further confirmation in prospective randomized trials. Trial registration: EU Clinical Trial Register, EudraCT number 2016-001352-21 and National Clinical Trials Number, NCT03366480. Registration on 19 September 2016.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Translating Muscle RNAseq Into the Clinic for the Diagnosis of Muscle Diseases

  • Segarra Casas, Alba|||0000-0001-5185-5031
  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Natera-de Benito, Daniel|||0000-0001-7764-2085
  • Kapetanovic, Solange
  • Hernández-Laín, Aurelio
  • Estévez-Arias, Berta|||0000-0002-1711-7489
  • Llansó, Laura|||0000-0003-4950-7657
  • Ortez, Carlos
  • Jou, Cristina|||0000-0002-2223-7880
  • Martí-Carrera, Itxaso
  • López-Márquez, Arístides
  • Rodríguez, Maria José
  • González Mera, Laura
  • Nedkova, Velina
  • Fernández-Torrón, Roberto
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
  • Juntas Morales, Raúl|||0000-0003-2205-1741
  • López-de Munain, Adolfo
  • Surralles, Jordi|||0000-0002-4041-7519
  • Nascimento, Andrés
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Gallano, Pia|||0000-0001-8104-2197
  • González Quereda, Lidia|||0000-0003-0715-6414
Objective: Approximately half of patients with hereditary myopathies remain without a definitive genetic diagnosis after DNA next-generation sequencing (NGS). Here, we implemented transcriptome analysis of muscle biopsies as a complementary diagnostic tool for patients with muscle disease but no definitive genetic diagnosis after exome sequencing. Methods: In total, 70 undiagnosed cases with suspected genetic muscular dystrophies or congenital myopathies were included in the study. Muscle RNAseq comprised the analysis of aberrant splicing, aberrant expression, and monoallelic expression. In addition, existing NGS data or variant calling from RNAseq were reanalyzed, and genome sequencing was performed in selected cases. Four aberrant splicing open-source tools were compared and assessed. Results: RNAseq established a diagnosis in 10/70 patients (14.3%) by identifying aberrant transcripts produced by single nucleotide variants (7/10) or copy number variants (3/10). Reanalysis of NGS data allowed the diagnosis in 9/70 individuals (12.9%). Based on this cohort, FRASER was the tool that reported more splicing outlier events per sample while showing the highest accuracy (81.26%). Conclusions: We demonstrate the utility of RNAseq in identifying causative variants in muscle diseases. Evaluation of four aberrant splicing tools allowed efficient identification of most pathogenic splicing events, obtaining a manageable number of candidate events for manual inspection, demonstrating feasibility for translation into a clinical setting. We also show how the integration of omic technologies reduces the turnaround time to identify causative variants.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multikinase Treatment of Glioblastoma, Evaluating the Rationale for Regorafenib

  • Muñoz-Mármol, Ana Maria|||0000-0003-1008-7763
  • Meléndez, Bárbara
  • Hernández, Ainhoa|||0000-0003-4678-6662
  • Sanz, Carolina
  • Domènech Viñolas, Marta|||0000-0003-4827-9170
  • Arpí-Llucia, Oriol
  • Gut, Marta|||0000-0002-4063-7159
  • Esteve, Anna|||0000-0002-1962-971X
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Parra, Genis
  • Carrato, Cristina|||0000-0002-1953-8287
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Pineda, Estela|||0000-0003-2128-747X
  • Alameda, Francesc|||0000-0002-7302-6901
  • de la Iglesia, Nuria|||0000-0002-1083-7715
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Estival, Anna|||0000-0002-2788-9159
  • Balañá, Carmen|||0000-0003-0771-0390
For a targeted drug to be effective, the target must be present. To determine if this condition was met for regorafenib in glioblastoma, we analyzed 46 genes encoding protein kinases (PKs) inhibited by regorafenib in preclinical studies. We further focused on a subset of 18 genes encoding PKs inhibited by regorafenib at clinically achievable concentrations, which-together with the anti-angiogenetic activity of regorafenib-constituted the rationale for the REGOMA and AGILE trials. Oncogenic/likely oncogenic mutations, gene amplification, fusions, and/or gene overexpression indicated a potential regorafenib target. Thirty-four (33%) and twenty-six (25.2%) patients harbored at least one such alteration in the 46- and 18-gene sets, respectively. However, these results may overestimate the effectiveness of regorafenib due to its difficulty in penetrating the blood-brain barrier to reach the target. Future use of multi-target drugs should be guided by a thorough understanding of target presence and the drug's ability to reach the target. We explored the rationale for treating glioblastoma (GBM) with regorafenib. In 103 newly diagnosed GBM patients, we assessed mutations, copy number variants (CNVs), fusions, and overexpression in 46 genes encoding protein kinases (PKs) potentially targeted by regorafenib or its metabolites and performed a functional enrichment analysis to assess their implications in angiogenesis. We analyzed regorafenib's binding inhibitory activity and target affinity for these 46 PKs and focused on a subset of 18 genes inhibited by regorafenib at clinically achievable concentrations and on 19 genes involved in angiogenesis. Putative oncogenic alterations were defined as oncogenic/likely oncogenic mutations, oncogenic fusions, CNVs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Platelet miRNA Biosignature Discriminates between Dementia with Lewy Bodies and Alzheimer's Disease

  • Gámez-Valero, Ana|||0000-0002-9530-2751
  • Campdelacreu, Jaume|||0000-0001-9196-7601
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Ispierto, Lourdes
  • Gascon Bayarri, Jordi|||0000-0002-9422-937X
  • Reñé, Ramón
  • Álvarez, Ramiro|||0000-0002-8053-7232
  • Armengol, Maria P.
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Beyer, Katrin|||0000-0001-8905-1514
Dementia with Lewy bodies (DLB) is one of the most common causes of degenerative dementia, after Alzheimer's disease (AD), and presents pathological and clinical overlap with both AD and Parkinson's disease (PD). Consequently, only one in three DLB cases is diagnosed correctly. Platelets, previously related to neurodegeneration, contain microRNAs (miRNAs) whose analysis may provide disease biomarkers. Here, we profiled the whole platelet miRNA transcriptome from DLB patients and healthy controls. Differentially expressed miRNAs were further validated in three consecutive studies from 2017 to 2019 enrolling 162 individuals, including DLB, AD, and PD patients, and healthy controls. Results comprised a seven-miRNA biosignature, showing the highest diagnostic potential for the differentiation between DLB and AD. Additionally, compared to controls, two miRNAs were down-regulated in DLB, four miRNAs were up-regulated in AD, and two miRNAs were down-regulated in PD. Predictive target analysis identified three disease-specific clusters of pathways as a result of platelet-miRNA deregulation. Our cross-sectional study assesses the identification of a novel, highly specific and sensitive platelet-associated miRNA-based biosignature, which distinguishes DLB from AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Autosomal dominant polycystic kidney disease, possibly the least silent cause of chronic kidney disease

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Furlano, Monica|||0000-0003-1025-3901
Pain is the highest prioritized patient-reported outcome in people with autosomal dominant polycystic kidney disease (ADPKD) but it remains infrequently and inconsistently measured across countries, studies and trials. The study by El-Damanawi et al. integrated a network of ADPKD expert clinicians, pain specialists, researchers and patient representatives from the national UK PKD charity, with the aim of addressing the lack of validated ADPKD-specific pain assessment tools (APATs). The APAT designed by the authors included several pain measurement tools and was tested in ADPKD patients, although further validation through assessment in larger cohorts is needed. Establishing a standardized instrument for pain measurement will ensure that pain is measured and reported in a consistent way to inform decision-making and identify effective interventions aimed at managing pain and minimizing the impact pain has on patients with ADPKD. In this context, the APAT established by the authors is to be warmly welcomed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Blood biomarker changes following therapeutic hypothermia in ischemic stroke

  • Palà, Elena|||0000-0002-1074-990X
  • Penalba, Anna
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • García-Berrocoso, Teresa|||0000-0001-7387-7389
  • Lamana-Vallverdu, Marcel
  • Meisel, Christian
  • Meisel, Andreas
  • van der Worp, H. Bart
  • R Macleod, Malcolm
  • Kallmünzer, Bernd
  • Schwab, Stefan
  • Montaner, Joan|||0000-0003-4845-2279
Therapeutic hypothermia is a promising candidate for stroke treatment although its efficacy has not yet been demonstrated in patients. Changes in blood molecules could act as surrogate markers to evaluate the efficacy and safety of therapeutic cooling. Blood samples from 54 patients included in the EuroHYP-1 study (27 treated with hypothermia, and 27 controls) were obtained at baseline, 24 ± 2 h, and 72 ± 4 h. The levels of a panel of 27 biomarkers, including matrix metalloproteinases and cardiac and inflammatory markers, were measured. Metalloproteinase-3 (MMP-3), fatty-acid-binding protein (FABP), and interleukin-8 (IL-8) increased over time in relation to the hypothermia treatment. Statistically significant correlations between the minimum temperature achieved by each patient in the hypothermia group and the MMP-3 level measured at 72 h, FABP level measured at 24 h, and IL-8 levels measured at 24 and 72 h were found. No differential biomarker levels were observed in patients with poor or favorable outcomes according to modified Rankin Scale scores. Although the exact roles of MMP3, FABP, and IL-8 in hypothermia-treated stroke patients are not known, further exploration is needed to confirm their roles in brain ischemia. Changes in blood molecules could act as surrogate markers to evaluate the efficacy and safety of therapeutic cooling. After evaluating a panel of 27 biomarkers including matrix metalloproteinases, cardiac, and inflammatory markers in the blood of patients treated with hypothermia and controls, MMP-3, FABP, and IL-8 increased over time in relation to the hypothermia treatment. These proteins deserve further exploration to confirm their role in brain ischemia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease

  • Martínez-Sánchez, Celia
  • Bassegoda, Octavi|||0000-0002-6036-6026
  • Deng, Hongping
  • Almodóvar, Xènia
  • Ibarzabal, Ainitze|||0000-0002-1220-6474
  • de Hollanda, Ana|||0000-0001-9114-8614
  • Martínez García de la Torre, Raquel-Adela
  • Blaya, Delia
  • Ariño, Silvia
  • Jiménez-Esquivel, Natalia
  • Aguilar-Bravo, Beatriz
  • Vallverdú, Julia
  • Montironi, Carla|||0000-0002-1453-2193
  • Osorio-Conles, Oscar
  • Fundora Suarez, Yiliam|||0000-0003-4950-6988
  • Sánchez Moreno, Francisco Javier
  • Gómez-Valadés, Alicia G.
  • Aguilar-Corominas, Laia
  • Soria, Anna|||0000-0001-5671-8343
  • Pose, Elisa|||0000-0002-0224-7686
  • Juanola, Adrià|||0000-0003-4832-5130
  • Cervera, Marta
  • Perez, Martina
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Affò, Silvia
  • Swanson, Kelly S.
  • Ferrer-Fàbrega, Joana
  • Balibrea Del Castillo, José María|||0000-0002-0764-7179
  • Sancho-Bru, Pau|||0000-0001-5569-9259
  • Vidal, Josep|||0000-0002-4564-4518
  • Ginès, Pere|||0000-0003-4657-4504
  • Smith, Andrew M.
  • Graupera, Isabel|||0000-0001-9170-9784
  • Coll, Mar|||0000-0003-3726-0087
: The accumulation of adipose tissue macrophages (ATMs) in obesity has been associated with hepatic injury. However, the contribution of ATMs to hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD) remains to be elucidated. Herein, we investigate the relationship between ATMs and liver fibrosis in patients with patients with NAFLD and evaluate the impact of modulation of ATMs over hepatic fibrosis in an experimental non-alcoholic steatohepatitis (NASH) model. Adipose tissue and liver biopsies from 42 patients with NAFLD with different fibrosis stages were collected. ATMs were characterised by immunohistochemistry and flow cytometry and the correlation between ATMs and liver fibrosis stages was assessed. Selective modulation of the ATM phenotype was achieved by i.p. administration of dextran coupled with dexamethasone in diet-induced obesity and NASH murine models. Chronic administration effects were evaluated by histology and gene expression analysis in adipose tissue and liver samples. In vitro crosstalk between human ATMs and hepatic stellate cells (HSCs) and liver spheroids was performed. Patients with NAFLD presented an increased accumulation of pro-inflammatory ATMs that correlated with hepatic fibrosis. Long-term modulation of ATMs significantly reduced pro-inflammatory phenotype and ameliorated adipose tissue inflammation. Moreover, ATMs modulation was associated with an improvement in steatosis and hepatic inflammation and significantly reduced fibrosis progression in an experimental NASH model. In vitro, the reduction of the pro-inflammatory phenotype of human ATMs with dextran-dexamethasone treatment reduced the secretion of inflammatory chemokines and directly attenuated the pro-fibrogenic response in HSCs and liver spheroids. Pro-inflammatory ATMs increase in parallel with fibrosis degree in patients with NAFLD and their modulation in an experimental NASH model improves liver fibrosis, uncovering the potential of ATMs as a therapeutic target to mitigate liver fibrosis in NAFLD. We report that human adipose tissue pro-inflammatory macrophages correlate with hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD). Furthermore, the modulation of adipose tissue macrophages (ATMs) by dextran-nanocarrier conjugated with dexamethasone shifts the pro-inflammatory phenotype of ATMs to an anti-inflammatory phenotype in an experimental murine model of non-alcoholic steatohepatitis. This shift ameliorates adipose tissue inflammation, hepatic inflammation, and fibrosis. Our results highlight the relevance of adipose tissue in NAFLD pathophysiology and unveil ATMs as a potential target for NAFLD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Longitudinal trajectories of maternal TSH in healthy pregnant women in Catalonia

  • Soldevila i Madorell, Berta|||0000-0002-4582-4201
  • Velasco Lopez, Maria Ines|||0000-0002-6143-6970
  • Muñoz, Carla
  • Díaz, Yesika|||0000-0002-3727-7340
  • Egea Cortés, Laia|||0000-0003-4002-8254
  • Ferrer-Escopiñan, Laura
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Martínez-Mondejar, Raquel
  • Casabona-Barbarà, Jordi|||0000-0003-4816-5536
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Longitudinal evaluation of thyroid function throughout pregnancy in the same subject could offer precise information about its dynamics as a physiological mechanism of adaption to the requirements. In this study, we evaluated longitudinal trajectories of maternal thyroid function during pregnancy by a latent class growth analysis and explored their association with maternal-fetal outcomes. A prospective observational study was carried out, including 414 healthy pregnant women, from the first trimester to delivery. Thyroid function and autoimmunity were measured in the three trimesters. Clinical data during pregnancy were obtained. Longitudinal mixed model techniques were performed to explore trajectories of gestational thyroid function. Three different longitudinal trajectories were obtained from maternal thyrotropin (TSH) levels: low-increasing TSH (class 1) in 86% of cases, high-increasing TSH (class 2) in 9.7%, and decreasing TSH (class 3) in 4.3%. No statistical differences in free thyroxine levels were found among the three classes. Differences in maternal age (P = 0.027) and initial maternal weight (P = 0.043) were observed among the groups. In logistic regression analysis, maternal age correlated with longitudinal trajectories. The three longitudinal classes remain when women with thyroid autoimmunity (TAI) are excluded. Multinomial logistic regression showed maternal age correlated with longitudinal trajectories independently of TAI status. Three differentiated TSH trajectories were found in healthy pregnant women living in Catalonia, as previously described. No association with obstetric outcomes was observed in these different chronological thyroid pathways, but maternal age might condition the longitudinal mechanism of thyroid function regulation throughout pregnancy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

  • Bastard, Paul|||0000-0002-5926-8437
  • Gervais, A.
  • Taniguchi, M.
  • Saare, L.
  • Särekannu, K.
  • Voyer, T.L.
  • Philippot, Q.
  • Rosain, J.
  • Bizien, L.
  • Asano, T.
  • Garcia-Prat, Marina|||0000-0001-5387-1908
  • Parra-Martínez, Alba|||0000-0002-9564-8912
  • Migaud, M.
  • Tsumura, M.
  • Conti, F.
  • Belot, Alexandre|||0000-0003-4902-5332
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Morio, T.
  • Tanaka, J.
  • Javouhey, E.
  • Haerynck, F.
  • Duvlis, S.
  • Ozcelik, Tayfun|||0000-0001-5937-1082
  • Keles, S.
  • Tandjaoui-Lambiotte, Y.
  • Escoda, S.
  • Husain, M.
  • Pan-Hammarström, Q.
  • Hammarström, L.
  • Ahlijah, G.
  • Haidar, A.A.
  • Soudee, C.
  • Arseguel, V.
  • Abolhassani, Hassan|||0000-0002-4838-0407
  • Sahanic, S.
  • Tancevski, I.
  • Nukui, Y.
  • Hayakawa, S.
  • Chrousos, G.P.
  • Michos, A.
  • Tatsi, E.B.
  • Filippatos, F.
  • Rodriguez-Palmero, A.
  • Troya, Jesús|||0000-0001-7323-114X
  • Tipu, I.
  • Meyts, I.
  • Roussel, L.
  • Ostrowski, S.R.
  • Schidlowski, L.
  • Prando, C.
  • Condino-Neto, Antonio|||0000-0002-1069-3117
  • Cheikh, N.
  • Bousfiha, A.A.
  • Bakkouri, J.E.
  • Peterson, P.
  • Pujol, Aurora|||0000-0002-9606-0600
  • Lévy, R.
  • Quartier, P.
  • Vinh, D.C.
  • Boisson, Bertrand|||0000-0001-5240-3555
  • Béziat, V.
  • Zhang, S.Y.
  • Borghesi, A.
  • Pession, A.
  • Andreakos, E.
  • Marr, N.
  • Mentis, A.F.A.
  • H.mogensen, T.
  • Rodríguez-Gallego, C.
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Tillmann, V.
  • Neven, B.
  • Trouillet-Assant, S.
  • Brodin, P.
  • Abel, Laurent|||0000-0001-7016-6493
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Zhang, Q.
  • Martinón Torres, Federico|||0000-0002-9023-581X
  • Salas, A.
  • Gómez-Carballa, A.
  • Gonzalez-Granado, L.I.
  • Kisand, K.
  • Okada, S.
  • Puel, A.
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • AlKhater, Suzan|||0000-0001-7315-6581
  • Alkan, G.
  • Castagnoli, R.
  • Cyrus, C.|||0000-0001-7333-6486
  • Bozdemir, S.E.
  • Emiroglu, M.
  • Gulhan, Belgin|||0000-0003-0839-1301
  • Erdeniz, E.H.
  • Hatipoglu, N.
  • Bayhan, G.I.|||0000-0002-1423-4348
  • Jabandziev, P.
  • Yuksek, S.K.
  • Karbuz, A.
  • Öz, Ş.K.T.
  • Marseglia, G.L.
  • Akcan, O.M.
  • Kılıç, A.O.
  • Parlakay, A.O.
  • Papadaki, M.
  • Slaba, K.
  • Sevketoglu, Esra|||0000-0002-8330-2877
  • Valencia-Ramos, J.
  • Yahşi, A.
  • Tuala, C.
  • Urbieta, A.I.D.
  • Esteban, B.D.
  • Santalla, M.J.D.
  • Pérez, C.F.
  • Villaverde, J.F.
  • Rodríguez, C.G.
  • Allut, J.L.G.
  • Vicente, L.G.
  • Vázquez, E.G.
  • Carballa, A.G.
  • Rial, J.G.
  • Barcala, F.J.G.
  • Liñares, B.G.
  • Iglesias, P.L.
  • Massa, B.L.
  • Fuentes, M.L.
  • Franco, M.L.
  • Lago, A.L.
  • Cruz, D.N.D.l
  • Masid, E.N.
  • Devesa, J.B.O.
  • Seco, J.P.
  • Núñez, M.P.
  • Bernal, M.P.D.M.
  • Freixo, H.P.
  • Rodríguez, L.P.
  • Pischedda, S.
  • Romero, M.P.
  • Reino, A.P.
  • Hervella, G.M.P.
  • Verdes, T.Q.
  • Redondo Collazo, Lorenzo|||0000-0002-3521-678X
  • Casuso, P.R.
  • García, S.R.
  • Vázquez, S.R.
  • Blanco, V.R.
  • Calle, I.R.
  • Velasco, C.R.
  • Núñez, N.R.
  • Sánchez, C.R.T.
  • Paz, E.S.
  • Orayyou, J.M.S.
  • Villanueva, C.S.
  • Fernández, S.S.
  • Sanmartín, P.S.
  • Muñiz, M.T.
  • Pena, R.T.
  • Castellano, M.T.
  • Cuadrado, L.V.
  • García, P.V.
  • Iglesias, M.S.V.
  • Lasheras, S.V.
  • Ferreiro Iglesias, Rocío|||0000-0002-0469-4332
  • Bastón-Rey, I.
  • Calviño-Suárez, C.
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Al-Muhsen, S.
  • Al-Mulla, F.
  • Amara, A.
  • Anderson, M.S.
  • Arias, A.A.
  • Arkin, L.M.
  • Feldman, H.B.
  • Biggs, C.M.
  • Bogunovic, Dusan|||0000-0002-9277-3232
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Bondarenko, A.|||0000-0002-9737-2868
  • Bryceson, Y.
  • Butte, M.J.
  • Casari, G.
  • Christodoulou, J.
  • Constantinescu, S.N.
  • Cooper, M.A.
  • Dalgard, C.L.
  • Desai, M.
  • Drolet, B.A.
  • Duval, X.
  • Baghdadi, J.E.
  • Eloy, P.
  • Espinosa-Padilla, S.
  • Fellay, Jacques|||0000-0002-8240-939X
  • Flores, Carlos|||0000-0001-5352-069X
  • Franco, J.L.
  • Froidure, A.
  • Gorochov, G.
  • Gregersen, P.K.
  • Grimbacher, B.
  • Hagin, D.
  • Halwani, R.
  • Heath, J.R.
  • Hsieh, E.W.Y.
  • Husebye, Eystein Sverre|||0000-0002-7886-2976
  • Imai, K.
  • Itan, Yuval
  • Jarvis, E.D.
  • Kaja, E.
  • Karamitros, T.
  • Ku, C.L.
  • Lau, Y.L.
  • Ling, Y.
  • Lucas, C.L.
  • Mansouri, D.
  • Maródi, L.
  • Mentré, F.
  • Milner, J.D.
  • Mironska, K.
  • Mogensen, T.H.
  • Ng, L.F.P.
  • Notarangelo, L.D.
  • Novelli, A.
  • Novelli, G.
  • O'Farrelly, C.
  • Okamoto, K.
  • Pape, J.W.
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Perez-Tur, J.
  • Perlin, D.S.
  • Pesole, G.
  • Planas, A.M.
  • Quintana-Murci, L.
  • Ramaswamy, S.
  • Renia, L.
  • Resnick, I.
  • Sancho-Shimizu, V.
  • Sediva, A.
  • Seppänen, M.R.J.
  • Shahrooei, M.
  • Shcherbina, A.
  • Slaby, O.
  • Snow, A.L.
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Soumelis, V.
  • Spaan, A.N.
  • Su, H.C.
  • Tangye, S.G.
  • Tayoun, A.A.
  • Temel, Ş.G.
  • Thorball, C.
  • Tiberghien, P.
  • Turvey, S.E.
  • Uddin, K.M.F.
  • Uddin, M.J.
  • Beek, D.v.d
  • Bernuth, H.v
  • Wauters, J.
  • Zatz, Mayana|||0000-0003-3970-8025
  • Zawadzki, Pawel
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7-9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2-5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6-35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1-9.6]) of IFN-ω and/or IFN-α2.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands

  • Díaz-Tejedor, A.
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Lorenzo-Mohamed, M.
  • González-Rodríguez, M.
  • Castellanos, B.
  • Sotolongo-Ravelo, J.
  • San-Segundo, L.
  • Corchete, L.A.
  • González-Méndez, L.
  • Martín Sánchez, Montserrat
  • Mateos, M. V.|||0000-0003-2390-1218
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Garayoa, M.
  • Paíno, T.
Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients' samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Repeat Expansions in PLIN4 Cause Autosomal Dominant Vacuolar Myopathy With Sarcolemmal Features

  • Llansó, Laura|||0000-0003-4950-7657
  • Stevanovski, Igor
  • Morís, Germán|||0000-0001-7608-2194
  • Collet Vidiella, Roger|||0000-0003-1668-1018
  • Segarra Casas, Alba|||0000-0001-5185-5031
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Gallano, Pia|||0000-0001-8104-2197
  • Alvarez, Rodrigo
  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Blanco, Rosa
  • San-Millán, Beatriz
  • Navarro, Carmen|||0000-0003-4445-8585
  • Illa, Isabel|||0000-0002-2186-2684
  • Ravenscroft, Gianina|||0000-0003-3634-211X
  • W. Deveson, Ira
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
Objective: We aim to describe and characterize two unrelated Spanish families suffering from an autosomal dominant autophagic vacuolar myopathy caused by repeat expansions in PLIN4. Methods: We evaluated the clinical phenotype and muscle imaging, and performed a genetic workup that included exome sequencing, muscle RNAseq, and long-read genome sequencing. Muscle pathology was assessed by means of histochemistry, electron microscopy, PLIN4, p62, LC3, and NBR1 immunofluorescence and/or western blotting. Detailed characterization of autophagic vacuoles was performed. Results: Patients presented around the age of 30 with mild proximal weakness followed by prominent distal weakness in lower legs, eventually spreading to other muscle groups. Muscle biopsies showed unique pathological features characterized by numerous rimmed vacuoles that displayed sarcolemmal features and were located beneath the sarcolemma and within the cytoplasm. Ultrastructural studies showed autophagic vacuoles, replications, and loops of the basal lamina and tubulofilamentous sarcoplasmic inclusions. p62 and NBR1 co-localized with PLIN4 at the sarcolemma and vacuoles. LC3 immunoreactivity and other lysosomal markers were increased at the vacuoles. Targeted long-read sequencing of PLIN4 in affected individuals revealed a single expanded allele of 39 × 99 bp repeats in family 1 and of 37 × 99 bp repeats in family 2. Interpretation: We characterize two new families suffering from an autosomal dominant myopathy carrying repeat expansions in PLIN4. Subsarcolemmal p62 expression is a powerful although nonspecific marker of this disease. No correlation between the size of the expansion and clinical severity can be clearly established. PLIN4 expansions should be considered in the diagnosis of autosomal dominant vacuolar myopathies, especially when sarcolemmal features are present.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

  • Pinato, David James|||0000-0002-3529-0103
  • Kaneko, Takahiro
  • D'Alessio, Antonio
  • Forner, Alejandro|||0000-0002-9014-4950
  • Fessas, Petros|||0000-0002-7472-8913
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Giannini, Edoardo G.
  • Grillo, Federica
  • Díaz, Alba|||0000-0002-0456-7085
  • Mauri, Francesco A.
  • Fulgenzi, Claudia A.M.
  • Dalla Pria, Alessia
  • Goldin, Robert D.
  • Pieri, Giulia
  • Toniutto, Pierluigi|||0000-0002-2566-3041
  • Avellini, Claudio
  • Plaz Torres, Maria Corina
  • Akarca, Ayse U.
  • Marafioti, Teresa
  • Bhoori, Sherrie
  • Miró, José M.|||0000-0001-8057-7755
  • Bower, Mark
  • Bräu, Norbert
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
HIV-seropositivity shortens survival in patients with hepatocellular carcinoma (HCC). Although risk factors for HCC including HCV infection can influence T cell phenotype, it is unknown whether HIV can influence functional characteristics of the T cell infiltrate. From the Liver Cancer in HIV biorepository, we derived 129 samples of transplanted (76%) or resected (20%) HCC in eight European and North American centres. We profiled intra- and peritumoural tissue to evaluate regulatory CD4+/FOXP3+ and immune-exhausted CD8+/PD1+ T cells in HIV+ (n = 66) and HIV- (n = 63) samples. We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples evaluated in relationship with HIV status. We correlated immunopathologic features with patients' characteristics including markers of HIV infection. Of the 66 HIV+ patients, 83% were HCV coinfected with an undetectable HIV viral load (51%) and a median blood CD4+ cell count of 430 cells/mm 3 (range 15-908). Patients who were HIV+ were compared with HIV- controls with similar staging characteristics including Barcelona Clinic Liver Cancer (BCLC) stage A-B (86% vs. 83%, p = 0.16), <3 nodules (90% vs. 83%, p = 0.3) and median alpha-foetoprotein values (10.9 vs. 12.8 ng/ml, p = 0.72). HIV+ samples had higher PD-L1 expression rates in tumour tissue (51% vs. 8% p <0.0001) and displayed denser intratumoural CD4+/FOXP3+ (p <0.0001), CD8+/PD1+ (p <0.0001), with lower total peritumoural CD4+ (p <0.0001) and higher peritumoural CD8+/PD1+ (p <0.0001). Gene set analysis revealed HIV+ cases to have evidence of dysregulated adaptive and innate immunity. Tumour-infiltrating lymphocyte clonality was not influenced by HIV status. HIV-associated HCC harbours a profoundly immune-exhausted tumour microenvironment, warranting prospective testing of immunotherapy in this treatment-deprived patient population. Hepatocellular carcinoma is a non-AIDS defining malignancy characterised by poor survival. The programmed cell death (PD-1) pathway governs antiviral and anticancer immune exhaustion and is a therapeutic target in HCC. This study highlights how HIV infection is associated with significantly higher PD-L1 expression in HCC cells and in the surrounding microenvironment, leading to changes in cytotoxic and regulatory T cell function and dysregulation of proinflammatory pathways. Taken together, our results suggest dysfunctional T cell immunity as a mechanism of worse outcome in these patients and suggest clinical testing of checkpoint inhibitors in HIV-associated HCC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Emotional intelligence, a comparison between patients after first episode mania and those suffering from chronic bipolar disorder type I

  • Varo, Cristina|||0000-0002-8859-3052
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Sparacino, Giulio
  • Jiménez, Esther
  • Solé, Brisa|||0000-0003-1673-8248
  • Bonnin, Caterina del Mar|||0000-0002-1197-1596
  • Montejo, Laura|||0000-0003-4407-9454
  • Serra-Navarro, Maria|||0000-0002-9736-4630
  • Torrent, Carla|||0000-0003-0335-582X
  • Salagre, Estela|||0000-0001-6352-5179
  • Benabarre, Antoni|||0000-0001-8814-2246
  • Salgado-Pineda, Pilar|||0000-0001-7720-0885
  • Montoro Salvatierra, Irene
  • Sáiz, Pilar A.|||0000-0002-5705-4523
  • García-Portilla, María Paz|||0000-0003-3643-1622
  • Sánchez Gistau, Vanessa|||0000-0002-8635-7144
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Pacchiarotti, Isabella|||0000-0002-7822-0367
  • Garcia Rizo, Clemente|||0000-0002-4855-1608
  • Undurraga, Juan|||0000-0001-6958-2369
  • Reinares, María|||0000-0001-8859-4453
  • Martínez-Àran, Anabel|||0000-0002-0623-6263
  • Vieta, Eduard|||0000-0002-0548-0053
  • Verdolini, Norma|||0000-0001-9488-2881
Deficits in emotional intelligence (EI) were detected in patients with bipolar disorder (BD), but little is known about whether these deficits are already present in patients after presenting a first episode mania (FEM). We sought (i) to compare EI in patients after a FEM, chronic BD and healthy controls (HC); (ii) to examine the effect exerted on EI by socio-demographic, clinical and neurocognitive variables in FEM patients. The Emotional Intelligence Quotient (EIQ) was calculated with the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT). Performance on MSCEIT was compared among the three groups using generalized linear models. In patients after a FEM, the influence of socio-demographic, clinical and neurocognitive variables on the EIQ was examined using a linear regression model. In total, 184 subjects were included (FEM n = 48, euthymic chronic BD type I n = 75, HC n = 61). BD patients performed significantly worse than HC on the EIQ [mean difference (MD) = 10.09, standard error ( = 3.14, p = 0.004] and on the understanding emotions branch (MD = 7.46, = 2.53, p = 0.010). FEM patients did not differ from HC and BD on other measures of MSCEIT. In patients after a FEM, EIQ was positively associated with female sex (β = -0.293, p = 0.034) and verbal memory performance (β = 0.374, p = 0.008). FEM patients performed worse than HC but better than BD on few neurocognitive domains. Patients after a FEM showed preserved EI, while patients in later stages of BD presented lower EIQ, suggesting that impairments in EI might result from the burden of disease and neurocognitive decline, associated with the chronicity of the illness.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vertical transmission of maternal DNA through extracellular vesicles associates with altered embryo bioenergetics during the periconception period

  • Bolumar, David
  • Moncayo-Arlandi, Javier|||0000-0002-3564-4063
  • Gonzalez-Fernandez, Javier|||0000-0002-9625-5264
  • Ochando Hernandez, Ana|||0000-0001-5255-8813
  • Moreno, Inmaculada
  • Monteagudo-Sánchez, Ana|||0000-0002-1432-1185
  • Marin, Carlos
  • Diez, Antonio
  • Fabra, Paula
  • Checa, Miguel Angel|||0000-0002-0226-3416
  • Espinós, Juan José|||0000-0003-4838-8940
  • Gardner, David K.
  • Simon, Carlos
  • Vilella, Felipe|||0000-0002-0039-9846
The transmission of DNA through extracellular vesicles (EVs) represents a novel genetic material transfer mechanism that may impact genome evolution and tumorigenesis. We aimed to investigate the potential for vertical DNA transmission within maternal endometrial EVs to the pre-implantation embryo and describe any effect on embryo bioenergetics. We discovered that the human endometrium secretes all three general subtypes of EV - apoptotic bodies (ABs), microvesicles (MVs), and exosomes (EXOs) - into the human endometrial fluid (EF) within the uterine cavity. EVs become uniformly secreted into the EF during the menstrual cycle, with the proportion of different EV populations remaining constant; however, MVs contain significantly higher levels of mitochondrial (mt)DNA than ABs or EXOs. During the window of implantation, MVs contain an eleven-fold higher level of mtDNA when compared to cells-of-origin within the receptive endometrium, which possesses a lower mtDNA content and displays the upregulated expression of mitophagy-related genes. Furthermore, we demonstrate the internalization of EV-derived nuclear-encoded (n)DNA/mtDNA by trophoblast cells of murine embryos, which associates with a reduction in mitochondrial respiration and ATP production. These findings suggest that the maternal endometrium suffers a reduction in mtDNA content during the preconceptional period, that nDNA/mtDNA become packaged into secreted EVs that the embryo uptakes, and that the transfer of DNA to the embryo within EVs occurs alongside the modulation of bioenergetics during implantation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Targeted Nanotoxin Inhibits Colorectal Cancer Growth Through Local Tumor Pyroptosis and Eosinophil Infiltration and Degranulation

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Álamo, Patricia|||0000-0003-0510-5701
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ranib
  • Alba Castellón, Lorena|||0000-0003-3449-7820
Background: Colorectal cancer (CRC) has traditionally been treated with genotoxic chemotherapy to activate pro-apoptotic proteins to induce anticancer effects. However, cancer cells develop resistance to apoptosis, which leads to recurrence and poor prognosis. Moreover, this kind of therapy has been shown to be highly toxic to healthy tissues and, therefore, to patients. To overcome this issue, we developed a self-assembly tumor-targeted nanoparticle, T22-DITOX-H6, that incorporates the T22 peptide (a CXCR4 ligand) to selectively target cells overexpressing CXCR4, fused to the catalytic domain of diphtheria toxin, that exhibits a potent cytotoxic effect on these CXCR4+ cancer cells that exhibits potent cytotoxic effects on CXCR4-overexpressing cancer cells through the activation of pyroptosis, an immunogenic type of cell death. Methods: Colorectal CXCR4-expressing tumor cells (CT26-CXCR4+) were implanted subcutaneously into immunocompetent mice to study the effects of T22-DITOX-H6 treatment on tumor growth, cell death and innate immune cell recruitment to the tumor. Results: Here, we demonstrated that the T22-DITOX-H6 nanoparticle selectively activated pyroptosis, an immunogenic cell death that differs from apoptosis, leading to cell death in CXCR4-expressing cells, without affecting the viability of CXCR4-lacking cells. In addition, the nanoparticle administered to tumor-bearing mice induced a local antitumor effect due to the selective activation of pyroptosis in CXCR4+ targeted cancer cells. Biochemical analysis of plasma and histological analysis of non-tumor tissues revealed no differences between the groups. Remarkably, pyroptosis activation stimulates eosinophil infiltration into the tumor microenvironment, an effect recently reported to have an anti-tumorigenic function. Conclusion: These results highlight the dual role of CXCR4-targeted cytotoxic nanoparticle in eliminating cancer cells and boosting the self-immune response without compromising healthy organs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Efficacy of cognitive rehabilitation in cognition and brain networks, A randomised clinical trial in patients with multiple sclerosis

  • Lopez-Soley, Elisabet
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Vivó Pascual, Francesc|||0000-0002-6409-1197
  • Calvi, Alberto|||0000-0002-1953-2803
  • Alba-Arbalat, Salut|||0000-0003-1662-2317
  • Romero Pinel, Lucía|||0000-0001-8054-0565
  • Martínez Yélamos, Sergio|||0000-0001-9889-2040
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Munteis, Elvira|||0000-0002-6195-9106
  • Martínez-Rodríguez, José Enrique
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Anglada, E.|||0000-0001-5074-4970
  • Meza-Murillo, Edwin Roger|||0000-0001-6065-3546
  • Arévalo, María Jesús|||0000-0003-0626-5555
  • Sánchez Carrión, Rocío
  • Pelayo, Raúl|||0000-0002-1313-0686
  • Bernabeu Guitart, Montserrat|||0000-0003-2037-3069
  • Sola-Valls, Nuria
  • Hervas, M.
  • Sepúlveda, María
  • Saiz, Albert|||0000-0002-5793-8791
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Solana, Elisabeth|||0000-0001-7973-2439
  • Llufriu, Sara|||0000-0003-4273-9121
This study evaluated the efficacy of the computerised Guttmann, NeuroPersonalTrainer® (GNPT) cognitive rehabilitation (CR) and characterised the induced changes in cerebral networks in patients with multiple sclerosis (MS). This multicentre, double-blind, randomised clinical trial compared upward intensity training (active treatment) to low-intensity static training (static treatment). Cognition was assessed using the Brief Repeatable battery before and after 12 weeks of training and at 10-months follow-up, and patients were classified as having a mild or severe cognitive impairment (CI). Brain MRI pre- and post-CR were analysed using an advanced tractography algorithm, based on multishell diffusion MRI, to obtain node-based graph metrics (local efficiency and strength) from microscopic fractional anisotropy. Seventy MS patients completed the study (age 48.9 ± 8.8, disease duration 16.8 ± 9.0 years); active treatment: 36, static treatment: 34. Verbal memory improved significantly post-CR in both groups (55 % active; 34 % static treatment), accompanied by increases in local efficiency and strength in multimodal regions. At follow-up, verbal memory declined in both groups but remained above the pre-CR assessment (-25 % and -17 %, respectively). Patients with severe-CI (n = 36) showed improvement only with active treatment, while those with mild-CI (n = 34) improved regardless of intensity treatment. Network changes were more pronounced in patients in active treatment and in those with severe-CI. Quality of life did not change at post-CR, and cognitive improvement was influenced by cognitive reserve (p = 0.011). In MS, GNPT temporarily improves verbal memory and increases network connectivity, reinforcing the CR as a valuable tool for enhancing cognitive skills and promoting neuronal plasticity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evolving epidemiology of HCC in Spain

  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Pascual, Sonia|||0000-0002-4265-5019
  • Rota Roca, Maria Rosa
  • Matilla, Ana María
  • Campos, Marta
  • Delgado, Manuel
  • Ferrer, María Teresa
  • Montero, José Luís
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Guerrero, Antonio
  • Aracil, Carlos|||0000-0002-8228-9041
  • Rodríguez Lope, Carlos|||0000-0002-6713-8800
  • Romero-Gutiérrez, Marta
  • Sogbe, Miguel|||0000-0002-2846-7812
  • Vázquez Rodríguez, Sergio|||0000-0001-6108-9449
  • Fuentes Olmo, Javier|||0000-0001-8637-510X
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Cortés-García, Luis|||0000-0003-3164-2703
  • Vallejo-Senra, N.
  • Rendón, Paloma|||0000-0002-6521-3766
  • Clos, Ariadna|||0000-0002-6414-2097
  • Díaz-Bethencourt, D.
  • García Sánchez, Araceli
  • Quiñones Castro, Raisa|||0000-0003-2446-9068
  • Bustamante, Javier|||0000-0002-5280-3038
  • Perelló, Christie|||0000-0003-0234-2330
  • Urquijo Ponce, J.J.
  • Andreu Serra, Hernán
  • Llamoza-Torres, Camilo J.|||0000-0001-8072-9413
  • Montoliu, Silvia|||0000-0002-3041-578X
  • Fernández Marcos, Cristina
  • Guiberteau, A.
  • Hernandez-Guerra, Manuel|||0000-0002-3478-9981
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Fernández-López, A.M.
  • Valer López-Fando, M.P.
  • Gutiérrez-García, M.L.
  • Hernáez-Alsina, T.|||0000-0002-3734-2448
  • Coll, Susanna|||0000-0002-0395-9685
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Morillas, M.J.
  • Rebolledo Olmedo, Susana
  • Fernández Bermejo, Miguel
  • Roget, Mercè
  • Calvo Ramos, Irina
  • Pacheco del Río, G.
  • Rifà, Raimon|||0000-0003-1911-3681
  • Conde Gacho, Pilar
  • Llorente Barrio, Mónica|||0000-0003-0267-989X
  • Gómez-Rubio, M.
  • Peñas, Irene
  • Serra Matamala, Isabel|||0000-0002-5694-9325
  • Cachero, Alba|||0000-0002-0010-4534
  • Reig, María|||0000-0002-5711-9534
  • Giráldez-Gallego, Álvaro|||0000-0001-6849-9272
  • Guerrero Misas, Marta
  • Segarra, J.X.|||0000-0002-7222-5191
  • Lledó, J.L.
  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Delgado, Carolina|||0000-0002-0808-4494
  • Iñarrairaegui, M.
  • Rodríguez-González, M.M.
  • Lázaro, M.
  • Bermúdez-Ramos, María|||0000-0002-5516-3902
  • Lué, A.|||0000-0002-9672-6038
  • Molina, E.
  • Macías-Rodríguez, M.A.|||0000-0003-2634-6125
  • Rodríguez, Manuel|||0000-0001-5763-7668
  • Chiminazzo, V.
  • Varela Calvo, Maria|||0000-0003-4288-2593
Background & Aims: The epidemiological landscape of hepatocellular carcinoma (HCC) in Europe is evolving. This study aims to provide an updated description of the current epidemiology of liver cancer in Spain. Methods: This multicenter prospective study collected demographic and clinical data on primary liver cancer between October 2022 and January 2023. We conducted descriptive and comparative analyses with data collected in 2008 and 2014. Results: Of the 767 cases of primary liver cancer collected from 52 centers, 91% were diagnosed as HCC. The majority of patients were male (83.3%), average age 68 years, 80.7% had cirrhosis. The primary causes were alcohol (29.9% alone, 55% combined with other etiologies), liver disease related to metabolic syndrome (LDrMS, 23%) and hepatitis C (17.3%). Treatments included ablation (15.7%), systemic therapy (14.7%), and chemoembolization (14.6%). Data from 29 centers (n = 1,351) across three registries revealed a significant increase in LDrMS (from 4.9% to 24%) and HCC in non-cirrhotic livers (from 4.2% to 7.9%). Meanwhile, hepatitis C decreased sharply (from 43% to 17.5%). Alcohol-related cases remained stable. There was a slight increase in male patients and hypertension, diabetes, and obesity. Patients with cirrhosis diagnosed outside of screening programs presented with larger tumors and more advanced disease. This led to fewer evaluations for curative treatments. Conclusions: Alcohol accounts for 30% of HCC cases and is the main etiology. The registry shows a decrease in hepatitis C-related HCC, an increase in LDrMS and HCC in non-cirrhotic livers. Surveillance was implemented in ∼80% of the recommended population. There is a need for improved screening and prevention strategies, particularly for alcohol abuse and LDrMS, to enhance HCC management. Impact and implications: Our study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, more than 80% of HCC diagnoses were made through screening leading to early-stage identification and curative treatment opportunities. Notably, there has been a shift in HCC etiology within the registries from hepatitis C to liver disease related to metabolic syndrome, with an increase in cases without cirrhosis. Findings indicate a need for the prevention and early detection of HCC, particularly focusing on alcohol and liver disease related to metabolic syndrome, along with greater involvement of health authorities, to improve the participation of at-risk patients in screening programs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cohort study exploring the association of cerebrospinal fluid metalloprotease levels and Microbiological characteristics to cerebral vasculitis complication in Pneumococcal meningitis

  • Guillem, Lluïsa|||0000-0001-7814-1303
  • Alía Ramos, Pedro|||0000-0001-9662-6283
  • Gonzalez Diaz, Aida|||0000-0002-8326-1307
  • Ardanuy, Carmen|||0000-0003-0225-607X
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • van den Eynde, Eva|||0000-0001-8512-0009
  • Cabellos, Carmen|||0000-0001-7392-7382
Cerebrovascular complications are frequent in pneumococcal meningitis and are associated with poor functional outcomes. Among these complications, the incidence of cerebral vasculitis (CV) has been increasingly reported, but neither its pathogenesis nor its relationship with cortisone treatment have been conclusively established. We wanted to describe cerebrospinal fluid (CSF) metalloprotease (MMP) levels, which are linked to cerebral damage and vasculitis (MMP-2, MMP-9, and the antagonist TIMP-1), and differences in microbiological serotypes or virulence factors that could be associated to the development of this complication. A prospective multicenter cohort study was performed from January 2019 to August 2022. All adult patients diagnosed with pneumococcal meningitis and for whom CSF samples from the initial lumbar puncture were available were included and followed up for six months after discharge. Streptococcus pneumoniae strains isolated from CSF or blood were assessed including whole genome sequencing and CSF levels of MMP-2, MMP-9, and TIMP-1 were measured. CV developed in three of 21 patients (14.3%). The serotypes of those who developed CV were 3, 9 N, and 35 F, with no microbiological differences with respect to the non-CV group. The CV group had higher CSF levels of MMP-9 (13.2 vs. 9.8 ng/L) and TIMP-1 (699 vs. 318 ng/L), but lower CSF levels of MMP-2 (5689 vs. 10,484 ng/L) compared with the non-CV group. Although no patients with CV died, they had worse clinical outcomes than the non-CV group. CV is a frequent complication of pneumococcal meningitis that may be associated with worse outcomes. No differences in microbiological serotypes or virulence factors were detected. Further analyses should be carried out to confirm whether CSF MMP levels may be markers of CV development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma, implications for immunotherapy.

  • Pinato, David James|||0000-0002-3529-0103
  • Murray, Sam M.
  • Forner, Alejandro|||0000-0002-9014-4950
  • Kaneko, Takahiro
  • Fessas, Petros|||0000-0002-7472-8913
  • Toniutto, Pierluigi|||0000-0002-2566-3041
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Cacciato, Valentina
  • Avellini, Claudio
  • Díaz, Alba|||0000-0002-0456-7085
  • Boyton, Rosemary J.
  • Altmann, Daniel M.
  • Goldin, Robert D.
  • Akarca, Ayse U.
  • Marafioti, Teresa
  • Mauri, Francesco A.
  • Casagrande, Edoardo
  • Grillo, Federica
  • Giannini, Edoardo
  • Bhoori, Sherrie
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
Modulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by phenotypic lymphocyte characterization in samples of patients undergoing surgery with (T+) or without (T-) prior-TACE treatment. We profiled intratumoral (IT), peritumoral (PT) and non-tumoral (NT) background tissue to evaluate regulatory CD4+/FOXP3+ (T-reg) and immune-exhausted CD8+/PD-1+ T-cells across T+ (n=58) and T- (n=61). We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples (n=24) evaluated in relationship with the expression of actionable drivers of anti-cancer immunity including PD-L1, indoleamine 2,3 dehydrogenase (IDO-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), Lag-3, Tim-3 and CD163. We analyzed 119 patients resected (n=25, 21%) or transplanted (n=94, 79%) for Child-Pugh A (n=65, 55%) and Barcelona Clinic Liver Cancer stage A (n=92, 77%) hepatocellular carcinoma. T+ samples displayed lower IT CD4+/FOXP3+ (p=0.006), CD8+ (p=0.002) and CD8+/PD-1+ and NT CD8+/PD-1+ (p<0.001) compared with T-. Lower IT (p=0.005) and NT CD4+/FOXP3+ (p=0.03) predicted for improved recurrence-free survival. In a subset of samples (n=24), transcriptomic analysis revealed upregulation of a pro-inflammatory response in T+. T+ samples were enriched for IRF2 expression (p=0.01), an interferon-regulated transcription factor implicated in cancer immune-evasion. T-cell clonality and expression of PD-L1, IDO-1, CTLA-4, Lag-3, Tim-3 and CD163 was similar in T+ versus T-. TACE is associated with lower IT density of immune-exhausted effector cytotoxic and T-regs, with significant upregulation of pro-inflammatory pathways. This highlights the pleiotropic effects of TACE in modulating the tumor microenvironment and strengthens the rationale for developing immunotherapy alongside TACE.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacological inhibition of the CCL2-CCR2 axis fails to reduce inflammation in a rat model of acute lung injury

  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Tantinyà, Neus
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
  • Guillamat-Prats, Raquel|||0000-0001-6960-0985
New therapeutic approaches are needed to regulate inflammation and control monocyte recruitment in acute respiratory distress syndrome (ARDS). Excessive monocyte influx into the alveolar space can exacerbate lung damage, worsening patient outcomes. Delaying or reducing monocyte recruitment into the alveoli space after the injury has been proposed as a strategy to balance the inflammatory response and mitigate lung damage. In the present study, we assessed the possible role of the CCL2-CCR2 axis as a therapy for controlling acute lung injury after the initial neutrophil-driven influx. We administered a CCL2-antibody (CCL2-Ab) or a CCR2-antagonist (CCR2-Ant) locally into the lung following lung injury induced by HCl/LPS instillation. Our results show that after 24 h, both treatments transiently reduced monocyte infiltration into the bronchoalveolar space. After 72 h, neither CCL2-Ab nor CCR2-Ant sustained a reduced monocyte infiltration or significantly alleviated alveolar or lung inflammation. CCR2-Ant prevented an increase of alveolar permeability, but neither of both treatments, CCL2-Ab nor CCR2-Ant, improved lung damage or function. Our findings indicate that blocking the CCL2-CCR2 axis to control monocyte trafficking at early stages of lung injury is insufficient to control inflammation or prevent disease progression. These results highlight the complexity of ARDS pathophysiology and suggest that alternative strategies may be required to effectively modulate monocyte-driven lung inflammation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Darnell, Anna
  • Forner, Alejandro|||0000-0002-9014-4950
  • Belmonte, Ernest|||0000-0003-3572-9769
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Rimola, Jordi|||0000-0002-1814-4198
  • Soler-Perromat, Alexandre|||0000-0003-2531-2484
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Mauro, Ezequiel|||0000-0002-0757-7676
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Ríos, José|||0000-0002-0716-8784
  • Bruix, Jordi|||0000-0002-9826-0753
  • Vilana, Ramon|||0000-0002-2249-1926
  • Reig, María|||0000-0002-5711-9534
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients' outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into 'suboptimal' vs. 'optimal' locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan-Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio-HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in 'suboptimal location' presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cerebrospinal fluid lipoprotein-mediated cholesterol delivery to neurons is impaired in Alzheimer's disease and involves APOE4

  • Borràs, Carla|||0000-0002-0998-7855
  • Canyelles, Marina|||0000-0002-0278-5337
  • Santos, David|||0000-0003-1157-4969
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Nuñez, Estefania|||0000-0002-0876-1264
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Zhao, Qi
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
In the central nervous system, apolipoprotein (APO)E-containing lipoprotein particles mediate the transport of glial-derived cholesterol to neurons, which is essential for neuronal membrane remodeling and maintenance of the myelin sheath. We aimed to examine cholesterol transport via lipoprotein particles in cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients compared to control individuals. Additionally, we explored the ability of reconstituted HDL containing different APOE isoforms to regulate cholesterol transport. We evaluated the capacity of CSF lipoprotein particles to facilitate radiolabeled unesterified cholesterol efflux from A172 human glioblastoma astrocytes and to deliver cholesterol to SH-SY5Y human neuronal cells. The CSF lipoprotein proteome was analyzed by LC-MS/MS. Reconstituted HDL nanoparticles were prepared by combining phospholipids and cholesterol with human APOE3 or APOE4, followed by radiolabeling with unesterified cholesterol. Our results showed that cholesterol efflux from astrocytes to CSF were similar between AD patients and controls, both under baseline conditions and after activation of ABCA1 and ABCG1. However, CSF lipoprotein-mediated neuronal cholesterol uptake was significantly reduced in the AD group. LC-MS/MS analysis identified 239 proteins associated with CSF lipoproteins in both groups, with no major alterations in proteins linked to cholesterol metabolism. However, 27 proteins involved in noncholesterol-related processes were differentially expressed. Notably, synthetic reconstituted HDL particles containing APOE4 exhibited reduced capacity to deliver cholesterol to neurons compared to those with APOE3. These findings indicate that CSF lipoproteins from patients with AD demonstrate impaired cholesterol delivery to neurons. Our study highlights APOE4 as a critical contributor to abnormal neuronal cholesterol uptake in AD pathophysiology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Alpha-synuclein co-pathology in Down syndrome-associated Alzheimer's disease

  • Bernhardt, Alexander Maximilian
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Longen, Sebastian
  • Trossbach, Svenja Verena
  • Giese, Armin
  • Matthias, Torsten
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Sanjuan, Aída
  • Fernández, Susana|||0000-0002-9777-1156
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Nübling, Georg|||0000-0003-4492-7302
  • Wagemann, Olivia
  • Stockbauer, Anna
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Fortea, Juan|||0000-0002-1340-638X
  • Levin, Johannes|||0000-0001-5092-4306
Alpha-synuclein (αSyn) seed amplification assay (SAA) enables in vivo study of αSyn but remains underexplored in Down syndrome-associated Alzheimer's disease (DSAD). We analyzed αSyn-SAA in cerebrospinal fluid (CSF) from 270 adults with Down syndrome, from the Down Alzheimer Barcelona Neuroimaging Initiative and from the AD21 cohort from the Department of Neurology at the University Hospital, Ludwig Maximilian University of Munich, Germany. Neuropathological examinations were conducted in 19 brain donors (five with ante mortem CSF). Participants were classified as asymptomatic or symptomatic (prodromal/dementia) Alzheimer's disease (AD). CSF Aβ1-42/1-40, CSF and plasma p-Tau181, and neurofilament light chain (NfL) levels were measured. Neuropathological evaluations assessed AD neuropathological changes and Lewy body pathology (LBP). ΑSyn-SAA was positive in 9.2% of cases, independent of age or cognitive status. Symptomatic αSyn-positive cases exhibited higher plasma NfL levels than αSyn-negative cases (31 vs 21 pg/mL, p = 0.027). LBP was observed in 47% of necropsies. The individual with severe neocortical LBP was αSyn-SAA-positive. These findings highlight LBP prevalence in DSAD but suggest current SAA may fail to detect limited αSyn deposition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-cell RNA sequencing highlights the role of distinct natural killer subsets in sporadic amyotrophic lateral sclerosis

  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Muñoz, Laia|||0000-0003-0578-3094
  • Aumatell Escabias, Joaquim
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Lleó, Alberto|||0000-0002-2568-5478
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Fortea, Juan|||0000-0002-1340-638X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Dols Icardo, Oriol|||0000-0003-2656-8748
Neuroinflammation plays a major role in amyotrophic lateral sclerosis (ALS), and cumulative evidence suggests that systemic inflammation and the infiltration of immune cells into the brain contribute to this process. However, no study has investigated the role of peripheral blood immune cells in ALS pathophysiology using single-cell RNA sequencing (scRNAseq). We aimed to characterize immune cells from blood and identify ALS-related immune alterations at single-cell resolution. For this purpose, peripheral blood mononuclear cells (PBMC) were isolated from 14 ALS patients and 14 cognitively unimpaired healthy individuals (HC), matched by age and gender, and cryopreserved until library preparation and scRNAseq. We analyzed differences in the proportions of PBMC, gene expression, and cell-cell communication patterns between ALS patients and HC, as well as their association with plasma neurofilament light (NfL) concentrations, a surrogate biomarker for neurodegeneration. Flow cytometry was used to validate alterations in cell type proportions. We identified the expansion of CD56 dim natural killer (NK) cells in ALS (fold change = 2; adj. p -value = 0.0051), mainly driven by a specific subpopulation, NK_2 cells (fold change = 3.12; adj. p -value = 0.0001), which represent a mature and cytotoxic CD56 dim NK subset. Our results revealed extensive gene expression alterations in NK_2 cells, pointing towards the activation of immune response (adj. p -value = 9.2 × 10 - 11) and the regulation of lymphocyte proliferation (adj. p -value = 6.46 × 10 - 6). We also identified gene expression changes in other immune cells, such as classical monocytes, and distinct CD8 + effector memory T cells which suggested enhanced antigen presentation via major histocompatibility class-II (adj. p -value = 1.23 × 10 - 8) in ALS. The inference of cell-cell communication patterns demonstrated that the interaction between HLA-E and CD94:NKG2C from different lymphocytes to NK_2 cells is unique to ALS blood compared to HC. Finally, regression analysis revealed that the proportion of CD56 bright NK cells along with the ALSFRS-r, disease duration, and gender, explained up to 76.4% of the variance in plasma NfL levels. Our results reveal a signature of relevant changes occurring in peripheral blood immune cells in ALS and underscore alterations in the proportion, gene expression, and signaling patterns of a cytotoxic and terminally differentiated CD56 dim NK subpopulation (NK_2), as well as a possible role of CD56 bright NK cells in neurodegeneration. The online version contains supplementary material available at 10.1186/s12974-025-03347-0.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk loci involved in giant cell arteritis susceptibility, a genome-wide association study

  • Borrego-Yaniz, Gonzalo|||0000-0003-1474-2884
  • Ortiz-Fernández, Lourdes|||0000-0002-0247-4280
  • Madrid-Paredes, Adela|||0000-0002-4606-2632
  • Kerick, Martin|||0000-0002-6298-4514
  • Hernández Rodríguez, José|||0000-0002-2357-2015
  • Mackie, Sarah L.
  • Vaglio, Augusto
  • Castañeda, Santos|||0000-0002-7748-853X
  • Solans, Roser|||0000-0002-0058-1293
  • Mestre Torres, Jaume|||0000-0001-6612-221X
  • Khalidi, Nader|||0000-0002-8270-2617
  • Langford, Carol|||0000-0001-9498-321X
  • Ytterberg, Steven
  • Beretta, Lorenzo|||0000-0002-6529-6258
  • Govoni, Marcello|||0000-0003-0499-5773
  • Emmi, Giacomo|||0000-0001-9575-8321
  • Cimmino, Marco Amedeo|||0000-0002-6956-7860
  • Witte, Torsten
  • Neumann, Thomas
  • Holle, Julia
  • Schönau, Verena
  • Pugnet, Gregory
  • Papo, Thomas|||0000-0002-7481-5099
  • Haroche, Julien
  • Mahr, Alfred
  • Mouthon, Luc
  • Molberg, Ø.|||0000-0003-4493-8853
  • Diamantopoulos, Andreas P.
  • Voskuyl, A.E.|||0000-0002-9699-1827
  • Daikeler, Thomas
  • Berger, Christoph T.
  • Molloy, Eamonn S.
  • Blockmans, Daniel|||0000-0001-9783-1780
  • van Sleen, Yannick|||0000-0002-7382-8322
  • Iles, Mark|||0000-0002-2603-6509
  • Sorensen, Louise
  • Luqmani, Raashid|||0000-0002-4446-5841
  • Reynolds, Gary|||0000-0002-8142-8708
  • Bukhari, Marwan
  • Bhagat, Shweta
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Brouwer, Elisabeth
  • Lamprecht, Peter
  • Klapa, Sebastian|||0000-0002-0012-0163
  • Salvarani, Carlo|||0000-0001-5426-5133
  • Merkel, Peter A.|||0000-0001-9284-7345
  • Cid, María Cinta|||0000-0002-4730-0938
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Morgan, Ann W.
  • Martín, Javier|||0000-0002-2202-0622
  • Márquez, Ana|||0000-0001-9913-7688
Giant cell arteritis is an age-related vasculitis that mainly affects the aorta and its branches in individuals aged 50 years and older. Current options for diagnosis and treatment are scarce, highlighting the need to better understand its underlying pathogenesis. Genome-wide association studies (GWAS) have emerged as a powerful tool for unravelling the pathogenic mechanisms involved in complex diseases. We aimed to characterise the genetic basis of giant cell arteritis by performing the largest GWAS of this vasculitis to date and to assess the functional consequences and clinical implications of identified risk loci. We collected and meta-analysed genomic data from patients with giant cell arteritis and healthy controls of European ancestry from ten cohorts across Europe and North America. Eligible patients required confirmation of giant cell arteritis diagnosis by positive temporal artery biopsy, positive temporal artery doppler ultrasonography, or imaging techniques confirming large-vessel vasculitis. We assessed the functional consequences of loci associated with giant cell arteritis using cell enrichment analysis, fine-mapping, and causal gene prioritisation. We also performed a drug repurposing analysis and developed a polygenic risk score to explore the clinical implications of our findings. We included a total of 3498 patients with giant cell arteritis and 15 550 controls. We identified three novel loci associated with risk of giant cell arteritis. Two loci, MFGE8 (rs8029053; p=4·96 × 10 -8 ; OR 1·19 [95% CI 1·12-1·26]) and VTN (rs704; p=2·75 × 10 -9 ; OR 0·84 [0·79-0·89]), were related to angiogenesis pathways and the third locus, CCDC25 (rs11782624; p=1·28 × 10 -8 ; OR 1·18 [1·12-1·25]), was related to neutrophil extracellular traps (NETs). We also found an association between this vasculitis and HLA region and PLG. Variants associated with giant cell arteritis seemed to fulfil a specific regulatory role in crucial immune cell types. Furthermore, we identified several drugs that could represent promising candidates for treatment of this disease. The polygenic risk score model was able to identify individuals at increased risk of developing giant cell arteritis (90th percentile OR 2·87 [95% CI 2·15-3·82]; p=1·73 × 10 -13). We have found several additional loci associated with giant cell arteritis, highlighting the crucial role of angiogenesis in disease susceptibility. Our study represents a step forward in the translation of genomic findings to clinical practice in giant cell arteritis, proposing new treatments and a method to measure genetic predisposition to this vasculitis. Institute of Health Carlos III, Spanish Ministry of Science and Innovation, UK Medical Research Council, and National Institute for Health and Care Research.